<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680109</article-id><article-id pub-id-type="doi">10.3390/vaccines12121344</article-id><article-id pub-id-type="publisher-id">vaccines-12-01344</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Protein Expression Platforms and the Challenges of Viral Antigen Production</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3155-1860</contrib-id><name><surname>Sookhoo</surname><given-names>Jamie R. V.</given-names></name><xref rid="af1-vaccines-12-01344" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01344" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4778-4941</contrib-id><name><surname>Schiffman</surname><given-names>Zachary</given-names></name><xref rid="af3-vaccines-12-01344" ref-type="aff">3</xref><xref rid="af4-vaccines-12-01344" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1783-2105</contrib-id><name><surname>Ambagala</surname><given-names>Aruna</given-names></name><xref rid="af1-vaccines-12-01344" ref-type="aff">1</xref><xref rid="af4-vaccines-12-01344" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6371-7493</contrib-id><name><surname>Kobasa</surname><given-names>Darwyn</given-names></name><xref rid="af3-vaccines-12-01344" ref-type="aff">3</xref><xref rid="af4-vaccines-12-01344" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Pardee</surname><given-names>Keith</given-names></name><xref rid="af5-vaccines-12-01344" ref-type="aff">5</xref><xref rid="af6-vaccines-12-01344" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1265-7264</contrib-id><name><surname>Babiuk</surname><given-names>Shawn</given-names></name><xref rid="af1-vaccines-12-01344" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01344" ref-type="aff">2</xref><xref rid="c1-vaccines-12-01344" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Tripp</surname><given-names>Ralph A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01344"><label>1</label>Canadian Food Inspection Agency, National Centre for Foreign Animal Disease, Winnipeg, MB R3E 3R2, Canada; <email>sookhooj@myumanitoba.ca</email> (J.R.V.S.); <email>aruna.ambagala@inspection.gc.ca</email> (A.A.)</aff><aff id="af2-vaccines-12-01344"><label>2</label>Department of Immunology, University of Manitoba, Winnipeg, MB R3E 0T5, Canada</aff><aff id="af3-vaccines-12-01344"><label>3</label>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada; <email>zachary.schiffman@phac-aspc.gc.ca</email> (Z.S.); <email>darwyn.kobasa@phac-aspc.gc.ca</email> (D.K.)</aff><aff id="af4-vaccines-12-01344"><label>4</label>Department of Medical Microbiology, University of Manitoba, Winnipeg, MB R3E 0W2, Canada</aff><aff id="af5-vaccines-12-01344"><label>5</label>Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada; <email>keith.pardee@utoronto.ca</email></aff><aff id="af6-vaccines-12-01344"><label>6</label>Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, ON M5S 3G8, Canada</aff><author-notes><corresp id="c1-vaccines-12-01344"><label>*</label>Correspondence: <email>shawn.babiuk@inspection.gc.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1344</elocation-id><history><date date-type="received"><day>20</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Several protein expression platforms exist for a wide variety of biopharmaceutical needs. A substantial proportion of research and development into protein expression platforms and their optimization since the mid-1900s is a result of the production of viral antigens for use in subunit vaccine research. This review discusses the seven most popular forms of expression systems used in the past decade&#x02014;bacterial, insect, mammalian, yeast, algal, plant and cell-free systems&#x02014;in terms of advantages, uses and limitations for viral antigen production in the context of subunit vaccine research. Post-translational modifications, immunogenicity, efficacy, complexity, scalability and the cost of production are major points discussed. Examples of licenced and experimental vaccines are included along with images which summarize the processes involved.</p></abstract><kwd-group><kwd>subunit vaccines</kwd><kwd>protein expression</kwd><kwd>synthetic biology</kwd><kwd>viral antigens</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01344"><title>1. Introduction</title><p>Vaccines have been the most successful intervention to respond to infectious disease. There are several types of vaccines including live-attenuated, vectored, DNA or mRNA, killed and subunit. Each vaccine type has its strengths and weaknesses. Although live-attenuated and vectored vaccines can induce strong protective immunity, it is more difficult to demonstrate the safety of these vaccine types, impeding their development as a rapid response to emerging disease outbreaks. DNA or mRNA vaccines use the host cells to produce the antigen offering improved safety over live and vectored vaccines. Killed and subunit vaccines are safer compared to live-attenuated and vectored vaccines, with subunit vaccines considered the most safe [<xref rid="B1-vaccines-12-01344" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-12-01344" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-12-01344" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01344" ref-type="bibr">4</xref>]. Unfortunately, both killed and subunit vaccines require adjuvants to induce protective immune responses. The immunogenicity of subunit vaccines can be increased by producing virus-like particles (VLPs), which are generated using the component proteins of a virus which spontaneously self-assemble into particles in the absence of a viral genome [<xref rid="B5-vaccines-12-01344" ref-type="bibr">5</xref>]. The repetitive structure of VLPs stimulates the innate and adaptive immune responses, resulting in improved antibody responses [<xref rid="B5-vaccines-12-01344" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-12-01344" ref-type="bibr">6</xref>]. An advantage of subunit vaccines, compared to conventional live-attenuated and most killed vaccines, is their potential for differentiating from infected and vaccinated animals (DIVA) when combined with companion diagnostics [<xref rid="B7-vaccines-12-01344" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01344" ref-type="bibr">8</xref>].</p><p>The biotechnology industry has rapidly advanced in the past half-century and the expression of recombinant proteins in different systems for a wide variety of applications is a major use of this technology. This has resulted in a range of proteins expressed for therapeutics and diagnostic kits which are discussed elsewhere [<xref rid="B2-vaccines-12-01344" ref-type="bibr">2</xref>,<xref rid="B9-vaccines-12-01344" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-12-01344" ref-type="bibr">10</xref>]. These major advances in genetic engineering have also allowed for the development of recombinant subunit vaccines consisting of protective viral antigens which is the focus of this review. Successful licenced recombinant subunit vaccines have been produced in different protein expression systems such as the Hepatitis B surface antigen (HBsAg) in yeast [<xref rid="B3-vaccines-12-01344" ref-type="bibr">3</xref>], the human papilloma virus-like particle (VLP) vaccine in baculovirus [<xref rid="B4-vaccines-12-01344" ref-type="bibr">4</xref>] and several systems for influenza [<xref rid="B11-vaccines-12-01344" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-12-01344" ref-type="bibr">12</xref>] and the dengue [<xref rid="B13-vaccines-12-01344" ref-type="bibr">13</xref>] in mammalian expression systems.</p><p>Advances in genetic engineering, including gene synthesis combined with the biotechnology of cell culture systems, has led to the availability of multiple different protein expression systems used to produce recombinant subunit vaccines [<xref rid="B10-vaccines-12-01344" ref-type="bibr">10</xref>]. After decades of research into the utilities of various protein expression systems, including bacterial, insect, mammalian, plant and cell-free systems, an empirical approach is still required for identifying an appropriate expression system for a specific viral glycoprotein [<xref rid="B2-vaccines-12-01344" ref-type="bibr">2</xref>,<xref rid="B14-vaccines-12-01344" ref-type="bibr">14</xref>]. Viral proteins as vaccine antigens often contain post-translational modifications including disulphide bonds and the unique glycosylation patterns that are required for proper folding and/or biological activity, preventing their expression in prokaryotes. The immunogenicity of a recombinant glycoprotein antigen can be highly dependent on its glycosylation and is influenced by the biology of the cell used and the protein being expressed [<xref rid="B2-vaccines-12-01344" ref-type="bibr">2</xref>,<xref rid="B15-vaccines-12-01344" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-12-01344" ref-type="bibr">16</xref>]. Eukaryotic expression systems can be used to express these proteins, including yeast, e.g., <italic toggle="yes">Pichia pastoris</italic> and <italic toggle="yes">Saccharomyces cerevisiae</italic>; baculovirus expression vector systems (BEVSs) using <italic toggle="yes">Autographa californica</italic> multiple nuclear polyhedrosis virus (AcMNPV) and insect cell hosts <italic toggle="yes">Spodoptera frugiperda</italic> (Sf) or <italic toggle="yes">Trichoplusia ni</italic> (Tni); and mammalian cell systems including a variety of transformed cell lines, such as the Chinese hamster ovary (CHO) and human embryonic kidney (HEK)293 [<xref rid="B17-vaccines-12-01344" ref-type="bibr">17</xref>]. Although all these expression systems can express protein antigens, the glycosylation patterns will differ between the antigen expression systems. The effect of the glycosylation patterns from the different expression systems can be important or not depending on the specific protein use of the protein; this makes the selection of the optimal protein production system difficult without prior knowledge of expression in different systems.</p><p>Variations in glycan types and the glycosylation of proteins is a major limiting factor in recombinant antigen production as glycosylation can dramatically impact efficacy. Several glycoproteins carry glycans derived from the initiation of N-Acetylgalactosamine (GalNAc) attached to Ser or Thr residues. Mucins are a class of glycoproteins that have the highest amount of O-GalNAc glycans. These have four core structures which can be extended by sugar residues to produce either linear or branched chains, similar to what is seen on N-glycans. N-glycans are attached by covalent bonds to asparagine residues by N-glycosidic bonds. The synthesis of N-glycans is highly complex in mammalian glycoproteins. Eukaryotic N-glycans have a common core sequence and are then classified into three types: (1) oligomannose, where only mannose residues extend the core; (2) complex types, where &#x02018;antennae&#x02019; structures derived from N-acetylglucosamine extend the core; and (3) hybrid types, where mannose extends an arm of the core and one or two N-acetylglucosamine antennae extend another arm [<xref rid="B18-vaccines-12-01344" ref-type="bibr">18</xref>].</p><p>Most viral vaccines produced by recombinant protein expression systems are viral proteins expressed on the surface [<xref rid="B19-vaccines-12-01344" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01344" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-12-01344" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-12-01344" ref-type="bibr">22</xref>], either capsid proteins in non-enveloped viruses or membrane proteins in enveloped viruses [<xref rid="B23-vaccines-12-01344" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01344" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-01344" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01344" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-12-01344" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-12-01344" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-12-01344" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-12-01344" ref-type="bibr">30</xref>]. In terms of viral subunit vaccines, <italic toggle="yes">Escherichia coli</italic> (<italic toggle="yes">E. coli</italic>) expression systems have been attempted but have not demonstrated significant enough effectiveness to be commercially viable, though they have been highly effective for bacterial subunit vaccines [<xref rid="B27-vaccines-12-01344" ref-type="bibr">27</xref>]. Prokaryotic systems have limitations when expressing mammalian (viral) membrane proteins as post-translational modifications are required for their correct folding into a fully functional protein.</p><p>This review will discuss the different protein expression systems and their applications for viral antigen expression. In addition, future areas of research for improving protein expression systems focussing on cell-free systems and transgenic animals will be discussed.</p></sec><sec id="sec2-vaccines-12-01344"><title>2. Bacterial Expression Systems</title><p><italic toggle="yes">E. coli</italic> is the most commonly used bacterial system for protein expression due to its simplicity in being able to use a plasmid encoding the gene of interest to transform the bacteria and the simple production and efficiency of producing protein (<xref rid="vaccines-12-01344-f001" ref-type="fig">Figure 1</xref> and <xref rid="vaccines-12-01344-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B31-vaccines-12-01344" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-12-01344" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-12-01344" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-12-01344" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-12-01344" ref-type="bibr">35</xref>]. The majority of viral glycoproteins are large proteins (greater than 60 kDa) that are difficult to express using <italic toggle="yes">E. coli.</italic> Though it has been shown that <italic toggle="yes">E. coli</italic> strains such as SHuffle [<xref rid="B32-vaccines-12-01344" ref-type="bibr">32</xref>] and other strains [<xref rid="B33-vaccines-12-01344" ref-type="bibr">33</xref>] can produce disulphide bonds in expressed proteins, a lack of post-translational machinery and protein expressed in inclusion bodies make <italic toggle="yes">E. coli</italic> expression not suitable for many viral glycoproteins [<xref rid="B34-vaccines-12-01344" ref-type="bibr">34</xref>].</p><p>Additional issues including the presence of endotoxins such as lipopolysaccharides [<xref rid="B35-vaccines-12-01344" ref-type="bibr">35</xref>] require additional bioprocessing steps [<xref rid="B36-vaccines-12-01344" ref-type="bibr">36</xref>] though some species of <italic toggle="yes">E. coli</italic> such as BL21 (DE3) are endotoxin-free [<xref rid="B37-vaccines-12-01344" ref-type="bibr">37</xref>]. Furthermore, even following endotoxin removal, many proteins still contain level of endotoxin able to activate dendritic cells [<xref rid="B38-vaccines-12-01344" ref-type="bibr">38</xref>], indicating the difficulty in removing endotoxin from recombinant proteins. In addition, protein expression in bacterial expression systems produces proteins which aggregate in insoluble inclusion bodies, which requires further protein purification procedures to solubilize the protein from the inclusion bodies [<xref rid="B39-vaccines-12-01344" ref-type="bibr">39</xref>]. Since certain expressed proteins may be insoluble, unstable or inactive without post-translational modifications, <italic toggle="yes">E. coli</italic> may only be the choice expression system for the production of small recombinant proteins without post-translational modification needs [<xref rid="B40-vaccines-12-01344" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-12-01344" ref-type="bibr">41</xref>].</p><sec><title>Applications of Bacterial Expression Systems</title><p>Several <italic toggle="yes">E. coli</italic> expressed viral antigen vaccine candidates have been developed and are at different stages of evaluation, as summarized in <xref rid="vaccines-12-01344-t001" ref-type="table">Table 1</xref>. The only licenced vaccine was developed by Xiamen Innovax Biotech Co., Ltd. (Xiamen, China) namely the hepatitis E virus (HEV) capsid polypeptide, HEV 239, from <italic toggle="yes">E. coli</italic>, and was the first VLP-based vaccine (Hecolin) against HEV licenced by the FDA of China in 2011 [<xref rid="B42-vaccines-12-01344" ref-type="bibr">42</xref>]. Antigen production and product consistency was demonstrated at different scales indicating the manufacturing process was robust and scalable [<xref rid="B43-vaccines-12-01344" ref-type="bibr">43</xref>].</p><p>Foot-and-mouth disease virus (FMDV) VLPs have also been produced in this system, providing protection in multiple species [<xref rid="B44-vaccines-12-01344" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-12-01344" ref-type="bibr">45</xref>]. VLPs mimicking viral capsids or chimeric VLPs by grafting epitopes of interest onto a VLP display vector are possible platforms for future vaccines via structure-based molecular design. One study used calcium phosphate-mineralized VLPs (CaP-VLPs) and tested three commercial mucosal adjuvants and found that the induction of local mucosal and systemic immune responses via intranasal immunization was specifically enhanced by the adjuvant: STR products [<xref rid="B46-vaccines-12-01344" ref-type="bibr">46</xref>]. The anti-influenza A M2e-Hbc vaccine candidate, ACAM-FLU-A was produced by <italic toggle="yes">E. coli</italic> using the recombinant hepatitis B core antigen as a carrier VLP, which is an approach that synergizes the benefits of broadly cross-protecting epitopes with rapid scale-up vaccine manufacture using bacterial expression systems [<xref rid="B48-vaccines-12-01344" ref-type="bibr">48</xref>]. This vaccine resulted in high seroconversion rates in Phase 1 trials but Phase II efficacy trials were cancelled due to a rapid decline in antibody titres [<xref rid="B49-vaccines-12-01344" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-12-01344" ref-type="bibr">50</xref>]. Recombinant VLPs for porcine circovirus type 2 capsid protein and porcine parvovirus (PPV) VP2 protein have been expressed in <italic toggle="yes">E. coli</italic> and have demonstrated immunogenicity in piglets and improved growth indices [<xref rid="B51-vaccines-12-01344" ref-type="bibr">51</xref>].</p><p>Since the start of the COVID-19 pandemic, several laboratories have produced SARS-CoV-2 spike and RBD fragments in <italic toggle="yes">E. coli</italic> expression systems [<xref rid="B52-vaccines-12-01344" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-12-01344" ref-type="bibr">53</xref>,<xref rid="B54-vaccines-12-01344" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-12-01344" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-12-01344" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-12-01344" ref-type="bibr">57</xref>]. In these systems, as described above, the proteins are produced insoluble in inclusion bodies which then require extra steps of centrifugation, ultrasonication, redissolving, refolding and then purification. In these studies, only fragments of the SARS-CoV-2 surface glycoproteins approximately 300 bp could be successfully produced. One study [<xref rid="B55-vaccines-12-01344" ref-type="bibr">55</xref>] was able to produce soluble spike and nucleocapsid protein fragments by fusing the fragments to carrier family 9 carbohydrate-binding module (CBM9) through a flexible linker. Studies using <italic toggle="yes">E. coli</italic> have been successful in producing the RBD of the spike protein [<xref rid="B57-vaccines-12-01344" ref-type="bibr">57</xref>]. As this system produces little glycosylation, one study [<xref rid="B52-vaccines-12-01344" ref-type="bibr">52</xref>] showed that non-glycosylated RBD adjuvanted with both 100 &#x003bc;g of Al(OH)<sub>3</sub> and 50 &#x003bc;g of CpG elicited a robust neutralizing antibody response in mice. While the <italic toggle="yes">E. coli</italic> expression system is a cost-effective system to produce many useful proteins, the requirements for disulphide bond formation and glycosylation for proper expression and folding for viral proteins make this a less desirable system.</p></sec></sec><sec id="sec3-vaccines-12-01344"><title>3. Insect Cell (Baculovirus) Expression Systems</title><p>Baculoviruses are large, double-stranded DNA viruses which infect insects and have been developed as a recombinant protein expression system using insect cells [<xref rid="B58-vaccines-12-01344" ref-type="bibr">58</xref>]. To produce recombinant proteins, the baculovirus, <italic toggle="yes">Autographa californica</italic> nuclear polyhedrosis virus (AcNPV), is genetically engineered to encode the gene of the protein of interest. These baculoviruses are then used to infect susceptible insect cells either <italic toggle="yes">Spodoptera frugiperda</italic> (Sf) or <italic toggle="yes">Trichoplusia ni</italic> (Tni) to transiently express the protein (<xref rid="vaccines-12-01344-f003" ref-type="fig">Figure 3</xref>).</p><p>Homologous recombination is used to generate recombinant baculoviruses in insect cells by the co-transfection of viral DNA and a plasmid containing the gene of interest under the control of the strong polyhedrin promoter of the baculovirus and is flanked by sequences from the polyhedron region [<xref rid="B59-vaccines-12-01344" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-12-01344" ref-type="bibr">60</xref>]. The selection of recombinant baculovirus is based on the removal of the polyhedrin gene and the detection of occlusion-negative plaques in insect cell monolayers. Several improvements have been made for the selection of recombinant baculovirus, including the linearization of the virus at the polyhedrin locus [<xref rid="B61-vaccines-12-01344" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-12-01344" ref-type="bibr">62</xref>]. Recombination recircularizes the viral genome, which allows for the amplification of the genome [<xref rid="B63-vaccines-12-01344" ref-type="bibr">63</xref>]. Combinations of this approach were also used, such as the incorporation of a lacZ gene at the polyhedrin locus and the subsequent linearization or engineering of unique restriction enzyme sites into an essential gene (ORF1629) which flanks the polyhedrin locus [<xref rid="B64-vaccines-12-01344" ref-type="bibr">64</xref>]. The linearization of these sites results in defective gene expression, and the part of the ORF1629 gene that is deleted from the baculovirus genome is incorporated into the transfer plasmid (bacmid) so that ORF1629 function is restored only in the recombinant viruses [<xref rid="B65-vaccines-12-01344" ref-type="bibr">65</xref>]. The recombinant bacmid DNA is then used to transfect insect cells using a transfection reagent in small cell cultures. Infected cells then give rise to live baculovirions used to infect larger cell cultures to produce and purify the protein of interest expressed in the insect cells [<xref rid="B66-vaccines-12-01344" ref-type="bibr">66</xref>].</p><p>Post-translational modifications are similar, although not identical, to mammalian cells. Glycoproteins produced in insect systems have O- and N-glycans with structures similar to those produced by other eukaryotes, although usually insect expressed proteins do not have antennae of peripheral sugars, but are mainly composed of sialic acids, which are often found on native mammalian glycans [<xref rid="B67-vaccines-12-01344" ref-type="bibr">67</xref>]. Sialic acids are often found as terminal residues on cell surface glycoproteins and are involved in several immunological interactions in higher eukaryotes. The absence of sialic acids in proteins expressed in insect cells is a significant and somewhat controversial issue in terms of recombinant glycoprotein production. Understanding the important roles that glycan moieties play in protein expression and the need for systems that can produce mammalian-type glycoproteins has led to an increased interest in protein glycosylation pathways and host cells that can be used for functional recombinant glycoprotein expression [<xref rid="B68-vaccines-12-01344" ref-type="bibr">68</xref>].</p><p>Glycoforms of recombinant proteins produced in the BEVS are sometimes different from those produced in mammalian expression systems [<xref rid="B69-vaccines-12-01344" ref-type="bibr">69</xref>]. Insect-expressed proteins mainly display paucimannose and hybrid-type N-glycans with, at most, minor fractions of complex-type and oligomannose-type N-glycan. Tni cells compared to Sf9 cells can also produce core &#x003b1;-1,3-fucose-linked glycans [<xref rid="B70-vaccines-12-01344" ref-type="bibr">70</xref>], which may cause hypersensitivity reactions when applied to patients with allergy and therefore should be avoided in cell line engineering [<xref rid="B71-vaccines-12-01344" ref-type="bibr">71</xref>]. This limitation has been addressed by genetically transforming insect cell lines with constitutively expressible mammalian genes which yield transgenic insect cell lines that can produce humanized recombinant glycoproteins [<xref rid="B72-vaccines-12-01344" ref-type="bibr">72</xref>]. Genetically modified insect cells include Mimic SF9, SfSWT-1, SfSWT-3, SfSWT-4, SfSWT-5, SfB4GalT, SfRVN<sup>lec1</sup>, DpN1 and A7S [<xref rid="B68-vaccines-12-01344" ref-type="bibr">68</xref>].</p><p>The baculovirus expression system is able to produce complex antigens unable to be effectively produced in prokaryotic systems [<xref rid="B73-vaccines-12-01344" ref-type="bibr">73</xref>]. However, their use in expressing secreted mammalian proteins is limited for several reasons, the simplest being that insect cell culture media is often just as costly as mammalian cell media. Both insect and mammalian cell lines can be cultured in classical media containing serum, chemically defined media or serum-free media and the overall costs of these are nearly identical for both cell types. Mammalian cells produce glycosylation patterns on proteins that are more representative of those seen in native organisms because insect cells do not produce sialylated complex glycans; however, protein yields in both are similar [<xref rid="B73-vaccines-12-01344" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-12-01344" ref-type="bibr">74</xref>]. The construction of the plasmid, amplification, titration and optimization are all time-consuming steps requiring approximately one month or more. Upon infection, the baculovirus genome including the trans-expression cassette is significantly amplified while host synthesis stops. Despite having to compete with viral genes, the expression cassette under the control of the strong viral polyhedrin promoter is itself transcribed and translated at exceptionally high levels. Complex secreted proteins such as viral glycoproteins require several host factors, including glycosylation machinery, chaperones for accurate folding and disulphide isomerases. Under these conditions, the insect cell host machinery is often overwhelmed and so secreted proteins may fail to substantially fold and are instead sometimes found trapped inside the cell in aggregates [<xref rid="B75-vaccines-12-01344" ref-type="bibr">75</xref>]. Extreme over-expression in the BEVS can result in lower yields of properly folded and secreted protein. This issue has been significantly improved, however, by the inclusion of honeybee melittin, silkworm SP1 and <italic toggle="yes">Drosophila</italic> Bip signal peptides in the trans-expression plasmid, which have allowed for improved and efficient recombinant protein secretion in the BEVS [<xref rid="B76-vaccines-12-01344" ref-type="bibr">76</xref>,<xref rid="B77-vaccines-12-01344" ref-type="bibr">77</xref>].</p><p>There are several studies which have produced protein antigens in insect cells without the use of the BEVS [<xref rid="B77-vaccines-12-01344" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-12-01344" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-12-01344" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-12-01344" ref-type="bibr">80</xref>,<xref rid="B81-vaccines-12-01344" ref-type="bibr">81</xref>,<xref rid="B82-vaccines-12-01344" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-12-01344" ref-type="bibr">83</xref>,<xref rid="B84-vaccines-12-01344" ref-type="bibr">84</xref>,<xref rid="B85-vaccines-12-01344" ref-type="bibr">85</xref>]. This involves the use of polyethylenimine (PEI)-based transient gene expression and has been shown in both Tni and Sf9 cells. PEI transfection is a high-efficiency nucleic acid delivery system based on transferrin receptor-mediated endocytosis to carry DNA into cells [<xref rid="B84-vaccines-12-01344" ref-type="bibr">84</xref>]. The expression vector is efficiently delivered by PEI using a variety of different expression vectors and protocols. A higher secreted protein yield has been demonstrated compared to BEVS [<xref rid="B79-vaccines-12-01344" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-12-01344" ref-type="bibr">80</xref>].</p><sec><title>Applications of Baculovirus Expression System</title><p>There are currently seven licenced BEVS-expressed subunits or VLP vaccines against human and animal viruses (<xref rid="vaccines-12-01344-t002" ref-type="table">Table 2</xref>) [<xref rid="B86-vaccines-12-01344" ref-type="bibr">86</xref>,<xref rid="B87-vaccines-12-01344" ref-type="bibr">87</xref>], and several other BEVS viral vaccines in development are described in <xref rid="vaccines-12-01344-t003" ref-type="table">Table 3</xref>. Examples of Drosophila S2 cell line-expressed vaccines are also included [<xref rid="B88-vaccines-12-01344" ref-type="bibr">88</xref>,<xref rid="B89-vaccines-12-01344" ref-type="bibr">89</xref>].</p><p>Two separate studies indicated the effectiveness of BEVS expressed VLPs produced against chikungunya virus (CHKV). One study showed that a single immunization with 1&#x000b5;g of non-adjuvanted CHIKV-S27 structural polyprotein (C, E3, E2, 6K, E1) induced high-titre neutralizing antibody responses and provided complete protection against viremia and joint inflammation upon challenge using an adult wild-type mouse model of CHIKV disease with the R&#x000e9;union Island CHIKV strain [<xref rid="B96-vaccines-12-01344" ref-type="bibr">96</xref>]. The other compared BEVS expressed CHKV VLPs to BEVS expressed CHKV glycoproteins E1 and E2 subunits and showed that the VLPs provided a superior immune response and protection against CHKV-induced disease in mice [<xref rid="B97-vaccines-12-01344" ref-type="bibr">97</xref>].</p><p>A classical swine fever (CSF) BEVS subunit vaccine developed in Vietnam was shown to be safe to administer and effectively stimulated protective immunity against CSFV with a two-dose vaccination [<xref rid="B98-vaccines-12-01344" ref-type="bibr">98</xref>]. The subunit VN91-E2 recombinant vaccine developed from the E2 CSFV envelope glycoprotein plus complete/incomplete adjuvant was shown to protect experimental pigs against high virulence CSFV&#x02019;s circulating in Vietnam, including genotypes 1.1, 1.2 and 2.2. E2-specific neutralizing antibodies appeared at day 24, peaked at day 35 and continued until day 63, but transplacental transmission was not described.</p><p>Intradermal immunization with VLPs of Ebolavirus (EBOV) GP and VP40 in guinea pigs were shown to induce broad antibody responses and all vaccinated guinea pigs survived challenge with a high dose of guinea pig-adapted EBOV, while all control animals succumbed to the challenge. Both IgG1 and IgG2 antibody responses were elicited by intradermal vaccination with BEVS-expressed EBOV VLPs representing a successful and possibly advantageous route of vaccine against EBOV infection [<xref rid="B99-vaccines-12-01344" ref-type="bibr">99</xref>].</p><p>BEVS recombinant VP2 proteins of epizootic hemorrhagic disease virus (EHDV)-2 and EHDV-6 were used as subunit vaccines in white-tailed deer against the disease. Following vaccination, no deer developed clinical disease or EHDV-induced lesions and in addition, no viral RNA was detected in blood or tissues [<xref rid="B100-vaccines-12-01344" ref-type="bibr">100</xref>].</p><p>Pandemic influenza H1N1 proteins HA, NA and M1 were produced as VLPs using the BEVS and were demonstrated to induce immunity and protect pigs from pandemic influenza challenge. The vaccinations induced robust levels of serum IgG, mucosal IgA and viral neutralizing antibodies. Following challenge with pandemic H1N1 2009, pigs showed reduced lung lesions, viral shedding and the inhibition of viral replication in the lungs compared to unvaccinated pigs [<xref rid="B101-vaccines-12-01344" ref-type="bibr">101</xref>].</p><p>Drosophila S2 cells were used to express recombinant Lassa virus (LASV) glycoprotein (GP) elicited high antibody titres when formulated with a suitable adjuvant after two doses [<xref rid="B88-vaccines-12-01344" ref-type="bibr">88</xref>]. The BEVS has been demonstrated to express Rift Valley fever virus (RVFV) Gn and Gc glycoproteins, which elicited strong neutralizing antibody responses in sheep and conferred complete protection in all vaccinated sheep demonstrated by the prevention of viremia and fever and the absence of RVFV-associated histopathological lesions [<xref rid="B104-vaccines-12-01344" ref-type="bibr">104</xref>,<xref rid="B105-vaccines-12-01344" ref-type="bibr">105</xref>].</p><p>Recently, insect cell lines and the baculovirus expression vector system have been used to produce SARS-CoV-2 proteins and VLPs with success [<xref rid="B105-vaccines-12-01344" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-12-01344" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-12-01344" ref-type="bibr">107</xref>,<xref rid="B108-vaccines-12-01344" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-12-01344" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-12-01344" ref-type="bibr">110</xref>,<xref rid="B111-vaccines-12-01344" ref-type="bibr">111</xref>,<xref rid="B112-vaccines-12-01344" ref-type="bibr">112</xref>]. SARS-CoV-2 RBD proteins have been expressed and purified in Tni insect cells in a baculovirus mediated Bac-to-Bac expression system in three separate studies, which showed high neutralizing titres [<xref rid="B112-vaccines-12-01344" ref-type="bibr">112</xref>] and protective immunity in NHPs [<xref rid="B105-vaccines-12-01344" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-12-01344" ref-type="bibr">106</xref>].</p><p>The E80 and EDIII domains of Zika virus (ZIKV) were produced using the Drosophila S2 cell line and were shown to efficiently elicit protective immunity in a mouse model. Mice were protected against lethal ZIKV challenge by the passive transfer of either anti-E80 or anti-EDIII sera [<xref rid="B89-vaccines-12-01344" ref-type="bibr">89</xref>].</p></sec></sec><sec id="sec4-vaccines-12-01344"><title>4. Mammalian Expression Systems</title><p>Mammalian protein expression systems have been modified and optimized over the past twenty years with Chinese hamster ovary (CHO), human embryonic kidney (HEK) and NS0 murine myeloma being the most preferred cell lines (<xref rid="vaccines-12-01344-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B113-vaccines-12-01344" ref-type="bibr">113</xref>]. The advantage to using mammalian cell lines is the requirement for post-translational modifications and the biosynthetic complexity of the proteins of interest [<xref rid="B114-vaccines-12-01344" ref-type="bibr">114</xref>]. Mammalian cells are more likely to express properly folded proteins with native post-translational modifications. Glycosylation patterns of mammalian-expressed secreted proteins are similar with those observed in vivo with minor differences between species of cell hosts [<xref rid="B115-vaccines-12-01344" ref-type="bibr">115</xref>,<xref rid="B116-vaccines-12-01344" ref-type="bibr">116</xref>]. For the expression of the protein of interest, this can be achieved by either transient expression using a plasmid or the generation of a stable cell line using lentiviral vectors. Unfortunately, most mammalian expression systems require using serum to support the growth of the cells, which is costly and requires additional safety testing of the serum used.</p><p>Lentiviral vectors play a major role in transferring the gene of interest into the mammalian cell line [<xref rid="B117-vaccines-12-01344" ref-type="bibr">117</xref>] and their broad tropism allows them to infect most mammalian cell types. Lentiviruses allow for stable integration into the host cell genome ensuring long term expression for stable cell line generation. They can infect both dividing and non-dividing cells such as hepatocytes and neurons, which are known to be difficult to infect. They can deliver transgene fragments as large as 10 kb (~350 kDa), which is well within the range of viral vaccine candidates of 100&#x02013;200 kDa, and great effort has been put into developing recombinant lentiviruses for clinical and research purposes with viral vaccine development being one major use. Precautions are needed to ensure that replication-competent lentiviruses are not accidentally generated via recombination between the delivered and endogenous viral elements in the producer cells [<xref rid="B118-vaccines-12-01344" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-12-01344" ref-type="bibr">119</xref>].</p><p>Lentiviral delivery systems have evolved over three generations to reduce biosafety risk. The first-generation system is no longer in use due to biosafety risks. The second-generation system splits essential components of the lentiviral system across three plasmids&#x02014;transfer, packaging and envelope&#x02014;that are delivered separately for safety. The transfer plasmid encodes for the transgene and contains cis-acting elements essential for the transcription of viral mRNA and genome packaging. The packaging plasmid is provided in trans and only encodes the essential trans-acting genes required for the entry and integration of the viral genome, and the envelope plasmid contains genes encoding for envelope proteins. The third generation of lentiviral vectors almost completely eliminates dangerous lentiviral recombination events by splitting the viral genome into four plasmids: the packaging plasmid containing only the packaging genes (gag and pol), a regulator plasmid containing only the regulatory gene (rev), a plasmid carrying only the envelope gene (env) and a transgene plasmid containing the gene of interest for producing the vaccine subunit protein [<xref rid="B119-vaccines-12-01344" ref-type="bibr">119</xref>,<xref rid="B120-vaccines-12-01344" ref-type="bibr">120</xref>]. Although the third generation is significantly safer, its viral yield is typically lower than that of the second-generation system.</p><p>As tropism is determined by the glycoproteins on the surface of the virus, the tropism of a lentivirus can be further broadened by replacing the HIV-1 env glycoprotein with the envelope glycoprotein (G) from the vesicular stomatitis virus (VSV-G). This widens the range of cell types the virus can bind to [<xref rid="B116-vaccines-12-01344" ref-type="bibr">116</xref>,<xref rid="B117-vaccines-12-01344" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-12-01344" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-12-01344" ref-type="bibr">119</xref>]. Lentiviral vectors have a comparatively high capacity for encoding transgenes and can be engineered with improved safety and efficiency parameters for high transduction efficiency, low anti-vector host immunity, low genotoxicity and persistent gene expression [<xref rid="B121-vaccines-12-01344" ref-type="bibr">121</xref>,<xref rid="B122-vaccines-12-01344" ref-type="bibr">122</xref>].</p><p>Transient gene expression is the temporary expression of genes following transfection with a plasmid using transfection reagents such as polyethylenimine (PEI) [<xref rid="B123-vaccines-12-01344" ref-type="bibr">123</xref>,<xref rid="B124-vaccines-12-01344" ref-type="bibr">124</xref>]. The use of suspension-adapted CHO and HEK cell lines, together with optimized commercial media and inexpensive transfection agents, has allowed transient transfection to be used at production scale to hundreds of litres in bioreactors [<xref rid="B125-vaccines-12-01344" ref-type="bibr">125</xref>]. This approach requires several milligrams of high-quality, purified plasmid DNA produced by <italic toggle="yes">E. coli</italic>, free of endotoxin and other contaminants [<xref rid="B123-vaccines-12-01344" ref-type="bibr">123</xref>,<xref rid="B126-vaccines-12-01344" ref-type="bibr">126</xref>].</p><p>Regulated, inducible expression in mammalian cells is often desirable, especially when the product is cytotoxic or cytostatic. Inducible expression is achieved using bacterial gene control elements and transactivator proteins, for example, combinations of hybrid viral transactivators, bacterial repressor proteins and simple chemical inducers provide induction ratios of over 1000-fold [<xref rid="B127-vaccines-12-01344" ref-type="bibr">127</xref>].</p><p>Stable mammalian protein expression can be induced when the transgene expression cassette is replicated extra-chromosomally using viral proteins and <italic toggle="yes">cis</italic>-acting elements, or when integrated into the host genome. This is usually expected for large-scale production and control over protein quality and homogeneity. Transient expression experiments require large quantities of consumable reagents such as transfection reagents and plasmid DNA. Protein yield is often dependent on the transfection efficiency, which varies considerably from one experiment or technician to the next. Protein transiently produced from older cells may not be qualitatively equivalent to protein produced in cells from an earlier passage due to the transformed nature of the cell lines used which increases protein heterogeneity and decreasing protein quality [<xref rid="B75-vaccines-12-01344" ref-type="bibr">75</xref>,<xref rid="B128-vaccines-12-01344" ref-type="bibr">128</xref>]. Transient expression requires much less time compared to establishing a stable clonal cell line. However, if several transient transfections are required, the cost of repeated transfections will make the time commitment required for the stable cell line production worthwhile [<xref rid="B17-vaccines-12-01344" ref-type="bibr">17</xref>].</p><p>Stable transgene expression can be maintained using either of two strategies: episomal expression or chromosomal integration and expression. Episomal vectors based on viral elements promote autonomous replication and retention in the nucleus and rely on a <italic toggle="yes">cis</italic>-acting viral origin of replication and <italic toggle="yes">trans</italic>-acting virally encoding protein [<xref rid="B129-vaccines-12-01344" ref-type="bibr">129</xref>]. Transgene amplification copy numbers can vary drastically, which is a factor that makes it less desirable than stable chromosomal integration [<xref rid="B129-vaccines-12-01344" ref-type="bibr">129</xref>]. Stable chromosomal integration and expression is reliant on the presence of a suitable selection marker for isolating and screening clonal cell lines. Several selection systems have been developed, such as methotrexate/DHFR and glutamine synthetase protein expression systems, as well as conventional selectable drug markers [<xref rid="B130-vaccines-12-01344" ref-type="bibr">130</xref>,<xref rid="B131-vaccines-12-01344" ref-type="bibr">131</xref>]. Stable expression is maintained by physically coupling the transgene expression cassette with a dominant selection marker. One issue with this method is that chromosomal integration is usually a random event, which in some cases results in gene silencing. These integration &#x0201c;position effects&#x0201d; are significant therefore clonal screening is necessary to achieve desirable levels of protein expression [<xref rid="B17-vaccines-12-01344" ref-type="bibr">17</xref>].</p><p>The CHO cell line is widely used due to its ability to grow at high densities in suspension cultures and its ease of adaptation to serum free conditions. This adaptability also has drawbacks as each production target requires the selection of clones that exhibit the necessary phenotypic properties. These include cell doubling time and long-term viability under bioprocess conditions to ensure product quality/uniformity. Even when a appropriate CHO clone is identified, phenotypic drift can occur, making working with CHO clones challenging [<xref rid="B132-vaccines-12-01344" ref-type="bibr">132</xref>]. For protein expression optimization in CHO cells, glycosylation has been shown to be important, since variation in glycosylation patterns affects protein function and stability, and in addition, non-natural glycoforms can be immunogenic [<xref rid="B131-vaccines-12-01344" ref-type="bibr">131</xref>,<xref rid="B132-vaccines-12-01344" ref-type="bibr">132</xref>,<xref rid="B133-vaccines-12-01344" ref-type="bibr">133</xref>,<xref rid="B134-vaccines-12-01344" ref-type="bibr">134</xref>,<xref rid="B135-vaccines-12-01344" ref-type="bibr">135</xref>]. This applies strongly to the terminal &#x003b1;-Gal epitope, which has been added to proteins produced in murine cell lines and is capable of inducing unwanted immune responses in humans [<xref rid="B136-vaccines-12-01344" ref-type="bibr">136</xref>]. It is therefore essential that CHO production clones are monitored to ensure proper glycosylation. The overexpression of appropriate glycosyltransferases can be used to enhance glycan quality by modifying oligosaccharide structures on a recombinant protein. Improvements are either made by increasing the homogeneity of native structures or introducing non-host cell residues to specialize glycan quality and function [<xref rid="B2-vaccines-12-01344" ref-type="bibr">2</xref>]. Medium supplementation with glucosamine and <italic toggle="yes">N</italic>-acetylmannosamine allowed for the glycosylation control of a recombinant glycoprotein produced in both NS0 and CHO cells [<xref rid="B137-vaccines-12-01344" ref-type="bibr">137</xref>,<xref rid="B138-vaccines-12-01344" ref-type="bibr">138</xref>].</p><sec><title>Applications of Mammalian Expression System</title><p>Several licenced (<xref rid="vaccines-12-01344-t004" ref-type="table">Table 4</xref>) and experimental (<xref rid="vaccines-12-01344-t005" ref-type="table">Table 5</xref>) vaccines have been developed using the mammalian expression system. </p><p>The CHO cell line been used to produce a novel subunit vaccine of the CSFV-E2 recombinant fusion protein as a mucosal vaccine. A major issue with most subunit vaccines is the inability to stimulate a significant cell-mediated response, but this study was able to show that the CHO-expressed CSFV-E2-FC protein enhanced IgA levels and induced a CSFV-specific T cell immune response and Th1-biased cellular immune response in pigs. Notably, the efficacy of this mucosal subunit vaccine was found to be comparable to the commercial live-attenuated CSFV C-strain vaccine [<xref rid="B152-vaccines-12-01344" ref-type="bibr">152</xref>].</p><p>A Hendra virus (HeV) G glycoprotein subunit vaccine produced using a soluble form of the HeV attachment (G) envelope glycoprotein (sG<sub>HeV</sub>) made in human HeLa [<xref rid="B155-vaccines-12-01344" ref-type="bibr">155</xref>,<xref rid="B161-vaccines-12-01344" ref-type="bibr">161</xref>] and human 293F [<xref rid="B156-vaccines-12-01344" ref-type="bibr">156</xref>] cells demonstrated protective efficacy in African Green Monkeys [<xref rid="B154-vaccines-12-01344" ref-type="bibr">154</xref>], cats [<xref rid="B155-vaccines-12-01344" ref-type="bibr">155</xref>] and ferrets [<xref rid="B156-vaccines-12-01344" ref-type="bibr">156</xref>] and is currently used to protect horses against Hendra virus in Australia [<xref rid="B157-vaccines-12-01344" ref-type="bibr">157</xref>]. All studies used CpG oligodeoxynucleotide and Alhydrogel<sup>TM</sup> as adjuvants. Nipah virus (NiV) and HeV are both closely related, zoonotic paramyxoviruses. In African Green Monkeys, vaccination provided complete protection against subsequent NiV infection with no evidence of clinical disease, virus replication or pathology observed in any challenged subjects [<xref rid="B154-vaccines-12-01344" ref-type="bibr">154</xref>]. Mucosal immunity was generated in cats vaccinated with recombinant sG<sub>HeV</sub> as all vaccinated cats possessed antigen-specific IgA on the mucosa. Upon oronasal challenge with NiV, all vaccinated cats were protected from disease even though virus was detected on day 21 post challenge in one cat [<xref rid="B155-vaccines-12-01344" ref-type="bibr">155</xref>].</p><p>Since the start of the COVID-19 pandemic, several studies have been conducted using mammalian expression systems to produce SARS-CoV-2 proteins for serological and vaccine research [<xref rid="B159-vaccines-12-01344" ref-type="bibr">159</xref>,<xref rid="B160-vaccines-12-01344" ref-type="bibr">160</xref>,<xref rid="B161-vaccines-12-01344" ref-type="bibr">161</xref>,<xref rid="B162-vaccines-12-01344" ref-type="bibr">162</xref>,<xref rid="B163-vaccines-12-01344" ref-type="bibr">163</xref>,<xref rid="B164-vaccines-12-01344" ref-type="bibr">164</xref>,<xref rid="B165-vaccines-12-01344" ref-type="bibr">165</xref>,<xref rid="B166-vaccines-12-01344" ref-type="bibr">166</xref>,<xref rid="B167-vaccines-12-01344" ref-type="bibr">167</xref>]. The HPLC analysis of RBD produced in HEK-293T cells was highly homogenous with a sharp elution peak in a reverse phase C18 column and was shown to produce soluble and properly folded polypeptides [<xref rid="B163-vaccines-12-01344" ref-type="bibr">163</xref>]. Another study, also using HEK-293 cells produced S1 and N proteins that were effective to identify sera from patients positive for COVID-19 by ELISA and immunofluorescence assays [<xref rid="B168-vaccines-12-01344" ref-type="bibr">168</xref>]. The use of engineered ferritin fused to viral immunogens has also been used to produce RBD vaccines against SARS-CoV-2 [<xref rid="B159-vaccines-12-01344" ref-type="bibr">159</xref>]. Here, the human codon-optimized RBD was fused to the IL-2 signal peptide at the amino terminus and ferritin at the C terminus to generate an RBD-ferritin fusion. These fusion proteins were readily purified from supernatants of transfected HEK-293 cells. Ferrets were then immunized with the RBD-ferritin fusion plus AddaVax adjuvant and challenged with two different doses of SARS-CoV-2. At challenge doses, the RBD-nanoparticle immunized animals showed strong neutralizing antibody responses and rapid viral clearance in nasal washes and lung tissue vs. control animals. Another study involved the use of an HEK-generated, pan-HLA-DR monoclonal antibody fused to SARS-CoV-2 RBD used as a vaccine in ferrets, which elicited robust protection, strong neutralizing antibody responses and viral clearance in ferret nasal washes vs. control animals [<xref rid="B160-vaccines-12-01344" ref-type="bibr">160</xref>].</p></sec></sec><sec id="sec5-vaccines-12-01344"><title>5. Yeast Expression Systems</title><p>Yeast is the simplest unicellular eukaryotic organism, and the species <italic toggle="yes">Saccharomyces cerevisiae</italic> is just as well studied and characterized as <italic toggle="yes">E. coli</italic>. Hepatitis B virus and HPV recombinant subunit vaccines produced in yeast are the first approved recombinant vaccines for human use [<xref rid="B169-vaccines-12-01344" ref-type="bibr">169</xref>,<xref rid="B170-vaccines-12-01344" ref-type="bibr">170</xref>]. The two major systems used for yeast protein expression are <italic toggle="yes">S. cerevisiae</italic> and <italic toggle="yes">Pichia pastoris</italic> (<xref rid="vaccines-12-01344-f005" ref-type="fig">Figure 5</xref>) [<xref rid="B2-vaccines-12-01344" ref-type="bibr">2</xref>]. Yeast systems have been able to produce high yields of secreted recombinant protein while also being fast and relatively inexpensive [<xref rid="B171-vaccines-12-01344" ref-type="bibr">171</xref>,<xref rid="B172-vaccines-12-01344" ref-type="bibr">172</xref>]. Culture media for yeast systems can be much less expensive than media for insect or mammalian cell culture, and yeast can easily be cultured to high densities in reusable shaker flasks or at higher densities in oxygen-sparged fermenters. The time commitment for developing a yeast expression cell line is relatively low, cell doubling is rapid and expression experiments are relatively straightforward [<xref rid="B173-vaccines-12-01344" ref-type="bibr">173</xref>,<xref rid="B174-vaccines-12-01344" ref-type="bibr">174</xref>]. One well-documented setback is that yeast express several proteases that can lead to significant, but often protein-dependent, protein degradation, though protease deficient cell lines do exist [<xref rid="B174-vaccines-12-01344" ref-type="bibr">174</xref>,<xref rid="B175-vaccines-12-01344" ref-type="bibr">175</xref>].</p><p>Beyond <italic toggle="yes">S. cerevisiae</italic>, there are other yeast species (<italic toggle="yes">P. pastoris</italic>, <italic toggle="yes">Yarrowia lipolytica</italic> and <italic toggle="yes">Hansenula polymorpha</italic>) that are &#x02018;generally regarded as safe&#x02019; (GRAS) for the production of therapeutics and heterologous proteins [<xref rid="B176-vaccines-12-01344" ref-type="bibr">176</xref>]. Their lower hyper-mannosylation compared to <italic toggle="yes">S. cerevisiae</italic> makes them good candidates for the secretion of human glycoproteins, especially by engineering their glycosylation patterns to resemble human post-translational modification pathways [<xref rid="B177-vaccines-12-01344" ref-type="bibr">177</xref>]. Both <italic toggle="yes">Pichia</italic> and <italic toggle="yes">Saccharomyces</italic> construct high-mannose-type N-glycosylations on proteins and are incapable of producing more complex glycosylation patterns often needed for efficient bioactivity in mammalian proteins [<xref rid="B178-vaccines-12-01344" ref-type="bibr">178</xref>]. This may be important, depending on the specific protein being produced. Proteins produced in yeast have a large number of O-glycans and it is usually difficult to predict glycosylation sites. N-glycosylation has been widely studied in yeast, and the signalling pathway has been found to be similar to that in mammalian cells. Glycosyltransferases in mammalian cells are significantly higher than in yeast such as <italic toggle="yes">S. cerevisiae.</italic> Glycosylated proteins in yeast species are also significantly longer than in mammalian cells but the components in mammalian cells are more complex. The engineering of N-glycosylation pathways in several yeast species has allowed for the production of proteins with hybrid N-glycosylation, galactosylation and sialyation complex glycans [<xref rid="B179-vaccines-12-01344" ref-type="bibr">179</xref>].</p><p>Though yeast can provide a robust expression system for many secreted proteins, their divergence from native mammalian post-translational modifications and variability in levels of expression renders them problematic for viral vaccine development, which usually requires the expression of complex mammalian viral surface glycoproteins. Sometimes more than 100 mannose residues are attached, which is called hyper-glycosylation. The artificial in vivo glycoengineering of <italic toggle="yes">P. pastoris</italic> strains has allowed for the development of practical tools for designer glycosylation pathways. This would allow yeast to produce different kinds of glycosylated proteins [<xref rid="B180-vaccines-12-01344" ref-type="bibr">180</xref>] valuable for recombinant viral vaccine production. Large amounts of protein secreted into an almost protein-free medium makes scaling-up, as well as downstream purification, a much easier task. <italic toggle="yes">Pichia</italic> also does not produce endotoxin, which is a major problem in bacterial expression, and since proteins produced in this yeast system are usually folded correctly and secreted into the medium, the fermentation of genetically engineered <italic toggle="yes">P. pastoris</italic> is an alternative to the <italic toggle="yes">E.coli</italic> system [<xref rid="B181-vaccines-12-01344" ref-type="bibr">181</xref>]. Yeast cells are also known to be able to enhance expression of MHC and costimulatory molecules on the surface of dendritic cells or antigen presenting cells, which allows for the efficient activation of T lymphocytes promoting cell-mediated immunity [<xref rid="B178-vaccines-12-01344" ref-type="bibr">178</xref>,<xref rid="B179-vaccines-12-01344" ref-type="bibr">179</xref>,<xref rid="B180-vaccines-12-01344" ref-type="bibr">180</xref>]. Though most yeast expression systems produce oligomannose glycans, the polymannose forms of these can be produced and result in strong inflammatory responses in humans. These are sensed by pattern recognition receptors on innate immune cells [<xref rid="B182-vaccines-12-01344" ref-type="bibr">182</xref>,<xref rid="B183-vaccines-12-01344" ref-type="bibr">183</xref>,<xref rid="B184-vaccines-12-01344" ref-type="bibr">184</xref>]. It has been seen that mannans lacking &#x003b2;-1,2-mannoside residues tend to induce the production of higher levels of inflammatory cytokines, such as IL-6 and TNF-&#x003b1;, in mouse DCs [<xref rid="B185-vaccines-12-01344" ref-type="bibr">185</xref>].</p><p>There is an emerging trend toward using <italic toggle="yes">P. pastoris</italic> over <italic toggle="yes">S. cerevisiae</italic> as the choice yeast host species for biopharmaceutical production made evident and as a result of the increased number of patents and publications using <italic toggle="yes">P. pastoris</italic> (see Applications). Host improvements via synthetic biology applications for improved promoters and secretion signals, the development of protease-deficient strains and the humanization of glycosylation patterns can further enhance the recombinant vaccine production potential of several yeast species and has been well-documented in <italic toggle="yes">P. pastoris</italic>. A further advantage includes an increasing toolkit, including the in silico mathematical models of metabolism and genomic approaches for the identification of systems regulating protein production that support the use of <italic toggle="yes">P.pastoris</italic> for biopharmaceutical production [<xref rid="B186-vaccines-12-01344" ref-type="bibr">186</xref>].</p><sec><title>Applications of Yeast Expression System</title><p>The best-known yeast-expressed vaccine is the licenced quadrivalent HPV vaccine Gardasil, which contains VLPs of hrHPV16 and 18 and lrHPV6 and 11, produced in yeast with aluminum hydroxyphosphate sulphate as an adjuvant [<xref rid="B187-vaccines-12-01344" ref-type="bibr">187</xref>]. Some of the more recent antigens expressed by various species of yeast are shown in <xref rid="vaccines-12-01344-t006" ref-type="table">Table 6</xref>.</p><p>Hepatitis C virus envelope glycoproteins E1E2, in both <italic toggle="yes">S. cerevisiae</italic> and <italic toggle="yes">H. polymorpha</italic> as vaccine candidates, have also been included in pending patents. The <italic toggle="yes">H.</italic> polymorpha system produced E1E2 proteins, which were not hyperglycosylated (as the <italic toggle="yes">S. cerevisiae</italic> was) and had sugar chains with a length similar to those produced in mammalian cells. A <italic toggle="yes">H. polymorpha</italic>-derived HCV-envelope protein vaccine were able to clear HCV infection in chimpanzees following challenge [<xref rid="B220-vaccines-12-01344" ref-type="bibr">220</xref>].</p><p>The <italic toggle="yes">P. pastoris</italic> system has been used to produce chikungunya VLPs (CHIK-VLPs), which were evaluated both in vivo and in vitro for efficacy as vaccine candidates. The VLPs elicited high titres of antibodies that recognized native CHIKV and neutralized different strains of CHIKV. <italic toggle="yes">P. pastoris</italic> is in multiple patent filings for expression of flavivirus VLPs proteins as vaccine candidates [<xref rid="B221-vaccines-12-01344" ref-type="bibr">221</xref>]. The RBD of SARS-CoV-2 has been produced in <italic toggle="yes">P. pastoris</italic> in several studies with appropriate N- and O-glycosylation [<xref rid="B163-vaccines-12-01344" ref-type="bibr">163</xref>,<xref rid="B207-vaccines-12-01344" ref-type="bibr">207</xref>,<xref rid="B222-vaccines-12-01344" ref-type="bibr">222</xref>,<xref rid="B223-vaccines-12-01344" ref-type="bibr">223</xref>,<xref rid="B224-vaccines-12-01344" ref-type="bibr">224</xref>,<xref rid="B225-vaccines-12-01344" ref-type="bibr">225</xref>]. The RBD of SARS coronavirus was expressed in <italic toggle="yes">P.pastoris</italic> X-33. When adjuvanted with aluminum hydroxide, it elicited high neutralizing antibody titres and high RBD-specific antibody titres [<xref rid="B226-vaccines-12-01344" ref-type="bibr">226</xref>]. RBD produced in the <italic toggle="yes">P. pastoris</italic> X-33 system and adjuvanted with 3M-052 alum was shown to induce robust humoural immunity, strong and durable RBD-specific CD8<sup>+</sup> and TH1-biased CD4<sup>+</sup> T cell responses and significantly reduced viral load in LRT and URT in rhesus macaques after SARS-CoV-2 challenge [<xref rid="B223-vaccines-12-01344" ref-type="bibr">223</xref>]. With the recombinant protein fused to <italic toggle="yes">Saccharomyces cerevisiae</italic> &#x003b1;-factor secretion signal, <italic toggle="yes">P. pastoris</italic> expression yielded 10&#x02013;13 mg/L in cell culture vs. 5 mg/L in an HEK293 cell line [<xref rid="B163-vaccines-12-01344" ref-type="bibr">163</xref>]. Yeast-derived SARS-CoV-2 RBD is highly glycosylated and, compared to mammalian and insect cell-derived RBD [<xref rid="B105-vaccines-12-01344" ref-type="bibr">105</xref>,<xref rid="B227-vaccines-12-01344" ref-type="bibr">227</xref>], yeast-derived RBD has a very distinct glycosylation pattern. In <italic toggle="yes">P. pastoris</italic>-derived proteins, N-glycans are high-mannose type without core fucose [<xref rid="B228-vaccines-12-01344" ref-type="bibr">228</xref>] and O-glycans are linear chains of four to five &#x003b1;-linked mannose residues [<xref rid="B229-vaccines-12-01344" ref-type="bibr">229</xref>]. RBD protein contains complex N-glycans and mainly Core-1 O-glycans when produced in CHO cells [<xref rid="B230-vaccines-12-01344" ref-type="bibr">230</xref>]. From several studies among expression systems discussed so far, the difference in glycosylation between yeast, CHO and insect-produced RBDs seems to not influence their immunogenicity. PichiaPink&#x02122; Strain 1 (Invitrogen, Waltham, MA, USA) cells were also used to produce SARS-CoV-2 RBD as both monomers and dimers, which were shown to elicit broadly neutralizing antibodies and long-lasting protective immunity against SARS-CoV-2 in mice [<xref rid="B207-vaccines-12-01344" ref-type="bibr">207</xref>]. However, these authors deglycosylated their purified RBD proteins before use in their experiments. Deglycosylation was performed under reducing conditions where purified RBD was denatured then digested with peptide-N-glycosidase F or endo-N-acetylglucosaminidase.</p><p>Patent filings have been disclosed for <italic toggle="yes">S. cerevisiae</italic> expressed VP1-4 proteins of enterovirus 71 (EV71) VLPs and for Coxsackievirus A16 (CA16) VLPs, both of which cause HFMD [<xref rid="B187-vaccines-12-01344" ref-type="bibr">187</xref>]. The VLPs of both viruses showed structural similarities to VLPs produced in EV71-or CA16-infected mammalian cells and mice immunized with the respective VLPs elicited strong and specific neutralizing antibodies and cellular responses that protected neonatal mice against lethal EV71 [<xref rid="B231-vaccines-12-01344" ref-type="bibr">231</xref>] and CA16 [<xref rid="B232-vaccines-12-01344" ref-type="bibr">232</xref>] challenge. Yeasts have been used for the production of other viral subunit vaccine antigens as well such as hantavirus, HIV1, poliovirus, rabies and influenza, which have been reviewed previously [<xref rid="B233-vaccines-12-01344" ref-type="bibr">233</xref>].</p></sec></sec><sec id="sec6-vaccines-12-01344"><title>6. Algal Expression Systems</title><p>Green algae are highly diverse and consist of unicellular and multicellular species. The best characterized and the alga of most interest in vaccine production is the unicellular <italic toggle="yes">Chlamydomonas reinhardtii</italic>. The nucleus, chloroplast and mitochondria of this algal species are easily transformed, and there is a short culture period between generating initial transformants and scale-up to production volumes. Gametogenesis can be induced that allows for genetic crossing; it can be grown either heterotrophically or phototropically, and a wide range of promoters are available and secreted, and glycosylated proteins can be produced and grown in cultures up to 500,000 L in a contained, cost-effective manner (<xref rid="vaccines-12-01344-f006" ref-type="fig">Figure 6</xref>) [<xref rid="B234-vaccines-12-01344" ref-type="bibr">234</xref>,<xref rid="B235-vaccines-12-01344" ref-type="bibr">235</xref>]. DNA can be delivered via mechanical agitation, surfactant permeabilization, electroporation, particle bombardment or bacterial DNA transfer using conjugation or Agrobacterium-mediated [<xref rid="B236-vaccines-12-01344" ref-type="bibr">236</xref>,<xref rid="B237-vaccines-12-01344" ref-type="bibr">237</xref>]. Emerging techniques also exist, such as cell-penetrating peptides, polymers, metal&#x02013;organic frameworks, nanoparticles and liposomes [<xref rid="B238-vaccines-12-01344" ref-type="bibr">238</xref>,<xref rid="B239-vaccines-12-01344" ref-type="bibr">239</xref>,<xref rid="B240-vaccines-12-01344" ref-type="bibr">240</xref>]. Algae exhibit three times greater photosynthetic efficiency than plants and contain large amounts of protein ranging from 50 to 70% of their fresh weight, which is a much higher percentage than the edible and harvestable parts of any higher plant or animal system [<xref rid="B234-vaccines-12-01344" ref-type="bibr">234</xref>]. Algae can be lyophilized, and studies have been performed on algal-produced vaccines where dried algae was stored at room temperature for six months [<xref rid="B240-vaccines-12-01344" ref-type="bibr">240</xref>] and up to twenty months [<xref rid="B241-vaccines-12-01344" ref-type="bibr">241</xref>]. Protein purified from these stored algae was able to demonstrate antigen effectiveness similar to fresh algae, showing that algae containing unpurified antigen can be stored and transported without the need for a cold chain.</p><p>The accumulation of biomass in algae is rapid and the entire biomass can be used for vaccine production, as opposed to plants that expend energy-producing tissues that are not used in the vaccine or cannot be easily harvested. Algae are also not restricted by seasons or soil fertility and media can be recycled to minimize water and nutrient loss. There is no concern regarding the cross-contamination of nearby food crops and enclosed bioreactors can be used to increase biomass yields and reduce concerns of environmental escape [<xref rid="B240-vaccines-12-01344" ref-type="bibr">240</xref>,<xref rid="B242-vaccines-12-01344" ref-type="bibr">242</xref>]. While it is evident that algae can produce complex vaccine antigens that are able to elicit immunogenic responses, identifying adjuvants to complement the antigens is critical. Viral antigens in particular require proper post-translational modification, such as glycosylation to be recognized properly by the immune system, but glycosylation does not occur in the chloroplast [<xref rid="B243-vaccines-12-01344" ref-type="bibr">243</xref>,<xref rid="B244-vaccines-12-01344" ref-type="bibr">244</xref>,<xref rid="B245-vaccines-12-01344" ref-type="bibr">245</xref>], so would not be considered suitable for viral vaccine antigen production.</p><p><italic toggle="yes">Dunaliella salina</italic> is another species of algae that has been used to produce recombinant protein. It has a strong adaptability to the environment and can live in various salt concentrations from 0.2% to 35% salt saturation, which prevents contamination from other microorganisms [<xref rid="B246-vaccines-12-01344" ref-type="bibr">246</xref>]. Like <italic toggle="yes">C. reinhardtii</italic>, <italic toggle="yes">D. salina</italic> is photosynthetic and can be easily, rapidly and inexpensively cultured by large-scale factory farming. As a eukaryotic organism, it can produce and modify recombinant proteins at the levels of transcription and translation. <italic toggle="yes">D. salina</italic> lacks a rigid cell wall and can be easily transformed with exogenous genes [<xref rid="B247-vaccines-12-01344" ref-type="bibr">247</xref>].</p><sec><title>Applications of Algal Expression System</title><p>In recent years, several other algal species have been investigated for their protein expression uses, such as other green algae, diatoms and cyanobacteria, in order to increase host range compatibility [<xref rid="B243-vaccines-12-01344" ref-type="bibr">243</xref>,<xref rid="B244-vaccines-12-01344" ref-type="bibr">244</xref>,<xref rid="B245-vaccines-12-01344" ref-type="bibr">245</xref>]. Over twenty species of algae have been transformed and several promoters and selectable markers have been characterized for many of these species [<xref rid="B248-vaccines-12-01344" ref-type="bibr">248</xref>,<xref rid="B249-vaccines-12-01344" ref-type="bibr">249</xref>,<xref rid="B250-vaccines-12-01344" ref-type="bibr">250</xref>,<xref rid="B251-vaccines-12-01344" ref-type="bibr">251</xref>].</p><p>The RBD of the SARS-CoV-2 spike protein has been produced in algal systems using <italic toggle="yes">Chlamydomonas reinhardtii</italic> [<xref rid="B252-vaccines-12-01344" ref-type="bibr">252</xref>,<xref rid="B253-vaccines-12-01344" ref-type="bibr">253</xref>], <italic toggle="yes">Chlorella vulgaris</italic> [<xref rid="B254-vaccines-12-01344" ref-type="bibr">254</xref>] and <italic toggle="yes">Phaeodactylum tricornutum</italic> [<xref rid="B255-vaccines-12-01344" ref-type="bibr">255</xref>]. In one study, <italic toggle="yes">Nicotiana benthamiana</italic> agrobacterium-mediated transformation vectors were used to transiently express SARS-CoV-2 RBD in both <italic toggle="yes">Chlamydomonas reinhardtii</italic> and <italic toggle="yes">Chlorella vulgaris</italic> [<xref rid="B254-vaccines-12-01344" ref-type="bibr">254</xref>] but the biological characterization of the recombinant RBD to the ACE2 receptor as well as the long term expression levels beyond 72 h post-transformation was not investigated. Another study used nuclear transformation in <italic toggle="yes">C. reinhardtii</italic> [<xref rid="B252-vaccines-12-01344" ref-type="bibr">252</xref>], where stable nuclear genome integration vectors were able to generate recombinant RBD expression levels that were an order of magnitude higher than when using agrobacterium-mediated transformation [<xref rid="B254-vaccines-12-01344" ref-type="bibr">254</xref>] and maintained this expression for at least one year post transformation. This approach consisted of a nuclear-stable transformation, where a linear vector is randomly integrated in the genome to code a fusion protein RBD::mClover (RBD + a fluorescent protein for monitoring expression). Constructs aimed at inducing expression in the chloroplast and ER, and it was shown that the ER approach was deemed better allowing for yields up to 31 &#x003bc;g/g of fresh algae biomass. The purified RBD from ER-Golgi was also able to bind ACE2 at a similar affinity as mammalian-expressed RBD. It was discussed that higher expression levels using nuclear transformation stems from the use of endogenous promoters, UTRs and a codon-optimized RBD sequence. Using stronger endogenous or synthetic promoters in new transgene designs and the addition of more introns into the RBD coding sequence could be used to boost expression further. However, it is known that several chloroplast genome engineering approaches undertaken in algae that allow for the highest transgene expression also negatively affect the photosynthetic ability of the organism, which removes the option of low-cost photosynthetic cultivation [<xref rid="B256-vaccines-12-01344" ref-type="bibr">256</xref>]. Another method used is transient expression [<xref rid="B253-vaccines-12-01344" ref-type="bibr">253</xref>], which implies a short production time and has no need for clone selection and characterization or fusing the antigen to a protein partner, but still yields up to 4 &#x000b5;g/g. Where RBD has also been transiently expressed in <italic toggle="yes">N. benthamiana</italic> [<xref rid="B257-vaccines-12-01344" ref-type="bibr">257</xref>], yields of up to 8 &#x003bc;g of pure antigen/g leaf mass was recorded. The diatom <italic toggle="yes">Phaeodactylum tricornutum</italic> has an N-linked glycosylation pathway that is like that found in mammals and may be a reason that the RBD made in <italic toggle="yes">P. tricornutum</italic> is bioequivalent to the RBD made in mammalian cells. Expressed RBD in this system was similar to that in <italic toggle="yes">Chlamydomonas</italic> [<xref rid="B252-vaccines-12-01344" ref-type="bibr">252</xref>]. The RBD purified from whole cell extracts was essentially homogenous and possessed N-linked glycosylation, which suggests that a portion of the expressed RBD is transited through the ER/Golgi apparatus and may be secreted at too low levels to be detected or is not secreted at all. It is possible that other secretory peptides are better optimized for RBD expression and secretion. In purification attempts from <italic toggle="yes">P. tricornutum</italic>, 90&#x02013;95% of expressed RBD did not bind the Ni-affinity column in their first chromatography step and the majority of RBD was lacking all or some of the C-terminal 6x-His tag, which is possibly because this alga encodes a protease which cleaves the C-terminal 6x-His tag or was due to premature transcription termination, post-translational processing or premature translation termination. Different tags may be better suited for the expression and purification of protein by this algal species.</p></sec></sec><sec id="sec7-vaccines-12-01344"><title>7. Plant Expression Systems</title><p>Plant-based expression systems are cost-effective, have high scalability and greater safety as plants do not harbour mammalian pathogens (<xref rid="vaccines-12-01344-f007" ref-type="fig">Figure 7</xref>). Plants are also able to provide post-translational modifications and appropriate folding resulting in functional, bioactive proteins [<xref rid="B258-vaccines-12-01344" ref-type="bibr">258</xref>]. Protein production in plants can used either stable or transient expression of transgenes. For stable expression, transgenes can be in the nuclear genome of transgenic plants or plant cell lines or in the chloroplast genome of transplastomic plants. For the transient expression of transgenes in plants an agrobacterial or agroviral vector can be used [<xref rid="B258-vaccines-12-01344" ref-type="bibr">258</xref>]. Virtually any genetically transformable plant can be used to produce recombinant proteins. Alfalfa, cereal crops like corn, rice and barley, as well as tobacco, are the most widely used as biofactories for biopharmaceuticals [<xref rid="B259-vaccines-12-01344" ref-type="bibr">259</xref>].</p><p>A plant-expressed vaccine should be stable and allow for high expression levels and low production and storage costs. Maize grain has evolved to maintain its proteins in a stable environment to allow germination after years of dormancy, which is in contrast to vegetative matter and fruits which degrade soon after harvesting [<xref rid="B260-vaccines-12-01344" ref-type="bibr">260</xref>]. This long-term stability has been shown in recombinant proteins where their activity is retained for years stored in the maize grain, which in fact allows for long-term storage and transportation at ambient temperatures and the grain can be processed at will, as opposed to needing to process large batches immediately upon harvest [<xref rid="B261-vaccines-12-01344" ref-type="bibr">261</xref>]. The removal of oils by supercritical fluid extraction (SFE) can also increase the stability of the grains and the immune response may be enhanced upon SFE treatment [<xref rid="B262-vaccines-12-01344" ref-type="bibr">262</xref>]. For crop plants, there is a well-established infrastructure for their cultivation, harvest and storage. The protein in cereal grains and oilseeds is stable as these seeds can be stored for long periods of time. Legumes such as alfalfa and soybean can fix nitrogen from the atmosphere and therefore have fewer chemical requirements for growth.</p><p>Plant production strategies involve either stable nuclear expression, stable chloroplast expression, transient expression or suspension cultures [<xref rid="B263-vaccines-12-01344" ref-type="bibr">263</xref>]. Nuclear expression allows for the stable integration of transgenes into the genome of plant cells, which is regulated by the transcription of the gene of interest and then translation in the cytoplasm. <italic toggle="yes">Agrobacterium tumefaciens</italic>-mediated transformation is the most widely used and offers the simplest method for the genetic modification of crops with horizontal transgene transfer and consistent recombinant protein expression. This method, however, can sometimes result in gene silencing, transgene contamination risk, potential interactions with natural products and low yields (&#x0003c;1% of total soluble protein) and can be time consuming [<xref rid="B264-vaccines-12-01344" ref-type="bibr">264</xref>]. The two methods used involve plant pathogens as vectors, plant viral infection or agroinfiltration by <italic toggle="yes">A. tumefaciens</italic>. High expression efficiency has been observed, but the risk of viral vector contamination and the environment must be carefully considered [<xref rid="B265-vaccines-12-01344" ref-type="bibr">265</xref>]. Plant cell cultures grown in suspension show more promise than using whole plants and biosafety and environmental concerns can be overcome by using bioreactors to prevent cross-fertilization and the transmission of pollen. Production costs are lower than mammalian systems as they require simple media [<xref rid="B266-vaccines-12-01344" ref-type="bibr">266</xref>].</p><p>The past twenty years has allowed plant expression systems to address technical issues such as expression, yield, purity and reproducibility as well as regulatory expectations like cGMP manufacture and the demonstration of efficacy in pre-clinical and clinical trials. This has allowed plant expression systems to become a commercially appealing approach to develop viral vaccines. In addition to this, there has been a recent shift in the expectation of plants to produce orally administered vaccines to established platforms to produce correctly folded, bioactive proteins, which can be used as injectable vaccines [<xref rid="B259-vaccines-12-01344" ref-type="bibr">259</xref>]. The major concerns associated with the plant expressed viral/vaccine antigens are oral tolerance, allergenicity, gene transfer to conventional food supplies and potential detrimental environmental impact.</p><p>The first USDA-approved plant expressed vaccine was against Newcastle disease in poultry produced by Dow Agro Sciences and was approved in 2006. The vaccine comprises the recombinant haemagglutinin&#x02013;neuraminidase antigen expressed in transgenic tobacco suspension cells [<xref rid="B267-vaccines-12-01344" ref-type="bibr">267</xref>,<xref rid="B268-vaccines-12-01344" ref-type="bibr">268</xref>]. The CSF vaccine, HERBAVAC<sup>&#x000ae;</sup>, was licenced in South Korea. It is a fusion protein of the E2 antigen and the cellulose-binding domain (CBD) and does not contain the E<sup>rns</sup> antigen present in field strains or live-attenuated vaccine, making it possible for pigs vaccinated with HERBAVAC<sup>&#x000ae;</sup> to be distinguishable from pigs infected with field strains or vaccinated with the live-attenuated vaccines [<xref rid="B269-vaccines-12-01344" ref-type="bibr">269</xref>].</p><sec><title>Applications of Plant Expression System</title><p>Several plant-expressed viral antigens are in development (<xref rid="vaccines-12-01344-t007" ref-type="table">Table 7</xref>).</p><p>H1 and H5 VLP vaccines produced in <italic toggle="yes">Nicotiana benthamiana</italic> elicited both strong antibody responses and poly-functional, cross-reactive memory T cells persisting for at least 6 months post vaccination [<xref rid="B270-vaccines-12-01344" ref-type="bibr">270</xref>]. Plant-derived VLP vaccines addressed several limitations of currently licenced vaccines. The proteins included in their VLPs are based on the genetic sequence of currently circulating human influenza viruses as opposed to egg-adapted influenza strains for optimal growth. With alum adjuvant, a single intramuscular (IM) injection of 3 &#x003bc;g of a plant-made H7 VLP vaccine induced a robust HI antibody response in both mice and ferrets [<xref rid="B271-vaccines-12-01344" ref-type="bibr">271</xref>]. The authors were also able to demonstrate clear induction of a strong, antigen-specific, T-cell response after immunization in ferrets. The humoral and cell-mediated immune responses provided 100% protection after lethal challenge with H7N9 in mice and a reduction in clinical signs and virus load ferret nasal and lung washes 3 dpi. Two doses of the unadjuvanted vaccine provided improved protection in mice [<xref rid="B271-vaccines-12-01344" ref-type="bibr">271</xref>]. This plant-expressed VLP vaccine contains low biological reactivity lipopolysaccharide (LPS) from Agrobacterium, which has been demonstrated to elicit immunological activity and may act as an adjuvant itself [<xref rid="B271-vaccines-12-01344" ref-type="bibr">271</xref>]. It is possible that this LPS may be partially responsible for the better protection that was observed after two immunizations with the unadjuvanted VLP. An H6 VLP produced in <italic toggle="yes">Nicotiana benthamiana</italic> was used in a challenge study with a heterologous H6N2 influenza virus in chickens [<xref rid="B273-vaccines-12-01344" ref-type="bibr">273</xref>]. A single dose elicited an immune response comparable to a commercial H6N2 (inactivated) vaccine administered with two doses. The H6 VLP vaccine also significantly reduced the proportion of chicken shedding virus as well as the level of shedding by &#x0003e;100-fold in oral and &#x0003e;6-fold in cloacal swabs.</p><p>VLPs displaying an S protein of the infectious bronchitis virus was produced using <italic toggle="yes">Agrobacterium</italic>-mediated <italic toggle="yes">Nicotiana benthamiana</italic> transient expression system [<xref rid="B274-vaccines-12-01344" ref-type="bibr">274</xref>]. When adjuvanted with Emulsigen<sup>&#x000ae;</sup>-P, specific pathogen-free chickens immunized intramuscularly seroconverted after two weeks with mean HA-inhibition titres of 9.1 to 10 log<sub>2</sub> depending on the dose. Studies showing virus neutralization potential and/or protection have not been undertaken.</p><p><italic toggle="yes">N. benthamiana</italic> was used to produce HAC1 and HAI-05, recombinant HA antigens of influenza A virus. Both subunits induced significant haemagglutinin inhibition and virus neutralizing serum antibody titres in mice, rabbits and ferrets. The use of Alhydrogel<sup>TM</sup> adjuvant also provided a dose-sparing effect [<xref rid="B272-vaccines-12-01344" ref-type="bibr">272</xref>].</p><p>A study used pmE2:pFc2 expressed using transgenic plants instead of a transient expression system to produce a CSFV E2 vaccine antigen [<xref rid="B276-vaccines-12-01344" ref-type="bibr">276</xref>]. While transient expression is generally expected to produce higher amount of target protein than stably expressing transgenic plants [<xref rid="B277-vaccines-12-01344" ref-type="bibr">277</xref>], the authors used transgenic plants instead as in transient expression systems, the expression level of the target genes is not uniform. Transgenic plants provide the stable expression of recombinant genes once homozygous transgenic lines are generated, which leads to easier large-scale production than in the transient system. Economically, upstream processes in transient expression require additional infrastructure, which can be eliminated in the transgenic approach allowing for inexpensive recombinant vaccine production [<xref rid="B278-vaccines-12-01344" ref-type="bibr">278</xref>], without lipopolysaccharide contamination [<xref rid="B279-vaccines-12-01344" ref-type="bibr">279</xref>].</p><p>Plant-based manufacturing systems have advantages with scalability compared to tissue-culture and egg-based production platforms and other recombinant technologies with capacity limitations of large-scale bioreactors. In 2012, Medicago demonstrated production of 10 million doses of plant-based H1N1 influenza vaccine within a month, demonstrating the capacity of this system [<xref rid="B280-vaccines-12-01344" ref-type="bibr">280</xref>,<xref rid="B281-vaccines-12-01344" ref-type="bibr">281</xref>].</p><p>The plant-based production of SARS-CoV-2 antigens has been well studied over the past 3 years, where some of the main drawbacks have been poor reproducibility, antigen stability and bioavailability [<xref rid="B275-vaccines-12-01344" ref-type="bibr">275</xref>,<xref rid="B282-vaccines-12-01344" ref-type="bibr">282</xref>,<xref rid="B283-vaccines-12-01344" ref-type="bibr">283</xref>,<xref rid="B284-vaccines-12-01344" ref-type="bibr">284</xref>,<xref rid="B285-vaccines-12-01344" ref-type="bibr">285</xref>,<xref rid="B286-vaccines-12-01344" ref-type="bibr">286</xref>,<xref rid="B287-vaccines-12-01344" ref-type="bibr">287</xref>]. A plant expression vector containing SARS-CoV-2 RBD was transformed into <italic toggle="yes">Agrobacterium tumefaciens</italic> strain GV3101 cells by electroporation then injected into 6-week-old <italic toggle="yes">N. benthamiana</italic> leaves [<xref rid="B275-vaccines-12-01344" ref-type="bibr">275</xref>]. The RBD was then used to immunize mice and NHPs with and without alum and was shown to induce neutralizing antibodies in mice and NHPs. Challenge studies were not performed; however, it was observed that a mixed Th1/Th2 response was induced, and even without alum, a SARS-CoV-2 RBD-specific T cell response was also generated [<xref rid="B275-vaccines-12-01344" ref-type="bibr">275</xref>].</p></sec></sec><sec id="sec8-vaccines-12-01344"><title>8. Cell-Free Expression Systems</title><p>Cell-free expression systems (<xref rid="vaccines-12-01344-f008" ref-type="fig">Figure 8</xref>) (CFSs) replicate the biology of transcription and translation in the absence of a cell. Protein synthesis is initiated in vitro using cell extracts prepared from cells by lysis and several washing steps to remove cell debris and cellular mRNA/DNA [<xref rid="B288-vaccines-12-01344" ref-type="bibr">288</xref>,<xref rid="B289-vaccines-12-01344" ref-type="bibr">289</xref>]. The extracts contain the components required for transcription and translation such as aminoacyl-tRNA synthetases, ribosomes, factors necessary for elongation, initiation and transcription. These are combined with amino acids, energy substrates, template DNA, cofactors, salts and nucleotides, and this is varies depending on the biochemical properties of the antigen. Translation is then initiated by adding the linear or circular template DNA or mRNA and the process is allowed to occur at a specified temperature and time period [<xref rid="B290-vaccines-12-01344" ref-type="bibr">290</xref>].</p><p>This work was pioneered in the 1960s [<xref rid="B291-vaccines-12-01344" ref-type="bibr">291</xref>,<xref rid="B292-vaccines-12-01344" ref-type="bibr">292</xref>] with major achievements made well into the 2000s, where fundamental &#x02018;operating systems&#x02019; were established for proof-of-concept research [<xref rid="B293-vaccines-12-01344" ref-type="bibr">293</xref>]. The terms &#x02018;cell-free biology&#x02019; and &#x02018;cell-free expression systems&#x02019; have since evolved to mean much more than described above and now involves the addition of repressor molecules, chaperone proteins, non-native co-factors and substrates to improve the performance and productivity of expression reactions [<xref rid="B294-vaccines-12-01344" ref-type="bibr">294</xref>,<xref rid="B295-vaccines-12-01344" ref-type="bibr">295</xref>]. A plasmid containing the gene of interest is directly added to the cell-free expression system to initiate protein production [<xref rid="B296-vaccines-12-01344" ref-type="bibr">296</xref>]. CFSs can be stored as freeze-dried products allowing for simplified storage and applications [<xref rid="B297-vaccines-12-01344" ref-type="bibr">297</xref>,<xref rid="B298-vaccines-12-01344" ref-type="bibr">298</xref>].</p><p>Different CFS reaction formats have since been developed, from easily handled and scalable batch reactions with short reaction times but relatively low protein yields to complex dialysis systems known as continuous-flow cell-free and continuous exchange cell-free systems [<xref rid="B299-vaccines-12-01344" ref-type="bibr">299</xref>,<xref rid="B300-vaccines-12-01344" ref-type="bibr">300</xref>]. Due to the ease of manipulation of reagents and the scalability of the CFS, automated high-throughput systems are in development [<xref rid="B301-vaccines-12-01344" ref-type="bibr">301</xref>].</p><p>By removing the need to sustain life, CFSs allow control over the molecular machinery for gene expression, enabling the researcher to manipulate the system by adding non-native substrates such as recombinant DNA templates [<xref rid="B302-vaccines-12-01344" ref-type="bibr">302</xref>]. Cell-free experiments can also circumvent mechanisms involved in species survival and bypass limitations on molecular transport, providing the ability to focus the cellular machinery on the biosynthesis of a specific product. The details of the progress made regarding the preparation of cell-free extracts and reaction mixtures, optimization and more background on cell-free protein expression have been discussed previously [<xref rid="B296-vaccines-12-01344" ref-type="bibr">296</xref>,<xref rid="B297-vaccines-12-01344" ref-type="bibr">297</xref>,<xref rid="B298-vaccines-12-01344" ref-type="bibr">298</xref>,<xref rid="B299-vaccines-12-01344" ref-type="bibr">299</xref>,<xref rid="B300-vaccines-12-01344" ref-type="bibr">300</xref>,<xref rid="B301-vaccines-12-01344" ref-type="bibr">301</xref>]. The most common cell lysates used (<xref rid="vaccines-12-01344-t008" ref-type="table">Table 8</xref>) are acquired from <italic toggle="yes">E. coli</italic> [<xref rid="B302-vaccines-12-01344" ref-type="bibr">302</xref>,<xref rid="B303-vaccines-12-01344" ref-type="bibr">303</xref>,<xref rid="B304-vaccines-12-01344" ref-type="bibr">304</xref>,<xref rid="B305-vaccines-12-01344" ref-type="bibr">305</xref>,<xref rid="B306-vaccines-12-01344" ref-type="bibr">306</xref>,<xref rid="B307-vaccines-12-01344" ref-type="bibr">307</xref>], but other bacterial sources [<xref rid="B308-vaccines-12-01344" ref-type="bibr">308</xref>,<xref rid="B309-vaccines-12-01344" ref-type="bibr">309</xref>,<xref rid="B310-vaccines-12-01344" ref-type="bibr">310</xref>,<xref rid="B311-vaccines-12-01344" ref-type="bibr">311</xref>,<xref rid="B312-vaccines-12-01344" ref-type="bibr">312</xref>] or eukaryotic systems such as mammalian [<xref rid="B313-vaccines-12-01344" ref-type="bibr">313</xref>,<xref rid="B314-vaccines-12-01344" ref-type="bibr">314</xref>,<xref rid="B315-vaccines-12-01344" ref-type="bibr">315</xref>,<xref rid="B316-vaccines-12-01344" ref-type="bibr">316</xref>], insect [<xref rid="B299-vaccines-12-01344" ref-type="bibr">299</xref>,<xref rid="B317-vaccines-12-01344" ref-type="bibr">317</xref>,<xref rid="B318-vaccines-12-01344" ref-type="bibr">318</xref>] or plant cells [<xref rid="B319-vaccines-12-01344" ref-type="bibr">319</xref>,<xref rid="B320-vaccines-12-01344" ref-type="bibr">320</xref>,<xref rid="B321-vaccines-12-01344" ref-type="bibr">321</xref>] have also been adapted, although these are more expensive [<xref rid="B322-vaccines-12-01344" ref-type="bibr">322</xref>,<xref rid="B323-vaccines-12-01344" ref-type="bibr">323</xref>].</p><p>Prokaryotic CFSs such as <italic toggle="yes">Bacillus subtilis</italic> [<xref rid="B310-vaccines-12-01344" ref-type="bibr">310</xref>], <italic toggle="yes">Pseudomonas putida</italic> [<xref rid="B312-vaccines-12-01344" ref-type="bibr">312</xref>], <italic toggle="yes">Streptomyces</italic> [<xref rid="B324-vaccines-12-01344" ref-type="bibr">324</xref>] and <italic toggle="yes">Vibrio natriegens</italic> [<xref rid="B308-vaccines-12-01344" ref-type="bibr">308</xref>] have been recently optimized, and eukaryotic CFS based on <italic toggle="yes">Tobacco</italic> [<xref rid="B325-vaccines-12-01344" ref-type="bibr">325</xref>], <italic toggle="yes">Leishmania</italic> [<xref rid="B326-vaccines-12-01344" ref-type="bibr">326</xref>], <italic toggle="yes">Neurospora crassa</italic> [<xref rid="B327-vaccines-12-01344" ref-type="bibr">327</xref>], <italic toggle="yes">Saccharomyces cerevisiae</italic> [<xref rid="B328-vaccines-12-01344" ref-type="bibr">328</xref>] and erythrocytes [<xref rid="B323-vaccines-12-01344" ref-type="bibr">323</xref>] have been characterized and optimized for certain proteins at the laboratory level.</p><p>Most therapeutic proteins like monoclonal antibodies and viral antigens have glycan moieties. Synthesizing these glycoproteins in vitro is challenging since the most common cellular lysate source for CFSs, <italic toggle="yes">E. coli</italic>, lacks native glycosylation machinery. Several solutions have been suggested such as using a eukaryotic CFS, which can be supplemented with purified microsomes with the necessary components for glycosylation, but these seem to produce much less functional folded protein than bacterial systems [<xref rid="B322-vaccines-12-01344" ref-type="bibr">322</xref>]. To address these issues, a group developed a novel cell-free glycoprotein synthesis (CFGpS) system which integrates protein biosynthesis with asparagine-linked protein glycosylation. This involved a glycol-optimized <italic toggle="yes">E. coli</italic> strain as the source of cell extracts selectively enriched with glycosylation components such as oligosaccharyltransferases and lipid-linked oligosaccharides. The authors indicated that it enabled a &#x02018;one-pot&#x02019; reaction scheme for the efficient and site-specific glycosylation of target proteins [<xref rid="B329-vaccines-12-01344" ref-type="bibr">329</xref>]. A major advantage of this system is that it allows a high level of control over all glycosylation components (catalysts, substrates and cofactors) in terms of important process variables such as input concentrations, time of addition and reaction time. Genome engineering makes the elimination of inhibitory enzymes, such as glycosidases, possible, which would hydrolyze necessary glycosidic linkages. The level of control with CFSs provides the opportunity to overcome bottlenecks that would otherwise limit glycosylation efficiency [<xref rid="B330-vaccines-12-01344" ref-type="bibr">330</xref>].</p><p>Various methods have been established to enhance the correct folding and solubility of transmembrane proteins such as supplementation with membrane-mimicking structures, such as micelle-forming detergents, nanodiscs, liposomes or exogenous microsomes [<xref rid="B324-vaccines-12-01344" ref-type="bibr">324</xref>,<xref rid="B325-vaccines-12-01344" ref-type="bibr">325</xref>,<xref rid="B326-vaccines-12-01344" ref-type="bibr">326</xref>]. Eukaryotic CFSs contain endogenous microsomes from the cellular endoplasmic reticulum (ER), which allows for the co-translational translocation of proteins and ER-associated post-translational modifications [<xref rid="B331-vaccines-12-01344" ref-type="bibr">331</xref>,<xref rid="B332-vaccines-12-01344" ref-type="bibr">332</xref>,<xref rid="B333-vaccines-12-01344" ref-type="bibr">333</xref>,<xref rid="B334-vaccines-12-01344" ref-type="bibr">334</xref>,<xref rid="B335-vaccines-12-01344" ref-type="bibr">335</xref>].</p><table-wrap position="anchor" id="vaccines-12-01344-t008"><object-id pub-id-type="pii">vaccines-12-01344-t008_Table 8</object-id><label>Table 8</label><caption><p>Comparisons of commonly used CFSs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">System</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantages</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disadvantages</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High protein yield. Simple cultivation, rapid cell growth and easy lysate preparation. Cost-efficient. Well-established genetic engineering methods. High levels of VLP production.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-translational modification issues. Lack of endogenous membrane structures for integral membrane protein synthesis. Only prokaryotic chaperones. Eukaryotic proteins often incorrectly folded.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B306-vaccines-12-01344" ref-type="bibr">306</xref>,<xref rid="B307-vaccines-12-01344" ref-type="bibr">307</xref>,<xref rid="B329-vaccines-12-01344" ref-type="bibr">329</xref>,<xref rid="B330-vaccines-12-01344" ref-type="bibr">330</xref>,<xref rid="B331-vaccines-12-01344" ref-type="bibr">331</xref>,<xref rid="B332-vaccines-12-01344" ref-type="bibr">332</xref>,<xref rid="B336-vaccines-12-01344" ref-type="bibr">336</xref>,<xref rid="B337-vaccines-12-01344" ref-type="bibr">337</xref>,<xref rid="B338-vaccines-12-01344" ref-type="bibr">338</xref>,<xref rid="B339-vaccines-12-01344" ref-type="bibr">339</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yeast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-translational modifications possible. Rapid, easy propagation of cells and lysate preparation. Well-established genetic engineering methods.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low protein yield. No mammalian-like post-translational modifications. Slightly more costly than <italic toggle="yes">E. coli</italic>. Moderate levels of VLP production.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B328-vaccines-12-01344" ref-type="bibr">328</xref>,<xref rid="B333-vaccines-12-01344" ref-type="bibr">333</xref>,<xref rid="B335-vaccines-12-01344" ref-type="bibr">335</xref>,<xref rid="B340-vaccines-12-01344" ref-type="bibr">340</xref>,<xref rid="B341-vaccines-12-01344" ref-type="bibr">341</xref>,<xref rid="B342-vaccines-12-01344" ref-type="bibr">342</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wheat germ</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High yield of complex proteins. Synthesis of disulphide bridged proteins. Correct protein folding and high solubility. Well-established genetic engineering methods.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Labour-intensive and expensive lysate preparation. Limited post-translational modifications. No endogenous membrane structures. Low protein yield compared to prokaryotic and cell-based wheat germ systems.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B319-vaccines-12-01344" ref-type="bibr">319</xref>,<xref rid="B334-vaccines-12-01344" ref-type="bibr">334</xref>,<xref rid="B343-vaccines-12-01344" ref-type="bibr">343</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tobacco</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High yield of complex proteins. Rapid, simple lysate preparation. Glycosylation and disulphide bridge formation possible.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Few studies on tobacco CFSs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B320-vaccines-12-01344" ref-type="bibr">320</xref>,<xref rid="B325-vaccines-12-01344" ref-type="bibr">325</xref>,<xref rid="B344-vaccines-12-01344" ref-type="bibr">344</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insect cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rapid, simple lysate preparation. Post-translational modifications possible. Endogenous microsomes available. Direct synthesis and integration of membrane proteins.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High cost of cell propagation. Moderate levels of VLP production.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B299-vaccines-12-01344" ref-type="bibr">299</xref>,<xref rid="B345-vaccines-12-01344" ref-type="bibr">345</xref>,<xref rid="B346-vaccines-12-01344" ref-type="bibr">346</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Contains endogenous microsomes. Mammalian PTMs. Direct production of membrane proteins. Well-established cell lines. IRES-mediated translation initiation allows high protein yield.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low yield compared to prokaryotic CFSs. High cost of cell propagation. Low levels of VLP production.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B347-vaccines-12-01344" ref-type="bibr">347</xref>,<xref rid="B348-vaccines-12-01344" ref-type="bibr">348</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human cell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Optimal environment for native protein folding and assembly of viral membrane proteins. Contain endogenous microsomes. Human post-translational modifications. Codon manipulation allows the synthesis of high molecular weight proteins.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low protein yield compared to prokaryotic CFS. High cell propagation costs. Labour intensive cell culture technologies needed as human cells are sensitive.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B323-vaccines-12-01344" ref-type="bibr">323</xref>,<xref rid="B349-vaccines-12-01344" ref-type="bibr">349</xref>,<xref rid="B350-vaccines-12-01344" ref-type="bibr">350</xref>]</td></tr></tbody></table></table-wrap><sec><title>Applications of Cell-Free Expression System</title><p>The <italic toggle="yes">E. coli</italic>-based CFS has also been used to rapidly produce domains from pH1N1 influenza virus HA. The stabilized HA head domain trimer was effectively recognized by antibodies from pH1N1 influenza vaccine recipients and bound to sialic acids, strongly indicating that the trimers were correctly formed and could be potentially effective as vaccines [<xref rid="B351-vaccines-12-01344" ref-type="bibr">351</xref>,<xref rid="B352-vaccines-12-01344" ref-type="bibr">352</xref>]. The <italic toggle="yes">E. coli</italic> CFS has been used to synthesize and assemble human norovirus (HuNoV) VLPs in 4 h with similar protein yield to other cell-based systems [<xref rid="B353-vaccines-12-01344" ref-type="bibr">353</xref>]. The extremely low level of endotoxin from the cell-free system could meet the demands for vaccine applications, referencing guidelines for toxoid-based vaccines [<xref rid="B298-vaccines-12-01344" ref-type="bibr">298</xref>,<xref rid="B354-vaccines-12-01344" ref-type="bibr">354</xref>]. Strains of <italic toggle="yes">E. coli</italic> such as ClearColi<sup>TM</sup> [<xref rid="B37-vaccines-12-01344" ref-type="bibr">37</xref>] or the use of an endotoxin binding column are also useful in reducing endotoxin levels.</p><p>A wheat germ CFS was used to produce highly soluble MERS-CoV nucleoprotein (NP) antigen, which was able to generate mAbs following the immunization of mice [<xref rid="B355-vaccines-12-01344" ref-type="bibr">355</xref>]. Hepatitis B core antigen VLPs produced in a <italic toggle="yes">Pichia pastoris</italic> cell-free expression system were found to have comparable characteristics to those previously produced in vivo and in vitro [<xref rid="B356-vaccines-12-01344" ref-type="bibr">356</xref>].</p><p>One study has produced the SARS-CoV-2 disulphide-bonded RBD protein in a wheat germ cell-free production system [<xref rid="B357-vaccines-12-01344" ref-type="bibr">357</xref>]. A wheat germ (WG) expression kit was used in a bilayer translation method [<xref rid="B358-vaccines-12-01344" ref-type="bibr">358</xref>], where by adding protein disulfide isomerase (PDI) and endoplasmic reticulum oxidase (ERO1&#x003b1;) to the translational reaction mixture, a functionally intact RBD protein that can interact with ACE2 was synthesized. The common problem with conventional WG expression is the use of dithiothreitol (DTT) in the wheat germ extract and substrate solution to enhance translation efficiency; however, DTT is known to disrupt disulphide bonds in the synthesized protein, which is detrimental to proteins where the disulphide linkage is important to its function. The modification of the WG (EP-WG) with the inclusion of the endoplasmic reticulum oxidoreductase-1 &#x003b1; (ERO1&#x003b1;) and protein disulfide isomerase (PDI) overcomes this drawback to produce biologically similar proteins with intact disulphide bonds. The RBD produced in this system had a different band shape compared to RBD produced in mammalian systems, which is possibly due to glycosylation or other post-translational modifications that occur in the mammalian system. The lack of glycosylation is one of the drawbacks of the WG system. RBD has two glycosylation sites, N331 and N343. In this study, RBD synthesized by EP-WG had slightly lowered affinity for ACE2 than RBD produced in the mammalian cell expression system. Vaccine-derived antibodies produced by conventional WG expression did not react with RBD whose conformation had been disrupted with DTT treatment, demonstrating that the disulfide bonds in the RBD are essential for its antigenicity.</p><p>The SARS-CoV-2 RBD has also been produced in a cell-free system derived from <italic toggle="yes">Nicotiana tabacum</italic> BY-2 cell culture (BY-2 lysate; BYL) within 48 h [<xref rid="B344-vaccines-12-01344" ref-type="bibr">344</xref>]. This work has improved on previous studies [<xref rid="B320-vaccines-12-01344" ref-type="bibr">320</xref>,<xref rid="B325-vaccines-12-01344" ref-type="bibr">325</xref>] and has now been optimized and commercialized by LenioBio GmbH as Almost Living Cell-free Extract (ALiCE)<sup>&#x000ae;</sup>. They were able to demonstrate that this system can easily and linearly scale across a 1000-fold difference from 100 &#x003bc;L reactions to 10 and 100 mL. The study also showed preliminary data from 1 L reactions in a commercial bioreactor, the first example of litre scale reactions from a eukaryotic cell-free protein synthesis system. In addition to SARS-CoV-2 RBD, they also produced a hepatitis B core VLP, the monoclonal antibody adalimumab, human epidermal growth factor and a G protein-coupled receptor membrane protein. These expressed proteins are monomeric and multimeric in nature with disulphide bonds, N-glycosylation and transmembrane domains, which demonstrates the versatility of BYL. Using anti-RBD antibodies from R&#x00026;D systems, serum samples from COVID-19 patients and pure protein samples produced by the BYL-ALiCE cell-free system, RBD-binding and serological assays were performed by ELISA. RBD produced in BYL was directly comparable to RBD produced in HEK-293 cells. The work shows the potential of BYL as an end-to-end R&#x00026;D protein synthesis platform, which could significantly reduce the time-to-market for vaccine antigens.</p></sec></sec><sec id="sec9-vaccines-12-01344"><title>9. Future Directions</title><p>Taking into consideration the time and various complexities involved in traditional cell-based expression, cell-free systems are an emerging vaccine production technology compared in <xref rid="vaccines-12-01344-t009" ref-type="table">Table 9</xref>. Vaccine antigens can be processed for downstream applications like purification and functional analysis without the transfection, selection and expansion of clones. The availability of cell-free lysates from commercial sources has increased; however, there are major challenges with respect to scalability, cost effectiveness, protein folding and functionality.</p><p>The BEVS is one of the most efficient cell-based protein production platforms in use as most of the proteins synthesized in this system are functionally, antigenically and immunogenically similar to the native protein. This is because the insect cell system is able to perform several post-translational modifications. Based on the evidence, <italic toggle="yes">Spodoptera frugiperda</italic> CFSs have been developed [<xref rid="B366-vaccines-12-01344" ref-type="bibr">366</xref>,<xref rid="B367-vaccines-12-01344" ref-type="bibr">367</xref>]. The ER is not fully removed during lysate preparation but allows the structures to rearrange themselves into endogenous microsomes, which are translocationally active and provide a somewhat natural lipid membrane for protein translocation and embedding. Performing repeated protein synthesis allows the same batch of microsomes to be used multiple times and enrichment of the target proteins in the lumen and membrane of microsomes was achieved [<xref rid="B368-vaccines-12-01344" ref-type="bibr">368</xref>]. In this insect CFS, post-translational modifications can be achieved without additional enzymes and cofactors as the glycosylation, phosphorylation and disulphide bond formation have been shown [<xref rid="B369-vaccines-12-01344" ref-type="bibr">369</xref>].</p><p>Studies involving CFSs based on CHO cell lysates have shown that the combination of well-known properties and safety aspects of CHO cells [<xref rid="B370-vaccines-12-01344" ref-type="bibr">370</xref>,<xref rid="B371-vaccines-12-01344" ref-type="bibr">371</xref>] with the versatility of cell-free technology [<xref rid="B314-vaccines-12-01344" ref-type="bibr">314</xref>,<xref rid="B347-vaccines-12-01344" ref-type="bibr">347</xref>,<xref rid="B372-vaccines-12-01344" ref-type="bibr">372</xref>] provides many advantages for recombinant protein production. The ability to synthesize proteins easily and quickly and the flexibility of the DNA template allows for potential screening technologies. Vaccine antigens are usually membrane proteins originating from humans, and mammalian expression systems fulfil all the requirements such as post-translational modifications, cofactors and chaperones for correct folding and efficient production, although the overexpression of membrane proteins can be toxic for cell cultures and result in cell death or truncated or misfolded proteins [<xref rid="B373-vaccines-12-01344" ref-type="bibr">373</xref>].</p><p>Currently, CHO-lysate CFS reactions are performed coupled with transcription and translation occurring in one reaction, which allows for the fast and convenient production of proteins for high-throughput screening [<xref rid="B372-vaccines-12-01344" ref-type="bibr">372</xref>]. A major limitation of most eukaryotic CFS is low protein yield, due to limiting translational initiation, but integrating internal ribosome entry sites (IRESs) into the DNA template improved protein production by bypassing several yield-limiting steps in eukaryotic translation initiation [<xref rid="B347-vaccines-12-01344" ref-type="bibr">347</xref>].</p><p>Research into standardization is important as the CFS evolves into a technique used by large laboratories for protein expression and several teams have already begun this work [<xref rid="B368-vaccines-12-01344" ref-type="bibr">368</xref>,<xref rid="B369-vaccines-12-01344" ref-type="bibr">369</xref>,<xref rid="B370-vaccines-12-01344" ref-type="bibr">370</xref>,<xref rid="B371-vaccines-12-01344" ref-type="bibr">371</xref>,<xref rid="B374-vaccines-12-01344" ref-type="bibr">374</xref>,<xref rid="B375-vaccines-12-01344" ref-type="bibr">375</xref>,<xref rid="B376-vaccines-12-01344" ref-type="bibr">376</xref>,<xref rid="B377-vaccines-12-01344" ref-type="bibr">377</xref>]. This allows researchers to obtain more statistically significant results and those implementing CFS for the first time can easily and successfully contribute to the establishment of CFS as a major protein expression technology.</p><p>Transgenic animals, and more so, transgenic milk, are another recent protein expression platform. Mammary gland-specific promoters have been modified to express a wide range of biopharmaceutical proteins in rodents, rabbits and livestock [<xref rid="B378-vaccines-12-01344" ref-type="bibr">378</xref>,<xref rid="B379-vaccines-12-01344" ref-type="bibr">379</xref>,<xref rid="B380-vaccines-12-01344" ref-type="bibr">380</xref>,<xref rid="B381-vaccines-12-01344" ref-type="bibr">381</xref>]. The mammary gland is the organ of choice as milk is easily collected in large volumes. Protein expression is commonly reported to be produced at rates of several <bold>grams</bold> per litre [<xref rid="B379-vaccines-12-01344" ref-type="bibr">379</xref>]. Blood, egg white, seminal plasma and urine are other theoretically possible systems and have been discussed previously [<xref rid="B3-vaccines-12-01344" ref-type="bibr">3</xref>]. Interest in transgenic eggs has also been shown as a single hen can lay up to 330 eggs per year, and egg white naturally contains approximately 4 g of protein [<xref rid="B382-vaccines-12-01344" ref-type="bibr">382</xref>]. Urine has also been explored as an abundant biological fluid for protein expression. An advantage of using the bladder is that transgenic animals can urinate earlier than they can lactate; however, the major limitation of this system is yield, as although the bladder epithelium does secrete proteins, production rates are extremely low [<xref rid="B383-vaccines-12-01344" ref-type="bibr">383</xref>]. Seminal fluid is another relatively abundant biological fluid in some species such as pigs and it can easily be collected. Pig semen contains approximately 30 mg of protein/mL and boars can produce 200&#x02013;300 mL of semen for a total of 6&#x02013;9 g of protein per ejaculate [<xref rid="B384-vaccines-12-01344" ref-type="bibr">384</xref>]. Protein secretion in the male boar&#x02019;s accessory sex glands is uniquely exocrine, minimizing the risk of a biologically active recombinant protein and upsetting the host&#x02019;s own physiology; however, it is not well-understood how complex proteins are matured and secreted in semen [<xref rid="B385-vaccines-12-01344" ref-type="bibr">385</xref>].</p><p>In terms of the transgenic animal expression of vaccine antigens, very few studies exist. Enterovirus 71 (EV71) VP1 capsid protein has been expressed and secreted into the milk of transgenic mice with a yield of 2.51 mg/mL. Mouse pups that received VP1-transgenic milk orally showed better health conditions after challenge with EV71 compared to a non-transgenic milk-fed group, and bodyweight of the VP-1-fed group was similar to the uninfected group. Serum neutralization assays and serum antibody detection showed the VP-1-fed mice generated antibodies specific to EV71 [<xref rid="B386-vaccines-12-01344" ref-type="bibr">386</xref>]. Transgenic rabbits have been used to produce rotavirus VP2 and VP6 proteins in their milk from 50 to 250 &#x000b5;g/mL. These proteins were able to elicit significant protection against rotavirus infection in rabbit babies when orally administered in the whole milk. Protection levels were similar to other studies where VLP2/6 were used as immunogens in oral vaccination protocols.</p><p>Recombinant protein production in the milk of livestock seems to be the optimal direction for this type of expression system, which may lead to the creation of animal lines where genomes are modified by the insertion of sequences for the directed recombination of the expression cassette into a milk protein-encoding gene. The insertion can be achieved with high efficiency Via microinjection into the oocytes of a genetic construct carrying an expression cassette as well as the corresponding recombinant integrase or its mRNA. These animal lines can be created using the CRISPR/Cas9 system or its analogues which are highly efficient and simple to design and implement. This is one of the most promising approaches to the generation of transgenic animals producing recombinant antigens in milk as the CRISPR/Cas9 targeted integration of the transgene into the genes that encode milk proteins allows for transgene expression to be controlled by the endogenous regulatory sequences of the recipient gene. Applications of this technology will simplify and standardize transgenic animal production for the generation of recombinant antigens. Synthetic biology allows the use of mini-genes with artificial introns as transgenes to facilitate the efficient expression of the transgene and the production of the target protein, which simplifies the design and creation of genetic constructs for transgenesis [<xref rid="B387-vaccines-12-01344" ref-type="bibr">387</xref>,<xref rid="B388-vaccines-12-01344" ref-type="bibr">388</xref>].</p><p>The purification of recombinant vaccine antigens from milk creates undefined regulatory hurdles; however, using the modern technology available makes compliance with regulatory requirements describing the transformation event simple. Major hurdles are the requirements regarding the biological safety of recombinant protein in milk, which will require revising the standards for farm animal welfare and veterinary oversight to exclude the presence of extraneous agents as well as controlled parameters of manufactured proteins for use as subunit vaccines.</p></sec><sec sec-type="conclusions" id="sec10-vaccines-12-01344"><title>10. Conclusions</title><p>Both procaryotic and eucaryotic expression systems have been demonstrated to be useful for production of viral vaccine antigens. However, the number of successfully demonstrated vaccines is much greater in the eucaryotic expressions systems compared to the procaryotic systems. Further advances are underway in improving both procaryotic and eucaryotic protein expression systems to produce proteins with glycosylation patterns like mammalian cells and to be more economical for production. In addition, new cell free systems offer new approaches for protein expression.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, J.R.V.S. and S.B., writing, J.R.V.S., Z.S., A.A., D.K., K.P. and S.B., images, Z.S. review, editing and draft preparation, J.R.V.S., Z.S., A.A., D.K., K.P. and S.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data and information presented in the review are from papers published (and cited) in the References section, with abstracts accessible in PubMed.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01344"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chadd</surname><given-names>H.E.</given-names></name>
<name><surname>Chamow</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Therapeutic antibody expression technology</article-title><source>Curr. Opin. Biotechnol.</source><year>2001</year><volume>12</volume><fpage>188</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/S0958-1669(00)00198-1</pub-id><pub-id pub-id-type="pmid">11287236</pub-id>
</element-citation></ref><ref id="B2-vaccines-12-01344"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andersen</surname><given-names>D.C.</given-names></name>
<name><surname>Krummen</surname><given-names>L.</given-names></name>
</person-group><article-title>Recombinant protein expression for therapeutic applications</article-title><source>Curr. Opin. Biotechnol.</source><year>2002</year><volume>13</volume><fpage>117</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/S0958-1669(02)00300-2</pub-id><pub-id pub-id-type="pmid">11950561</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01344"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Van Damme</surname><given-names>P.</given-names></name>
</person-group><source>Hepatitis B Vaccines BT&#x02014;Pediatric Vaccines and Vaccinations: A European Textbook</source><person-group person-group-type="editor">
<name><surname>Vesikari</surname><given-names>T.</given-names></name>
<name><surname>Van Damme</surname><given-names>P.</given-names></name>
</person-group><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2017</year><fpage>109</fpage><lpage>116</lpage></element-citation></ref><ref id="B4-vaccines-12-01344"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McNeil</surname><given-names>C.</given-names></name>
</person-group><article-title>Who invented the VLP cervical cancer vaccines?</article-title><source>J. Natl. Cancer Inst.</source><year>2006</year><volume>98</volume><fpage>433</fpage><pub-id pub-id-type="doi">10.1093/jnci/djj144</pub-id><pub-id pub-id-type="pmid">16595773</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01344"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rold&#x000e3;o</surname><given-names>A.</given-names></name>
<name><surname>Mellado</surname><given-names>M.C.M.</given-names></name>
<name><surname>Castilho</surname><given-names>L.R.</given-names></name>
<name><surname>Carrondo</surname><given-names>M.J.T.</given-names></name>
<name><surname>Alves</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Virus-like particles in vaccine development</article-title><source>Expert Rev. Vaccines</source><year>2010</year><volume>9</volume><fpage>1149</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1586/erv.10.115</pub-id><pub-id pub-id-type="pmid">20923267</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01344"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crisci</surname><given-names>E.</given-names></name>
<name><surname>B&#x000e1;rcena</surname><given-names>J.</given-names></name>
<name><surname>Montoya</surname><given-names>M.</given-names></name>
</person-group><article-title>Virus-like particles: The new frontier of vaccines for animal viral infections</article-title><source>Vet. Immunol. Immunopathol.</source><year>2012</year><volume>148</volume><fpage>211</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2012.04.026</pub-id><pub-id pub-id-type="pmid">22705417</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01344"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teffera</surname><given-names>M.</given-names></name>
<name><surname>Babiuk</surname><given-names>S.</given-names></name>
</person-group><article-title>Potential of Using Capripoxvirus Vectored Vaccines Against Arboviruses in Sheep, Goats, and Cattle</article-title><source>Front. Vet. Sci.</source><year>2019</year><volume>6</volume><elocation-id>450</elocation-id><comment>Available online: <ext-link xlink:href="https://www.frontiersin.org/article/10.3389/fvets.2019.00450" ext-link-type="uri">https://www.frontiersin.org/article/10.3389/fvets.2019.00450</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-01">(accessed on 1 June 2024)</date-in-citation><pub-id pub-id-type="doi">10.3389/fvets.2019.00450</pub-id><pub-id pub-id-type="pmid">31921911</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01344"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>A.</given-names></name>
</person-group><article-title>Modern Vaccines with DIVA Capability: An Overview</article-title><source>Res. Rev. A J. Immunol.</source><year>2019</year><volume>5</volume><fpage>195</fpage><lpage>205</lpage></element-citation></ref><ref id="B9-vaccines-12-01344"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>L.</given-names></name>
<name><surname>Robinson</surname><given-names>D.K.</given-names></name>
</person-group><article-title>Industrial choices for protein production by large-scale cell culture</article-title><source>Curr. Opin. Biotechnol.</source><year>2001</year><volume>12</volume><fpage>180</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/S0958-1669(00)00197-X</pub-id><pub-id pub-id-type="pmid">11287235</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01344"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mascola</surname><given-names>J.R.</given-names></name>
<name><surname>Fauci</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Novel vaccine technologies for the 21st century</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>87</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0243-3</pub-id><pub-id pub-id-type="pmid">31712767</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01344"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>C.Y.-Y.</given-names></name>
<name><surname>Tambyah</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Preflucel<sup>&#x000ae;</sup>: A Vero-cell culture-derived trivalent influenza vaccine</article-title><source>Expert Rev. Vaccines</source><year>2012</year><volume>11</volume><fpage>759</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1586/erv.12.55</pub-id><pub-id pub-id-type="pmid">22913252</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01344"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manini</surname><given-names>I.</given-names></name>
<name><surname>Domnich</surname><given-names>A.</given-names></name>
<name><surname>Amicizia</surname><given-names>D.</given-names></name>
<name><surname>Rossi</surname><given-names>S.</given-names></name>
</person-group><article-title>Flucelvax (Optaflu) for seasonal influenza</article-title><source>Expert Rev. Vaccines</source><year>2015</year><volume>14</volume><fpage>789</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1586/14760584.2015.1039520</pub-id><pub-id pub-id-type="pmid">25968069</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01344"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>S.J.</given-names></name>
<name><surname>Yoon</surname><given-names>I.-K.</given-names></name>
</person-group><article-title>A review of Dengvaxia<sup>&#x000ae;</sup>: Development to deployment</article-title><source>Hum. Vaccines Immunother.</source><year>2019</year><volume>15</volume><fpage>2295</fpage><lpage>2314</lpage><pub-id pub-id-type="doi">10.1080/21645515.2019.1658503</pub-id><pub-id pub-id-type="pmid">31589551</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01344"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andr&#x000e9;ll</surname><given-names>J.</given-names></name>
<name><surname>Tate</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Overexpression of membrane proteins in mammalian cells for structural studies</article-title><source>Mol. Membr. Biol.</source><year>2013</year><volume>30</volume><fpage>52</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.3109/09687688.2012.703703</pub-id><pub-id pub-id-type="pmid">22963530</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01344"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>S.K.</given-names></name>
<name><surname>Shukla</surname><given-names>P.</given-names></name>
</person-group><article-title>Glycosylation control technologies for recombinant therapeutic proteins</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>10457</fpage><lpage>10468</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-9430-6</pub-id><pub-id pub-id-type="pmid">30334089</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01344"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>D.</given-names></name>
<name><surname>Liang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Nakao</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Guan</surname><given-names>Y.</given-names></name>
<name><surname>Fukuyama</surname><given-names>S.</given-names></name>
<name><surname>Bu</surname><given-names>Z.</given-names></name>
<name><surname>Kawaoka</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Glycosylation of the Hemagglutinin Protein of H<sub>5</sub>N<sub>1</sub> Influenza Virus Increases Its Virulence in Mice by Exacerbating the Host Immune Response</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>e02215-16</fpage><pub-id pub-id-type="doi">10.1128/JVI.02215-16</pub-id><pub-id pub-id-type="pmid">28100622</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01344"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dalton</surname><given-names>A.C.</given-names></name>
<name><surname>Barton</surname><given-names>W.A.</given-names></name>
</person-group><article-title>Over-expression of secreted proteins from mammalian cell lines</article-title><source>Protein Sci.</source><year>2014</year><volume>23</volume><fpage>517</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1002/pro.2439</pub-id><pub-id pub-id-type="pmid">24510886</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01344"><label>18.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<name><surname>Varki</surname><given-names>A.</given-names></name>
<name><surname>Cummings</surname><given-names>R.D.</given-names></name>
<name><surname>Esko</surname><given-names>J.D.</given-names></name>
<name><surname>Stanley</surname><given-names>P.</given-names></name>
<name><surname>Hart</surname><given-names>G.W.</given-names></name>
<name><surname>Aebi</surname><given-names>M.</given-names></name>
<name><surname>Darvill</surname><given-names>A.G.</given-names></name>
<name><surname>Kinoshita</surname><given-names>T.</given-names></name>
<name><surname>Packer</surname><given-names>N.H.</given-names></name>
<name><surname>Prestegard</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Essentials of Glycobiology [Internet]</article-title><year>2015</year><comment>Available online: <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/27010055/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/27010055/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-01">(accessed on 1 June 2024)</date-in-citation></element-citation></ref><ref id="B19-vaccines-12-01344"><label>19.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Qian</surname><given-names>H.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Bian</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Bai</surname><given-names>Z.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Che</surname><given-names>Y.</given-names></name>
<name><surname>Lv</surname><given-names>Y.</given-names></name>
<name><surname>Zha</surname><given-names>Y.</given-names></name>
</person-group><article-title>Porcine Epidemic Diarrhea Virus S Protein and Subunit Vaccine Thereof as Well as Method for Preparing Subunit Vaccine and Application Thereof</article-title><source>U.S. Patent</source><patent>App. 16/600,334</patent><day>18</day><month>June</month><year>2020</year></element-citation></ref><ref id="B20-vaccines-12-01344"><label>20.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Fattom</surname><given-names>A.I.</given-names></name>
<name><surname>Hamouda</surname><given-names>T.</given-names></name>
<name><surname>Bitko</surname><given-names>V.</given-names></name>
<name><surname>Baker</surname><given-names>J.R.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Nanoemulsion Respiratory Syncytial Virus (RSV) Subunit Vaccine</article-title><source>U.S. Patent</source><patent>10,596,251</patent><day>24</day><month>March</month><year>2020</year></element-citation></ref><ref id="B21-vaccines-12-01344"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eldemery</surname><given-names>F.</given-names></name>
<name><surname>Joiner</surname><given-names>K.S.</given-names></name>
<name><surname>Toro</surname><given-names>H.</given-names></name>
<name><surname>Van Santen</surname><given-names>V.L.</given-names></name>
</person-group><article-title>Protection against infectious bronchitis virus by spike ectodomain subunit vaccine</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>5864</fpage><lpage>5871</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.09.013</pub-id><pub-id pub-id-type="pmid">28899630</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01344"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>von Schaewen</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Tao</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Heller</surname><given-names>B.</given-names></name>
<name><surname>Hrebikova</surname><given-names>G.</given-names></name>
<name><surname>Deng</surname><given-names>Q.</given-names></name>
<name><surname>Ploss</surname><given-names>A.</given-names></name>
</person-group><article-title>Altered glycosylation patterns increase immunogenicity of a subunit hepatitis C virus vaccine, inducing neutralizing antibodies which confer protection in mice</article-title><source>J. Virol.</source><year>2016</year><volume>90</volume><fpage>10486</fpage><lpage>10498</lpage><pub-id pub-id-type="doi">10.1128/JVI.01462-16</pub-id><pub-id pub-id-type="pmid">27630242</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01344"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lehrer</surname><given-names>A.T.</given-names></name>
<name><surname>Wong</surname><given-names>T.-A.S.</given-names></name>
<name><surname>Lieberman</surname><given-names>M.M.</given-names></name>
<name><surname>Johns</surname><given-names>L.</given-names></name>
<name><surname>Medina</surname><given-names>L.</given-names></name>
<name><surname>Feldmann</surname><given-names>F.</given-names></name>
<name><surname>Feldmann</surname><given-names>H.</given-names></name>
<name><surname>Marzi</surname><given-names>A.</given-names></name>
</person-group><article-title>Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>6942</fpage><lpage>6950</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.06.035</pub-id><pub-id pub-id-type="pmid">31324500</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01344"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morcol</surname><given-names>T.</given-names></name>
<name><surname>Nagappan</surname><given-names>P.</given-names></name>
<name><surname>Bell</surname><given-names>S.J.D.</given-names></name>
<name><surname>Cawthon</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Influenza A (H<sub>5</sub>N<sub>1</sub>) virus subunit vaccine administered with CaPNP adjuvant induce high virus neutralization antibody titers in mice</article-title><source>AAPS PharmSciTech</source><year>2019</year><volume>20</volume><fpage>315</fpage><pub-id pub-id-type="doi">10.1208/s12249-019-1530-9</pub-id><pub-id pub-id-type="pmid">31591662</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01344"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Medina</surname><given-names>L.O.</given-names></name>
<name><surname>To</surname><given-names>A.</given-names></name>
<name><surname>Lieberman</surname><given-names>M.M.</given-names></name>
<name><surname>Wong</surname><given-names>T.A.S.</given-names></name>
<name><surname>Namekar</surname><given-names>M.</given-names></name>
<name><surname>Nakano</surname><given-names>E.</given-names></name>
<name><surname>Andersen</surname><given-names>H.</given-names></name>
<name><surname>Yalley-Ogunro</surname><given-names>J.</given-names></name>
<name><surname>Greenhouse</surname><given-names>J.</given-names></name>
<name><surname>Higgs</surname><given-names>S.</given-names></name>
</person-group><article-title>A recombinant subunit based zika virus vaccine is efficacious in non-human primates</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>2464</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02464</pub-id><pub-id pub-id-type="pmid">30467501</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01344"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Durbin</surname><given-names>A.P.</given-names></name>
<name><surname>Pierce</surname><given-names>K.K.</given-names></name>
<name><surname>Kirkpatrick</surname><given-names>B.D.</given-names></name>
<name><surname>Grier</surname><given-names>P.</given-names></name>
<name><surname>Sabundayo</surname><given-names>B.P.</given-names></name>
<name><surname>He</surname><given-names>H.</given-names></name>
<name><surname>Sausser</surname><given-names>M.</given-names></name>
<name><surname>Russell</surname><given-names>A.F.</given-names></name>
<name><surname>Martin</surname><given-names>J.</given-names></name>
<name><surname>Hyatt</surname><given-names>D.</given-names></name>
</person-group><article-title>Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2020</year><volume>103</volume><fpage>855</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.20-0042</pub-id><pub-id pub-id-type="pmid">32394880</pub-id>
</element-citation></ref><ref id="B27-vaccines-12-01344"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holmgren</surname><given-names>J.</given-names></name>
<name><surname>Bourgeois</surname><given-names>L.</given-names></name>
<name><surname>Carlin</surname><given-names>N.</given-names></name>
<name><surname>Clements</surname><given-names>J.</given-names></name>
<name><surname>Gustafsson</surname><given-names>B.</given-names></name>
<name><surname>Lundgren</surname><given-names>A.</given-names></name>
<name><surname>Nygren</surname><given-names>E.</given-names></name>
<name><surname>Tobias</surname><given-names>J.</given-names></name>
<name><surname>Walker</surname><given-names>R.</given-names></name>
<name><surname>Svennerholm</surname><given-names>A.-M.</given-names></name>
</person-group><article-title>Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated <italic toggle="yes">E. coli</italic> bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered al</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>2457</fpage><lpage>2464</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.03.027</pub-id><pub-id pub-id-type="pmid">23541621</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01344"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Xia</surname><given-names>N.</given-names></name>
<name><surname>Zhao</surname><given-names>Q.</given-names></name>
</person-group><article-title><italic toggle="yes">Escherichia coli</italic>-derived virus-like particles in vaccine development</article-title><source>npj Vaccines</source><year>2017</year><volume>2</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1038/s41541-017-0006-8</pub-id><pub-id pub-id-type="pmid">29263864</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01344"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Xin</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Fang</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Xia</surname><given-names>N.</given-names></name>
<name><surname>Zhao</surname><given-names>Q.</given-names></name>
</person-group><article-title>Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins</article-title><source>Hum. Vaccines Immunother.</source><year>2015</year><volume>11</volume><fpage>1277</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1016675</pub-id><pub-id pub-id-type="pmid">25751641</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01344"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>S.-W.</given-names></name>
<name><surname>Zhao</surname><given-names>Q.</given-names></name>
<name><surname>Wu</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Xia</surname><given-names>N.-S.</given-names></name>
</person-group><article-title>The development of a recombinant hepatitis E vaccine HEV 239</article-title><source>Hum. Vaccines Immunother.</source><year>2015</year><volume>11</volume><fpage>908</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1008870</pub-id><pub-id pub-id-type="pmid">25714510</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01344"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Babiuk</surname><given-names>S.</given-names></name>
<name><surname>Asper</surname><given-names>D.J.</given-names></name>
<name><surname>Rogan</surname><given-names>D.</given-names></name>
<name><surname>Mutwiri</surname><given-names>G.K.</given-names></name>
<name><surname>Potter</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Subcutaneous and intranasal immunization with type III secreted proteins can prevent colonization and shedding of <italic toggle="yes">Escherichia coli</italic> O157:H7 in mice</article-title><source>Microb. Pathog.</source><year>2008</year><volume>45</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2008.01.005</pub-id><pub-id pub-id-type="pmid">18487034</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01344"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lobstein</surname><given-names>J.</given-names></name>
<name><surname>Emrich</surname><given-names>C.A.</given-names></name>
<name><surname>Jeans</surname><given-names>C.</given-names></name>
<name><surname>Faulkner</surname><given-names>M.</given-names></name>
<name><surname>Riggs</surname><given-names>P.</given-names></name>
<name><surname>Berkmen</surname><given-names>M.</given-names></name>
</person-group><article-title>SHuffle, a novel <italic toggle="yes">Escherichia coli</italic> protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm</article-title><source>Microb. Cell Fact.</source><year>2012</year><volume>11</volume><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/1475-2859-11-56</pub-id><pub-id pub-id-type="pmid">22569138</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01344"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dopp</surname><given-names>J.L.</given-names></name>
<name><surname>Reuel</surname><given-names>N.F.</given-names></name>
</person-group><article-title>Simple, functional, inexpensive cell extract for in vitro prototyping of proteins with disulfide bonds</article-title><source>Biochem. Eng. J.</source><year>2020</year><volume>164</volume><elocation-id>107790</elocation-id><pub-id pub-id-type="doi">10.1016/j.bej.2020.107790</pub-id></element-citation></ref><ref id="B34-vaccines-12-01344"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosano</surname><given-names>G.L.</given-names></name>
<name><surname>Ceccarelli</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Recombinant protein expression in <italic toggle="yes">Escherichia coli</italic>: Advances and challenges</article-title><source>Front. Microbiol.</source><year>2014</year><volume>5</volume><elocation-id>172</elocation-id><comment>Available online: <ext-link xlink:href="https://www.frontiersin.org/article/10.3389/fmicb.2014.00172" ext-link-type="uri">https://www.frontiersin.org/article/10.3389/fmicb.2014.00172</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-01">(accessed on 1 June 2024)</date-in-citation><pub-id pub-id-type="doi">10.3389/fmicb.2014.00172</pub-id><pub-id pub-id-type="pmid">24860555</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01344"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeltins</surname><given-names>A.</given-names></name>
</person-group><article-title>Construction and characterization of virus-like particles: A review</article-title><source>Mol. Biotechnol.</source><year>2013</year><volume>53</volume><fpage>92</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1007/s12033-012-9598-4</pub-id><pub-id pub-id-type="pmid">23001867</pub-id>
</element-citation></ref><ref id="B36-vaccines-12-01344"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mamat</surname><given-names>U.</given-names></name>
<name><surname>Wilke</surname><given-names>K.</given-names></name>
<name><surname>Bramhill</surname><given-names>D.</given-names></name>
<name><surname>Schromm</surname><given-names>A.B.</given-names></name>
<name><surname>Lindner</surname><given-names>B.</given-names></name>
<name><surname>Kohl</surname><given-names>T.A.</given-names></name>
<name><surname>Corchero</surname><given-names>J.L.</given-names></name>
<name><surname>Villaverde</surname><given-names>A.</given-names></name>
<name><surname>Schaffer</surname><given-names>L.</given-names></name>
<name><surname>Head</surname><given-names>S.R.</given-names></name>
<etal/>
</person-group><article-title>Detoxifying <italic toggle="yes">Escherichia coli</italic> for endotoxin-free production of recombinant proteins</article-title><source>Microb. Cell Fact.</source><year>2015</year><volume>14</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.1186/s12934-015-0241-5</pub-id><pub-id pub-id-type="pmid">25890161</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01344"><label>37.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Mamat</surname><given-names>U.</given-names></name>
<name><surname>Woodard</surname><given-names>R.W.</given-names></name>
<name><surname>Wilke</surname><given-names>K.</given-names></name>
<name><surname>Souvignier</surname><given-names>C.</given-names></name>
<name><surname>Mead</surname><given-names>D.</given-names></name>
<name><surname>Steinmetz</surname><given-names>E.</given-names></name>
<name><surname>Terry</surname><given-names>K.</given-names></name>
<name><surname>Kovacich</surname><given-names>C.</given-names></name>
<name><surname>Zegers</surname><given-names>A.</given-names></name>
<name><surname>Knox</surname><given-names>C.</given-names></name>
</person-group><source>Endotoxin-Free Protein Production&#x02014;ClearColi<sup>TM</sup> Technology</source><publisher-name>Nature Publishing Group</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2013</year></element-citation></ref><ref id="B38-vaccines-12-01344"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwarz</surname><given-names>H.</given-names></name>
<name><surname>Schmittner</surname><given-names>M.</given-names></name>
<name><surname>Duschl</surname><given-names>A.</given-names></name>
<name><surname>Horejs-Hoeck</surname><given-names>J.</given-names></name>
</person-group><article-title>Residual endotoxin contaminations in recombinant proteins are sufficient to activate human CD1c+ dendritic cells</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e113840</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0113840</pub-id><pub-id pub-id-type="pmid">25478795</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01344"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palmer</surname><given-names>I.</given-names></name>
<name><surname>Wingfield</surname><given-names>P.T.</given-names></name>
</person-group><article-title>Preparation and extraction of insoluble (inclusion-body) proteins from <italic toggle="yes">Escherichia coli</italic></article-title><source>Curr. Protoc. Protein Sci.</source><year>2012</year><volume>70</volume><fpage>3</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/0471140864.ps0603s70</pub-id><pub-id pub-id-type="pmid">23151747</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01344"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanchez-Garcia</surname><given-names>L.</given-names></name>
<name><surname>Mart&#x000ed;n</surname><given-names>L.</given-names></name>
<name><surname>Mangues</surname><given-names>R.</given-names></name>
<name><surname>Ferrer-Miralles</surname><given-names>N.</given-names></name>
<name><surname>V&#x000e1;zquez</surname><given-names>E.</given-names></name>
<name><surname>Villaverde</surname><given-names>A.</given-names></name>
</person-group><article-title>Recombinant pharmaceuticals from microbial cells: A 2015 update</article-title><source>Microb. Cell Fact.</source><year>2016</year><volume>15</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s12934-016-0437-3</pub-id><pub-id pub-id-type="pmid">26861699</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01344"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kyriakopoulos</surname><given-names>S.</given-names></name>
<name><surname>Kontoravdi</surname><given-names>C.</given-names></name>
</person-group><article-title>Analysis of the landscape of biologically-derived pharmaceuticals in Europe: Dominant production systems, molecule types on the rise and approval trends</article-title><source>Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci.</source><year>2013</year><volume>48</volume><fpage>428</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2012.11.016</pub-id><pub-id pub-id-type="pmid">23262060</pub-id>
</element-citation></ref><ref id="B42-vaccines-12-01344"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Proffitt</surname><given-names>A.</given-names></name>
</person-group><article-title>First HEV vaccine approved</article-title><source>Nat. Biotechnol.</source><year>2012</year><volume>30</volume><elocation-id>300</elocation-id><pub-id pub-id-type="doi">10.1038/nbt0412-300a</pub-id><pub-id pub-id-type="pmid">22491268</pub-id>
</element-citation></ref><ref id="B43-vaccines-12-01344"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Wei</surname><given-names>M.</given-names></name>
<name><surname>Pan</surname><given-names>H.</given-names></name>
<name><surname>Lin</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Weng</surname><given-names>Z.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Xin</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(<sup>&#x000ae;</sup>)</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>4039</fpage><lpage>4050</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.05.064</pub-id><pub-id pub-id-type="pmid">24892250</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01344"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>H.-C.</given-names></name>
<name><surname>Sun</surname><given-names>S.-Q.</given-names></name>
<name><surname>Jin</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>S.-L.</given-names></name>
<name><surname>Wei</surname><given-names>Y.-Q.</given-names></name>
<name><surname>Sun</surname><given-names>D.-H.</given-names></name>
<name><surname>Yin</surname><given-names>S.-H.</given-names></name>
<name><surname>Ma</surname><given-names>J.-W.</given-names></name>
<name><surname>Liu</surname><given-names>Z.-X.</given-names></name>
<name><surname>Guo</surname><given-names>J.-H.</given-names></name>
<etal/>
</person-group><article-title>Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in <italic toggle="yes">Escherichia coli</italic> induce potent protective immune responses in guinea pigs, swine and cattle</article-title><source>Vet. Res.</source><year>2013</year><volume>44</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/1297-9716-44-48</pub-id><pub-id pub-id-type="pmid">23826638</pub-id>
</element-citation></ref><ref id="B45-vaccines-12-01344"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>H.-Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Yin</surname><given-names>B.</given-names></name>
<name><surname>Lv</surname><given-names>C.</given-names></name>
<name><surname>Mo</surname><given-names>X.</given-names></name>
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Xuan</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Pang</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Large-scale production of foot-and-mouth disease virus (serotype Asia1) VLP vaccine in <italic toggle="yes">Escherichia coli</italic> and protection potency evaluation in cattle</article-title><source>BMC Biotechnol.</source><year>2016</year><volume>16</volume><elocation-id>56</elocation-id><pub-id pub-id-type="doi">10.1186/s12896-016-0285-6</pub-id><pub-id pub-id-type="pmid">27371162</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01344"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>R.</given-names></name>
<name><surname>Song</surname><given-names>H.</given-names></name>
<name><surname>Pan</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Dong</surname><given-names>H.</given-names></name>
<name><surname>Bai</surname><given-names>M.</given-names></name>
<name><surname>Sun</surname><given-names>S.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Yin</surname><given-names>S.</given-names></name>
</person-group><article-title>Local and systemic immune responses induced by intranasal immunization with biomineralized foot-and-mouth disease virus-like particles</article-title><source>Front. Microbiol.</source><year>2023</year><volume>14</volume><elocation-id>1112641</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2023.1112641</pub-id><pub-id pub-id-type="pmid">36819011</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01344"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chathuranga</surname><given-names>W.A.G.</given-names></name>
<name><surname>Hewawaduge</surname><given-names>C.</given-names></name>
<name><surname>Nethmini</surname><given-names>N.A.N.</given-names></name>
<name><surname>Kim</surname><given-names>T.-H.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Ahn</surname><given-names>Y.-H.</given-names></name>
<name><surname>Yoon</surname><given-names>I.-J.</given-names></name>
<name><surname>Yoo</surname><given-names>S.-S.</given-names></name>
<name><surname>Park</surname><given-names>J.-H.</given-names></name>
<name><surname>Lee</surname><given-names>J.-S.</given-names></name>
</person-group><article-title>Efficacy of a Novel Multiepitope Vaccine Candidate against Foot-and-Mouth Disease Virus Serotype O and A</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>2181</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10122181</pub-id><pub-id pub-id-type="pmid">36560591</pub-id>
</element-citation></ref><ref id="B48-vaccines-12-01344"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wibowo</surname><given-names>N.</given-names></name>
<name><surname>Hughes</surname><given-names>F.K.</given-names></name>
<name><surname>Fairmaid</surname><given-names>E.J.</given-names></name>
<name><surname>Lua</surname><given-names>L.H.L.</given-names></name>
<name><surname>Brown</surname><given-names>L.E.</given-names></name>
<name><surname>Middelberg</surname><given-names>A.P.J.</given-names></name>
</person-group><article-title>Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: Extending the potential of broadly cross-protecting epitopes</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>3651</fpage><lpage>3655</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.062</pub-id><pub-id pub-id-type="pmid">24795225</pub-id>
</element-citation></ref><ref id="B49-vaccines-12-01344"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deng</surname><given-names>L.</given-names></name>
<name><surname>Cho</surname><given-names>K.J.</given-names></name>
<name><surname>Fiers</surname><given-names>W.</given-names></name>
<name><surname>Saelens</surname><given-names>X.</given-names></name>
</person-group><article-title>M2e-based universal influenza a vaccines</article-title><source>Vaccines</source><year>2015</year><volume>3</volume><fpage>105</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.3390/vaccines3010105</pub-id><pub-id pub-id-type="pmid">26344949</pub-id>
</element-citation></ref><ref id="B50-vaccines-12-01344"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watkins</surname><given-names>H.C.</given-names></name>
<name><surname>Pagan</surname><given-names>C.L.</given-names></name>
<name><surname>Childs</surname><given-names>H.R.</given-names></name>
<name><surname>Posada</surname><given-names>S.</given-names></name>
<name><surname>Chau</surname><given-names>A.</given-names></name>
<name><surname>Rios</surname><given-names>J.</given-names></name>
<name><surname>Guarino</surname><given-names>C.</given-names></name>
<name><surname>DeLisa</surname><given-names>M.P.</given-names></name>
<name><surname>Whittaker</surname><given-names>G.R.</given-names></name>
<name><surname>Putnam</surname><given-names>D.</given-names></name>
</person-group><article-title>A single dose and long lasting vaccine against pandemic influenza through the controlled release of a heterospecies tandem M2 sequence embedded within detoxified bacterial outer membrane vesicles</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>5373</fpage><lpage>5380</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.08.013</pub-id><pub-id pub-id-type="pmid">28866291</pub-id>
</element-citation></ref><ref id="B51-vaccines-12-01344"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>G.</given-names></name>
<name><surname>Qiao</surname><given-names>X.</given-names></name>
<name><surname>Chang</surname><given-names>C.</given-names></name>
<name><surname>Hua</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
</person-group><article-title>Reduction of Postweaning Multisystemic Wasting Syndrome-Associated Clinical Symptoms by Virus-Like Particle Vaccine Against Porcine Parvovirus and Porcine Circovirus Type 2</article-title><source>Viral Immunol.</source><year>2020</year><volume>33</volume><fpage>444</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1089/vim.2019.0201</pub-id><pub-id pub-id-type="pmid">32255758</pub-id>
</element-citation></ref><ref id="B52-vaccines-12-01344"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ke</surname><given-names>Q.</given-names></name>
<name><surname>Sun</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Mi</surname><given-names>T.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
</person-group><article-title>Non-glycosylated SARS-CoV-2 RBD elicited a robust neutralizing antibody response in mice</article-title><source>J. Immunol. Methods</source><year>2022</year><volume>506</volume><fpage>113279</fpage><pub-id pub-id-type="doi">10.1016/j.jim.2022.113279</pub-id><pub-id pub-id-type="pmid">35533747</pub-id>
</element-citation></ref><ref id="B53-vaccines-12-01344"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Chang</surname><given-names>X.</given-names></name>
<name><surname>Rothen</surname><given-names>D.</given-names></name>
<name><surname>Derveni</surname><given-names>M.</given-names></name>
<name><surname>Krenger</surname><given-names>P.</given-names></name>
<name><surname>Roongta</surname><given-names>S.</given-names></name>
<name><surname>Wright</surname><given-names>E.</given-names></name>
<name><surname>Vogel</surname><given-names>M.</given-names></name>
<name><surname>Tars</surname><given-names>K.</given-names></name>
<name><surname>Mohsen</surname><given-names>M.O.</given-names></name>
</person-group><article-title>AP205 VLPs based on dimerized capsid proteins accommodate RBM domain of SARS-CoV-2 and serve as an attractive vaccine candidate</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>403</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9040403</pub-id><pub-id pub-id-type="pmid">33921677</pub-id>
</element-citation></ref><ref id="B54-vaccines-12-01344"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>W.S.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Ka</surname><given-names>S.Y.</given-names></name>
<name><surname>Chae</surname><given-names>H.D.</given-names></name>
<name><surname>Jung</surname><given-names>I.</given-names></name>
<name><surname>Jung</surname><given-names>S.T.</given-names></name>
<name><surname>Na</surname><given-names>J.-H.</given-names></name>
</person-group><article-title>Functional expression of the recombinant spike receptor binding domain of SARS-CoV-2 Omicron in the periplasm of <italic toggle="yes">Escherichia coli</italic></article-title><source>Bioengineering</source><year>2022</year><volume>9</volume><elocation-id>670</elocation-id><pub-id pub-id-type="doi">10.3390/bioengineering9110670</pub-id><pub-id pub-id-type="pmid">36354581</pub-id>
</element-citation></ref><ref id="B55-vaccines-12-01344"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGuire</surname><given-names>B.E.</given-names></name>
<name><surname>Mela</surname><given-names>J.E.</given-names></name>
<name><surname>Thompson</surname><given-names>V.C.</given-names></name>
<name><surname>Cucksey</surname><given-names>L.R.</given-names></name>
<name><surname>Stevens</surname><given-names>C.E.</given-names></name>
<name><surname>McWhinnie</surname><given-names>R.L.</given-names></name>
<name><surname>Winkler</surname><given-names>D.F.H.</given-names></name>
<name><surname>Pelech</surname><given-names>S.</given-names></name>
<name><surname>Nano</surname><given-names>F.E.</given-names></name>
</person-group><article-title><italic toggle="yes">Escherichia coli</italic> recombinant expression of SARS-CoV-2 protein fragments</article-title><source>Microb. Cell Fact.</source><year>2022</year><volume>21</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s12934-022-01753-0</pub-id><pub-id pub-id-type="pmid">35123472</pub-id>
</element-citation></ref><ref id="B56-vaccines-12-01344"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fitzgerald</surname><given-names>G.A.</given-names></name>
<name><surname>Komarov</surname><given-names>A.</given-names></name>
<name><surname>Kaznadzey</surname><given-names>A.</given-names></name>
<name><surname>Mazo</surname><given-names>I.</given-names></name>
<name><surname>Kireeva</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Expression of SARS-CoV-2 surface glycoprotein fragment 319&#x02013;640 in <italic toggle="yes">E. coli</italic>, and its refolding and purification</article-title><source>Protein Expr. Purif.</source><year>2021</year><volume>183</volume><fpage>105861</fpage><pub-id pub-id-type="doi">10.1016/j.pep.2021.105861</pub-id><pub-id pub-id-type="pmid">33667651</pub-id>
</element-citation></ref><ref id="B57-vaccines-12-01344"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Qi</surname><given-names>J.</given-names></name>
<name><surname>Xiao</surname><given-names>L.</given-names></name>
<name><surname>Shen</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>W.</given-names></name>
<name><surname>Hu</surname><given-names>T.</given-names></name>
</person-group><article-title>Purification and characterization of the receptor-binding domain of SARS-CoV-2 spike protein from <italic toggle="yes">Escherichia coli</italic></article-title><source>Eng. Life Sci.</source><year>2021</year><volume>21</volume><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1002/elsc.202000106</pub-id><pub-id pub-id-type="pmid">34140855</pub-id>
</element-citation></ref><ref id="B58-vaccines-12-01344"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clem</surname><given-names>R.J.</given-names></name>
<name><surname>Passarelli</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Baculoviruses: Sophisticated pathogens of insects</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003729</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003729</pub-id><pub-id pub-id-type="pmid">24244160</pub-id>
</element-citation></ref><ref id="B59-vaccines-12-01344"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pennock</surname><given-names>G.D.</given-names></name>
<name><surname>Shoemaker</surname><given-names>C.</given-names></name>
<name><surname>Miller</surname><given-names>L.K.</given-names></name>
</person-group><article-title>Strong and regulated expression of <italic toggle="yes">Escherichia coli</italic> beta-galactosidase in insect cells with a baculovirus vector</article-title><source>Mol. Cell. Biol.</source><year>1984</year><volume>4</volume><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1128/MCB.4.3.399</pub-id><pub-id pub-id-type="pmid">6325875</pub-id>
</element-citation></ref><ref id="B60-vaccines-12-01344"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>G.E.</given-names></name>
<name><surname>Summers</surname><given-names>M.D.</given-names></name>
<name><surname>Fraser</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Production of human beta interferon in insect cells infected with a baculovirus expression vector</article-title><source>Mol. Cell. Biol.</source><year>1983</year><volume>3</volume><fpage>2156</fpage><lpage>2165</lpage><pub-id pub-id-type="doi">10.1128/mcb.3.12.2156</pub-id><pub-id pub-id-type="pmid">6318086</pub-id>
</element-citation></ref><ref id="B61-vaccines-12-01344"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hitchman</surname><given-names>R.B.</given-names></name>
<name><surname>Possee</surname><given-names>R.D.</given-names></name>
<name><surname>King</surname><given-names>L.A.</given-names></name>
</person-group><article-title>High-throughput baculovirus expression in insect cells</article-title><source>Methods Mol. Biol.</source><year>2012</year><volume>824</volume><fpage>609</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-433-9_33</pub-id><pub-id pub-id-type="pmid">22160923</pub-id>
</element-citation></ref><ref id="B62-vaccines-12-01344"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hitchman</surname><given-names>R.B.</given-names></name>
<name><surname>Locanto</surname><given-names>E.</given-names></name>
<name><surname>Possee</surname><given-names>R.D.</given-names></name>
<name><surname>King</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Optimizing the baculovirus expression vector system</article-title><source>Methods</source><year>2011</year><volume>55</volume><fpage>52</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2011.06.011</pub-id><pub-id pub-id-type="pmid">21945427</pub-id>
</element-citation></ref><ref id="B63-vaccines-12-01344"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitts</surname><given-names>P.A.</given-names></name>
<name><surname>Ayres</surname><given-names>M.D.</given-names></name>
<name><surname>Possee</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Linearization of baculovirus DNA enhances the recovery of recombinant virus expression vectors</article-title><source>Nucleic Acids Res.</source><year>1990</year><volume>18</volume><fpage>5667</fpage><lpage>5672</lpage><pub-id pub-id-type="doi">10.1093/nar/18.19.5667</pub-id><pub-id pub-id-type="pmid">2216760</pub-id>
</element-citation></ref><ref id="B64-vaccines-12-01344"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitts</surname><given-names>P.A.</given-names></name>
<name><surname>Possee</surname><given-names>R.D.</given-names></name>
</person-group><article-title>A method for producing recombinant baculovirus expression vectors at high frequency</article-title><source>Biotechniques</source><year>1993</year><volume>14</volume><fpage>810</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">8512707</pub-id>
</element-citation></ref><ref id="B65-vaccines-12-01344"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luckow</surname><given-names>V.A.</given-names></name>
<name><surname>Lee</surname><given-names>S.C.</given-names></name>
<name><surname>Barry</surname><given-names>G.F.</given-names></name>
<name><surname>Olins</surname><given-names>P.O.</given-names></name>
</person-group><article-title>Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in <italic toggle="yes">Escherichia coli</italic></article-title><source>J. Virol.</source><year>1993</year><volume>67</volume><fpage>4566</fpage><lpage>4579</lpage><pub-id pub-id-type="doi">10.1128/jvi.67.8.4566-4579.1993</pub-id><pub-id pub-id-type="pmid">8392598</pub-id>
</element-citation></ref><ref id="B66-vaccines-12-01344"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berger</surname><given-names>I.</given-names></name>
<name><surname>Poterszman</surname><given-names>A.</given-names></name>
</person-group><article-title>Baculovirus expression: Old dog, new tricks</article-title><source>Bioengineered</source><year>2015</year><volume>6</volume><fpage>316</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1080/21655979.2015.1104433</pub-id><pub-id pub-id-type="pmid">26488462</pub-id>
</element-citation></ref><ref id="B67-vaccines-12-01344"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>X.</given-names></name>
<name><surname>Jarvis</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Protein N-glycosylation in the baculovirus-insect cell system</article-title><source>Curr. Drug Targets</source><year>2007</year><volume>8</volume><fpage>1116</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.2174/138945007782151360</pub-id><pub-id pub-id-type="pmid">17979671</pub-id>
</element-citation></ref><ref id="B68-vaccines-12-01344"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hong</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Xue</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Cui</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>Gu</surname><given-names>Y.</given-names></name>
<name><surname>Xia</surname><given-names>N.</given-names></name>
</person-group><article-title>Genetic engineering of baculovirus-insect cell system to improve protein production</article-title><source>Front. Bioeng. Biotechnol.</source><year>2022</year><volume>10</volume><elocation-id>994743</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2022.994743</pub-id><pub-id pub-id-type="pmid">36204465</pub-id>
</element-citation></ref><ref id="B69-vaccines-12-01344"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geisler</surname><given-names>C.</given-names></name>
<name><surname>Mabashi-Asazuma</surname><given-names>H.</given-names></name>
<name><surname>Jarvis</surname><given-names>D.L.</given-names></name>
</person-group><article-title>An overview and history of glyco-engineering in insect expression systems</article-title><source>Glyco-Eng. Methods Protoc.</source><year>2015</year><volume>1321</volume><fpage>131</fpage><lpage>152</lpage></element-citation></ref><ref id="B70-vaccines-12-01344"><label>70.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Palomares</surname><given-names>L.A.</given-names></name>
<name><surname>Srivastava</surname><given-names>I.K.</given-names></name>
<name><surname>Ram&#x000ed;rez</surname><given-names>O.T.</given-names></name>
<name><surname>Cox</surname><given-names>M.M.J.</given-names></name>
</person-group><article-title>Glycobiotechnology of the insect cell-baculovirus expression system technology</article-title><source>Advances in Glycobiotechnology</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2018</year><fpage>71</fpage><lpage>92</lpage></element-citation></ref><ref id="B71-vaccines-12-01344"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palmberger</surname><given-names>D.</given-names></name>
<name><surname>Ashjaei</surname><given-names>K.</given-names></name>
<name><surname>Strell</surname><given-names>S.</given-names></name>
<name><surname>Hoffmann-Sommergruber</surname><given-names>K.</given-names></name>
<name><surname>Grabherr</surname><given-names>R.</given-names></name>
</person-group><article-title>Minimizing fucosylation in insect cell-derived glycoproteins reduces binding to IgE antibodies from the sera of patients with allergy</article-title><source>Biotechnol. J.</source><year>2014</year><volume>9</volume><fpage>1206</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1002/biot.201300061</pub-id><pub-id pub-id-type="pmid">24753388</pub-id>
</element-citation></ref><ref id="B72-vaccines-12-01344"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jarvis</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production</article-title><source>Virology</source><year>2003</year><volume>310</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/S0042-6822(03)00120-X</pub-id><pub-id pub-id-type="pmid">12788624</pub-id>
</element-citation></ref><ref id="B73-vaccines-12-01344"><label>73.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Unger</surname><given-names>T.</given-names></name>
<name><surname>Peleg</surname><given-names>Y.</given-names></name>
</person-group><article-title>Recombinant protein expression in the baculovirus-infected insect cell system</article-title><source>Chemical Genomics and Proteomics</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2012</year><fpage>187</fpage><lpage>199</lpage></element-citation></ref><ref id="B74-vaccines-12-01344"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rendi&#x00107;</surname><given-names>D.</given-names></name>
<name><surname>Wilson</surname><given-names>I.B.H.</given-names></name>
<name><surname>Paschinger</surname><given-names>K.</given-names></name>
</person-group><article-title>The glycosylation capacity of insect cells</article-title><source>Croat. Chem. Acta</source><year>2008</year><volume>81</volume><fpage>7</fpage><lpage>21</lpage></element-citation></ref><ref id="B75-vaccines-12-01344"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frenzel</surname><given-names>A.</given-names></name>
<name><surname>Hust</surname><given-names>M.</given-names></name>
<name><surname>Schirrmann</surname><given-names>T.</given-names></name>
</person-group><article-title>Expression of recombinant antibodies</article-title><source>Front. Immunol.</source><year>2013</year><volume>4</volume><elocation-id>217</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00217</pub-id><pub-id pub-id-type="pmid">23908655</pub-id>
</element-citation></ref><ref id="B76-vaccines-12-01344"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Futatsumori-Sugai</surname><given-names>M.</given-names></name>
<name><surname>Tsumoto</surname><given-names>K.</given-names></name>
</person-group><article-title>Signal peptide design for improving recombinant protein secretion in the baculovirus expression vector system</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2010</year><volume>391</volume><fpage>931</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.11.167</pub-id><pub-id pub-id-type="pmid">19962965</pub-id>
</element-citation></ref><ref id="B77-vaccines-12-01344"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soejima</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>J.M.</given-names></name>
<name><surname>Nagata</surname><given-names>Y.</given-names></name>
<name><surname>Mon</surname><given-names>H.</given-names></name>
<name><surname>Iiyama</surname><given-names>K.</given-names></name>
<name><surname>Kitano</surname><given-names>H.</given-names></name>
<name><surname>Matsuyama</surname><given-names>M.</given-names></name>
<name><surname>Kusakabe</surname><given-names>T.</given-names></name>
</person-group><article-title>Comparison of signal peptides for efficient protein secretion in the baculovirus-silkworm system</article-title><source>Cent. Eur. J. Biol.</source><year>2013</year><volume>8</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2478/s11535-012-0112-6</pub-id></element-citation></ref><ref id="B78-vaccines-12-01344"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mori</surname><given-names>K.</given-names></name>
<name><surname>Hamada</surname><given-names>H.</given-names></name>
<name><surname>Ogawa</surname><given-names>T.</given-names></name>
<name><surname>Ohmuro-Matsuyama</surname><given-names>Y.</given-names></name>
<name><surname>Katsuda</surname><given-names>T.</given-names></name>
<name><surname>Yamaji</surname><given-names>H.</given-names></name>
</person-group><article-title>Efficient production of antibody Fab fragment by transient gene expression in insect cells</article-title><source>J. Biosci. Bioeng.</source><year>2017</year><volume>124</volume><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.jbiosc.2017.03.007</pub-id><pub-id pub-id-type="pmid">28410897</pub-id>
</element-citation></ref><ref id="B79-vaccines-12-01344"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bleckmann</surname><given-names>M.</given-names></name>
<name><surname>Sch&#x000fc;rig</surname><given-names>M.</given-names></name>
<name><surname>Endres</surname><given-names>M.</given-names></name>
<name><surname>Samuels</surname><given-names>A.</given-names></name>
<name><surname>Gebauer</surname><given-names>D.</given-names></name>
<name><surname>Konisch</surname><given-names>N.</given-names></name>
<name><surname>van den Heuvel</surname><given-names>J.</given-names></name>
</person-group><article-title>Identifying parameters to improve the reproducibility of transient gene expression in High Five cells</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0217878</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0217878</pub-id><pub-id pub-id-type="pmid">31170233</pub-id>
</element-citation></ref><ref id="B80-vaccines-12-01344"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bleckmann</surname><given-names>M.</given-names></name>
<name><surname>Schmelz</surname><given-names>S.</given-names></name>
<name><surname>Schinkowski</surname><given-names>C.</given-names></name>
<name><surname>Scrima</surname><given-names>A.</given-names></name>
<name><surname>van den Heuvel</surname><given-names>J.</given-names></name>
</person-group><article-title>Fast plasmid based protein expression analysis in insect cells using an automated SplitGFP screen</article-title><source>Biotechnol. Bioeng.</source><year>2016</year><volume>113</volume><fpage>1975</fpage><lpage>1983</lpage><pub-id pub-id-type="doi">10.1002/bit.25956</pub-id><pub-id pub-id-type="pmid">26913471</pub-id>
</element-citation></ref><ref id="B81-vaccines-12-01344"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>X.</given-names></name>
<name><surname>Pitol</surname><given-names>A.K.</given-names></name>
<name><surname>Bachmann</surname><given-names>V.</given-names></name>
<name><surname>Hacker</surname><given-names>D.L.</given-names></name>
<name><surname>Baldi</surname><given-names>L.</given-names></name>
<name><surname>Wurm</surname><given-names>F.M.</given-names></name>
</person-group><article-title>A simple plasmid-based transient gene expression method using High Five cells</article-title><source>J. Biotechnol.</source><year>2015</year><volume>216</volume><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2015.10.007</pub-id><pub-id pub-id-type="pmid">26476358</pub-id>
</element-citation></ref><ref id="B82-vaccines-12-01344"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>X.</given-names></name>
<name><surname>Hacker</surname><given-names>D.L.</given-names></name>
<name><surname>Baldi</surname><given-names>L.</given-names></name>
<name><surname>Wurm</surname><given-names>F.M.</given-names></name>
</person-group><article-title>Virus-free transient protein production in Sf9 cells</article-title><source>J. Biotechnol.</source><year>2014</year><volume>171</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2013.11.018</pub-id><pub-id pub-id-type="pmid">24333123</pub-id>
</element-citation></ref><ref id="B83-vaccines-12-01344"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Korn</surname><given-names>J.</given-names></name>
<name><surname>Sch&#x000e4;ckermann</surname><given-names>D.</given-names></name>
<name><surname>Kirmann</surname><given-names>T.</given-names></name>
<name><surname>Bertoglio</surname><given-names>F.</given-names></name>
<name><surname>Steinke</surname><given-names>S.</given-names></name>
<name><surname>Heisig</surname><given-names>J.</given-names></name>
<name><surname>Ruschig</surname><given-names>M.</given-names></name>
<name><surname>Rojas</surname><given-names>G.</given-names></name>
<name><surname>Langreder</surname><given-names>N.</given-names></name>
<name><surname>Wenzel</surname><given-names>E.V.</given-names></name>
<etal/>
</person-group><article-title>Baculovirus-free insect cell expression system for high yield antibody and antigen production</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>21393</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-78425-9</pub-id><pub-id pub-id-type="pmid">33288836</pub-id>
</element-citation></ref><ref id="B84-vaccines-12-01344"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogay</surname><given-names>I.D.</given-names></name>
<name><surname>Lihoradova</surname><given-names>O.A.</given-names></name>
<name><surname>Azimova</surname><given-names>S.S.</given-names></name>
<name><surname>Abdukarimov</surname><given-names>A.A.</given-names></name>
<name><surname>Slack</surname><given-names>J.M.</given-names></name>
<name><surname>Lynn</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Transfection of insect cell lines using polyethylenimine</article-title><source>Cytotechnology</source><year>2006</year><volume>51</volume><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">19002899</pub-id>
</element-citation></ref><ref id="B85-vaccines-12-01344"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Puente-Massaguer</surname><given-names>E.</given-names></name>
<name><surname>Lecina</surname><given-names>M.</given-names></name>
<name><surname>G&#x000f2;dia</surname><given-names>F.</given-names></name>
</person-group><article-title>Nanoscale characterization coupled to multi-parametric optimization of Hi5 cell transient gene expression</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>10495</fpage><lpage>10510</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-9423-5</pub-id><pub-id pub-id-type="pmid">30317441</pub-id>
</element-citation></ref><ref id="B86-vaccines-12-01344"><label>86.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Pandey</surname><given-names>D.</given-names></name>
<name><surname>Halder</surname><given-names>A.</given-names></name>
</person-group><source>Preventive, Diagnostic and Therapeutic Applications of Baculovirus Expression Vector System BT&#x02014;Trends in Insect Molecular Biology and Biotechnology</source><person-group person-group-type="editor">
<name><surname>Kumar</surname><given-names>D.</given-names></name>
<name><surname>Gong</surname><given-names>C.</given-names></name>
</person-group><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2018</year><fpage>163</fpage><lpage>191</lpage></element-citation></ref><ref id="B87-vaccines-12-01344"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Felberbaum</surname><given-names>R.S.</given-names></name>
</person-group><article-title>The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors</article-title><source>Biotechnol. J.</source><year>2015</year><volume>10</volume><fpage>702</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1002/biot.201400438</pub-id><pub-id pub-id-type="pmid">25800821</pub-id>
</element-citation></ref><ref id="B88-vaccines-12-01344"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>To</surname><given-names>A.</given-names></name>
<name><surname>Lai</surname><given-names>C.-Y.</given-names></name>
<name><surname>Wong</surname><given-names>T.A.</given-names></name>
<name><surname>Namekar</surname><given-names>M.</given-names></name>
<name><surname>Lehrer</surname><given-names>A.T.</given-names></name>
</person-group><article-title>A recombinant subunit Lassa virus vaccine elicits strong antibody responses</article-title><source>J. Immunol.</source><year>2020</year><volume>204</volume><fpage>167.30</fpage><pub-id pub-id-type="doi">10.4049/jimmunol.204.Supp.167.30</pub-id></element-citation></ref><ref id="B89-vaccines-12-01344"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qu</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Dai</surname><given-names>W.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Leng</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Insect cell-produced recombinant protein subunit vaccines protect against Zika virus infection</article-title><source>Antivir. Res.</source><year>2018</year><volume>154</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2018.04.010</pub-id><pub-id pub-id-type="pmid">29665376</pub-id>
</element-citation></ref><ref id="B90-vaccines-12-01344"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blome</surname><given-names>S.</given-names></name>
<name><surname>Meindl-B&#x000f6;hmer</surname><given-names>A.</given-names></name>
<name><surname>Loeffen</surname><given-names>W.</given-names></name>
<name><surname>Moennig</surname><given-names>V.</given-names></name>
</person-group><article-title>Assessment of classical swine fever diagnostics and vaccine performance</article-title><source>Int. Off. Epizoot.</source><year>2006</year><volume>25</volume><fpage>1025</fpage><lpage>1038</lpage></element-citation></ref><ref id="B91-vaccines-12-01344"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monie</surname><given-names>A.</given-names></name>
<name><surname>Hung</surname><given-names>C.-F.</given-names></name>
<name><surname>Roden</surname><given-names>R.</given-names></name>
<name><surname>Wu</surname><given-names>T.-C.</given-names></name>
</person-group><article-title>Cervarix: A vaccine for the prevention of HPV 16, 18-associated cervical cancer</article-title><source>Biologics</source><year>2008</year><volume>2</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.2147/btt.s1877</pub-id></element-citation></ref><ref id="B92-vaccines-12-01344"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cox</surname><given-names>M.M.J.</given-names></name>
<name><surname>Patriarca</surname><given-names>P.A.</given-names></name>
<name><surname>Treanor</surname><given-names>J.</given-names></name>
</person-group><article-title>FluBlok, a recombinant hemagglutinin influenza vaccine</article-title><source>Influenza Other Respi. Viruses</source><year>2008</year><volume>2</volume><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1111/j.1750-2659.2008.00053.x</pub-id><pub-id pub-id-type="pmid">19453397</pub-id>
</element-citation></ref><ref id="B93-vaccines-12-01344"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fort</surname><given-names>M.</given-names></name>
<name><surname>Sibila</surname><given-names>M.</given-names></name>
<name><surname>P&#x000e9;rez-Mart&#x000ed;n</surname><given-names>E.</given-names></name>
<name><surname>Nofrar&#x000ed;as</surname><given-names>M.</given-names></name>
<name><surname>Mateu</surname><given-names>E.</given-names></name>
<name><surname>Segal&#x000e9;s</surname><given-names>J.</given-names></name>
</person-group><article-title>One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>4031</fpage><lpage>4037</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.04.028</pub-id><pub-id pub-id-type="pmid">19379787</pub-id>
</element-citation></ref><ref id="B94-vaccines-12-01344"><label>94.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Coll</surname><given-names>T.</given-names></name>
<name><surname>Villalba</surname><given-names>D.</given-names></name>
<name><surname>Maass</surname><given-names>P.</given-names></name>
</person-group><article-title>Meta-Analysis of Globally Published Results on the Efficacy of Ingelvac CircoFLEX&#x000ae; Vaccination</article-title><year>2010</year><comment>Available online: <ext-link xlink:href="https://hdl.handle.net/11299/135564" ext-link-type="uri">https://hdl.handle.net/11299/135564</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-01">(accessed on 1 June 2024)</date-in-citation></element-citation></ref><ref id="B95-vaccines-12-01344"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sno</surname><given-names>M.</given-names></name>
<name><surname>Cox</surname><given-names>E.</given-names></name>
<name><surname>Holtslag</surname><given-names>H.</given-names></name>
<name><surname>Nell</surname><given-names>T.</given-names></name>
<name><surname>Pel</surname><given-names>S.</given-names></name>
<name><surname>Segers</surname><given-names>R.</given-names></name>
<name><surname>Fachinger</surname><given-names>V.</given-names></name>
<name><surname>Witvliet</surname><given-names>M.</given-names></name>
</person-group><article-title>Efficacy and safety of a new intradermal PCV2 vaccine in pigs</article-title><source>Trials Vaccinol.</source><year>2016</year><volume>5</volume><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.trivac.2016.01.002</pub-id></element-citation></ref><ref id="B96-vaccines-12-01344"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Metz</surname><given-names>S.W.</given-names></name>
<name><surname>Gardner</surname><given-names>J.</given-names></name>
<name><surname>Geertsema</surname><given-names>C.</given-names></name>
<name><surname>Le</surname><given-names>T.T.</given-names></name>
<name><surname>Goh</surname><given-names>L.</given-names></name>
<name><surname>Vlak</surname><given-names>J.M.</given-names></name>
<name><surname>Suhrbier</surname><given-names>A.</given-names></name>
<name><surname>Pijlman</surname><given-names>G.P.</given-names></name>
</person-group><article-title>Effective chikungunya virus-like particle vaccine produced in insect cells</article-title><source>PLoS Negl. Trop. Dis.</source><year>2013</year><volume>7</volume><elocation-id>e2124</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002124</pub-id><pub-id pub-id-type="pmid">23516657</pub-id>
</element-citation></ref><ref id="B97-vaccines-12-01344"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Metz</surname><given-names>S.W.</given-names></name>
<name><surname>Martina</surname><given-names>B.E.</given-names></name>
<name><surname>van den Doel</surname><given-names>P.</given-names></name>
<name><surname>Geertsema</surname><given-names>C.</given-names></name>
<name><surname>Osterhaus</surname><given-names>A.D.</given-names></name>
<name><surname>Vlak</surname><given-names>J.M.</given-names></name>
<name><surname>Pijlman</surname><given-names>G.P.</given-names></name>
</person-group><article-title>Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>6092</fpage><lpage>6096</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.09.045</pub-id><pub-id pub-id-type="pmid">24099875</pub-id>
</element-citation></ref><ref id="B98-vaccines-12-01344"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tran</surname><given-names>H.T.T.</given-names></name>
<name><surname>Truong</surname><given-names>D.A.</given-names></name>
<name><surname>Ly</surname><given-names>V.D.</given-names></name>
<name><surname>Vu</surname><given-names>H.T.</given-names></name>
<name><surname>Van Hoang</surname><given-names>T.</given-names></name>
<name><surname>Nguyen</surname><given-names>C.T.</given-names></name>
<name><surname>Chu</surname><given-names>N.T.</given-names></name>
<name><surname>Nguyen</surname><given-names>V.T.</given-names></name>
<name><surname>Nguyen</surname><given-names>D.T.</given-names></name>
<name><surname>Miyazawa</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>The potential efficacy of the E2-subunit vaccine to protect pigs against different genotypes of classical swine fever virus circulating in Vietnam</article-title><source>Clin. Exp. Vaccine Res.</source><year>2020</year><volume>9</volume><fpage>26</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.7774/cevr.2020.9.1.26</pub-id><pub-id pub-id-type="pmid">32095438</pub-id>
</element-citation></ref><ref id="B99-vaccines-12-01344"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Wen</surname><given-names>Z.</given-names></name>
<name><surname>Carrion</surname><given-names>R.J.</given-names></name>
<name><surname>Nunneley</surname><given-names>J.</given-names></name>
<name><surname>Staples</surname><given-names>H.</given-names></name>
<name><surname>Ticer</surname><given-names>A.</given-names></name>
<name><surname>Patterson</surname><given-names>J.L.</given-names></name>
<name><surname>Compans</surname><given-names>R.W.</given-names></name>
<name><surname>Ye</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
</person-group><article-title>Intradermal Immunization of EBOV VLPs in Guinea Pigs Induces Broader Antibody Responses Against GP Than Intramuscular Injection</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>304</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.00304</pub-id><pub-id pub-id-type="pmid">32174901</pub-id>
</element-citation></ref><ref id="B100-vaccines-12-01344"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sunwoo</surname><given-names>S.Y.</given-names></name>
<name><surname>Noronha</surname><given-names>L.E.</given-names></name>
<name><surname>Morozov</surname><given-names>I.</given-names></name>
<name><surname>Trujillo</surname><given-names>J.D.</given-names></name>
<name><surname>Kim</surname><given-names>I.J.</given-names></name>
<name><surname>Schirtzinger</surname><given-names>E.E.</given-names></name>
<name><surname>Faburay</surname><given-names>B.</given-names></name>
<name><surname>Drolet</surname><given-names>B.S.</given-names></name>
<name><surname>Urbaniak</surname><given-names>K.</given-names></name>
<name><surname>Scott Mcvey</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of a baculovirus-expressed VP2 subunit vaccine for the protection of white-tailed deer (<italic toggle="yes">Odocoileus virginianus</italic>) from epizootic hemorrhagic disease</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>59</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8010059</pub-id><pub-id pub-id-type="pmid">32023812</pub-id>
</element-citation></ref><ref id="B101-vaccines-12-01344"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pyo</surname><given-names>H.-M.</given-names></name>
<name><surname>Masic</surname><given-names>A.</given-names></name>
<name><surname>Woldeab</surname><given-names>N.</given-names></name>
<name><surname>Embury-Hyatt</surname><given-names>C.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Shin</surname><given-names>Y.-K.</given-names></name>
<name><surname>Song</surname><given-names>J.-Y.</given-names></name>
<name><surname>Babiuk</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
</person-group><article-title>Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>1297</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.12.083</pub-id><pub-id pub-id-type="pmid">22207090</pub-id>
</element-citation></ref><ref id="B102-vaccines-12-01344"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>W.-Z.</given-names></name>
<name><surname>Wen</surname><given-names>Y.-C.</given-names></name>
<name><surname>Lin</surname><given-names>S.-Y.</given-names></name>
<name><surname>Chen</surname><given-names>T.-C.</given-names></name>
<name><surname>Chen</surname><given-names>H.-W.</given-names></name>
</person-group><article-title>Anti-influenza protective efficacy of a H6 virus-like particle in chickens</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>465</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8030465</pub-id><pub-id pub-id-type="pmid">32825685</pub-id>
</element-citation></ref><ref id="B103-vaccines-12-01344"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faburay</surname><given-names>B.</given-names></name>
<name><surname>Wilson</surname><given-names>W.C.</given-names></name>
<name><surname>Gaudreault</surname><given-names>N.N.</given-names></name>
<name><surname>Davis</surname><given-names>A.S.</given-names></name>
<name><surname>Shivanna</surname><given-names>V.</given-names></name>
<name><surname>Bawa</surname><given-names>B.</given-names></name>
<name><surname>Sunwoo</surname><given-names>S.Y.</given-names></name>
<name><surname>Ma</surname><given-names>W.</given-names></name>
<name><surname>Drolet</surname><given-names>B.S.</given-names></name>
<name><surname>Morozov</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>27719</elocation-id><pub-id pub-id-type="doi">10.1038/srep27719</pub-id><pub-id pub-id-type="pmid">27296136</pub-id>
</element-citation></ref><ref id="B104-vaccines-12-01344"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faburay</surname><given-names>B.</given-names></name>
<name><surname>Lebedev</surname><given-names>M.</given-names></name>
<name><surname>McVey</surname><given-names>D.S.</given-names></name>
<name><surname>Wilson</surname><given-names>W.</given-names></name>
<name><surname>Morozov</surname><given-names>I.</given-names></name>
<name><surname>Young</surname><given-names>A.</given-names></name>
<name><surname>Richt</surname><given-names>J.A.</given-names></name>
</person-group><article-title>A Glycoprotein Subunit Vaccine Elicits a Strong Rift Valley Fever Virus Neutralizing Antibody Response in Sheep</article-title><source>Vector-Borne Zoonotic Dis.</source><year>2014</year><volume>14</volume><fpage>746</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1089/vbz.2014.1650</pub-id><pub-id pub-id-type="pmid">25325319</pub-id>
</element-citation></ref><ref id="B105-vaccines-12-01344"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Lu</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Bi</surname><given-names>Z.</given-names></name>
<name><surname>Bao</surname><given-names>L.</given-names></name>
<name><surname>Mo</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
</person-group><article-title>A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>572</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2599-8</pub-id><pub-id pub-id-type="pmid">32726802</pub-id>
</element-citation></ref><ref id="B106-vaccines-12-01344"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hong</surname><given-names>S.-H.</given-names></name>
<name><surname>Oh</surname><given-names>H.</given-names></name>
<name><surname>Park</surname><given-names>Y.W.</given-names></name>
<name><surname>Kwak</surname><given-names>H.W.</given-names></name>
<name><surname>Oh</surname><given-names>E.Y.</given-names></name>
<name><surname>Park</surname><given-names>H.-J.</given-names></name>
<name><surname>Kang</surname><given-names>K.W.</given-names></name>
<name><surname>Kim</surname><given-names>G.</given-names></name>
<name><surname>Koo</surname><given-names>B.-S.</given-names></name>
<name><surname>Hwang</surname><given-names>E.-H.</given-names></name>
<etal/>
</person-group><article-title>Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates</article-title><source>Sci. Adv.</source><year>2023</year><volume>7</volume><fpage>eabg7156</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abg7156</pub-id><pub-id pub-id-type="pmid">34049881</pub-id>
</element-citation></ref><ref id="B107-vaccines-12-01344"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>B.</given-names></name>
<name><surname>Castro</surname><given-names>R.</given-names></name>
<name><surname>Bhoelan</surname><given-names>F.</given-names></name>
<name><surname>Bemelman</surname><given-names>D.</given-names></name>
<name><surname>Gomes</surname><given-names>R.A.</given-names></name>
<name><surname>Costa</surname><given-names>J.</given-names></name>
<name><surname>Gomes-Alves</surname><given-names>P.</given-names></name>
<name><surname>Stegmann</surname><given-names>T.</given-names></name>
<name><surname>Amacker</surname><given-names>M.</given-names></name>
<name><surname>Alves</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Insect cells for high-yield production of SARS-CoV-2 spike protein: Building a virosome-based COVID-19 vaccine candidate</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>854</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14040854</pub-id><pub-id pub-id-type="pmid">35456687</pub-id>
</element-citation></ref><ref id="B108-vaccines-12-01344"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mi</surname><given-names>Y.</given-names></name>
<name><surname>Xie</surname><given-names>T.</given-names></name>
<name><surname>Zhu</surname><given-names>B.</given-names></name>
<name><surname>Tan</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Luo</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Niu</surname><given-names>H.</given-names></name>
<name><surname>Han</surname><given-names>J.</given-names></name>
<name><surname>Lv</surname><given-names>W.</given-names></name>
</person-group><article-title>Production of SARS-CoV-2 virus-like particles in insect cells</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>554</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9060554</pub-id><pub-id pub-id-type="pmid">34073159</pub-id>
</element-citation></ref><ref id="B109-vaccines-12-01344"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaron</surname><given-names>M.</given-names></name>
<name><surname>Lehky</surname><given-names>M.</given-names></name>
<name><surname>Zar&#x000e0;</surname><given-names>M.</given-names></name>
<name><surname>Zaydowicz</surname><given-names>C.N.</given-names></name>
<name><surname>Lak</surname><given-names>A.</given-names></name>
<name><surname>Ballmann</surname><given-names>R.</given-names></name>
<name><surname>Heine</surname><given-names>P.A.</given-names></name>
<name><surname>Wenzel</surname><given-names>E.V.</given-names></name>
<name><surname>Schneider</surname><given-names>K.-T.</given-names></name>
<name><surname>Bertoglio</surname><given-names>F.</given-names></name>
</person-group><article-title>Baculovirus-Free SARS-CoV-2 Virus-like Particle Production in Insect Cells for Rapid Neutralization Assessment</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>2087</elocation-id><pub-id pub-id-type="doi">10.3390/v14102087</pub-id><pub-id pub-id-type="pmid">36298643</pub-id>
</element-citation></ref><ref id="B110-vaccines-12-01344"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Struble</surname><given-names>L.R.</given-names></name>
<name><surname>Smith</surname><given-names>A.L.</given-names></name>
<name><surname>Lutz</surname><given-names>W.E.</given-names></name>
<name><surname>Grubbs</surname><given-names>G.</given-names></name>
<name><surname>Sagar</surname><given-names>S.</given-names></name>
<name><surname>Bayles</surname><given-names>K.W.</given-names></name>
<name><surname>Radhakrishnan</surname><given-names>P.</given-names></name>
<name><surname>Khurana</surname><given-names>S.</given-names></name>
<name><surname>El-Gamal</surname><given-names>D.</given-names></name>
<name><surname>Borgstahl</surname><given-names>G.E.O.</given-names></name>
</person-group><article-title>Insect cell expression and purification of recombinant SARS-COV-2 spike proteins that demonstrate ACE2 binding</article-title><source>Protein Sci.</source><year>2022</year><volume>31</volume><fpage>e4300</fpage><pub-id pub-id-type="doi">10.1002/pro.4300</pub-id><pub-id pub-id-type="pmid">35481636</pub-id>
</element-citation></ref><ref id="B111-vaccines-12-01344"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Hu</surname><given-names>W.</given-names></name>
<name><surname>Hao</surname><given-names>P.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
</person-group><article-title>Impact of expressing cells on glycosylation and glycan of the SARS-CoV-2 spike glycoprotein</article-title><source>ACS Omega</source><year>2021</year><volume>6</volume><fpage>15988</fpage><lpage>15999</lpage><pub-id pub-id-type="doi">10.1021/acsomega.1c01785</pub-id><pub-id pub-id-type="pmid">34179644</pub-id>
</element-citation></ref><ref id="B112-vaccines-12-01344"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Zheng</surname><given-names>Q.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Wu</surname><given-names>D.</given-names></name>
<name><surname>Xue</surname><given-names>W.</given-names></name>
<name><surname>Xiong</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Nie</surname><given-names>M.</given-names></name>
<name><surname>Yue</surname><given-names>M.</given-names></name>
<name><surname>Rong</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates</article-title><source>Emerg. Microbes Infect.</source><year>2020</year><volume>9</volume><fpage>2076</fpage><lpage>2090</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1821583</pub-id><pub-id pub-id-type="pmid">32897177</pub-id>
</element-citation></ref><ref id="B113-vaccines-12-01344"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bandaranayake</surname><given-names>A.D.</given-names></name>
<name><surname>Almo</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Recent advances in mammalian protein production</article-title><source>FEBS Lett.</source><year>2014</year><volume>588</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2013.11.035</pub-id><pub-id pub-id-type="pmid">24316512</pub-id>
</element-citation></ref><ref id="B114-vaccines-12-01344"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>J.</given-names></name>
</person-group><article-title>Mammalian cell protein expression for biopharmaceutical production</article-title><source>Biotechnol. Adv.</source><year>2012</year><volume>30</volume><fpage>1158</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2011.08.022</pub-id><pub-id pub-id-type="pmid">21968146</pub-id>
</element-citation></ref><ref id="B115-vaccines-12-01344"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jenkins</surname><given-names>N.</given-names></name>
<name><surname>Meleady</surname><given-names>P.</given-names></name>
<name><surname>Tyther</surname><given-names>R.</given-names></name>
<name><surname>Murphy</surname><given-names>L.</given-names></name>
</person-group><article-title>Strategies for analysing and improving the expression and quality of recombinant proteins made in mammalian cells</article-title><source>Biotechnol. Appl. Biochem.</source><year>2009</year><volume>53</volume><fpage>73</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1042/BA20080258</pub-id><pub-id pub-id-type="pmid">19397493</pub-id>
</element-citation></ref><ref id="B116-vaccines-12-01344"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Butler</surname><given-names>M.</given-names></name>
</person-group><article-title>Animal cell cultures: Recent achievements and perspectives in the production of biopharmaceuticals</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2005</year><volume>68</volume><fpage>283</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1007/s00253-005-1980-8</pub-id><pub-id pub-id-type="pmid">15834715</pub-id>
</element-citation></ref><ref id="B117-vaccines-12-01344"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wiznerowicz</surname><given-names>M.</given-names></name>
<name><surname>Trono</surname><given-names>D.</given-names></name>
</person-group><article-title>Harnessing HIV for therapy, basic research and biotechnology</article-title><source>Trends Biotechnol.</source><year>2005</year><volume>23</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2004.11.001</pub-id><pub-id pub-id-type="pmid">15629857</pub-id>
</element-citation></ref><ref id="B118-vaccines-12-01344"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giry-Laterri&#x000e8;re</surname><given-names>M.</given-names></name>
<name><surname>Verhoeyen</surname><given-names>E.</given-names></name>
<name><surname>Salmon</surname><given-names>P.</given-names></name>
</person-group><article-title>Lentiviral vectors</article-title><source>Methods Mol. Biol.</source><year>2011</year><volume>737</volume><fpage>183</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-095-9_8</pub-id><pub-id pub-id-type="pmid">21590398</pub-id>
</element-citation></ref><ref id="B119-vaccines-12-01344"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramezani</surname><given-names>A.</given-names></name>
<name><surname>Hawley</surname><given-names>R.G.</given-names></name>
</person-group><article-title>Overview of the HIV-1 Lentiviral Vector System</article-title><source>Curr. Protoc. Mol. Biol.</source><year>2002</year><volume>60</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1002/0471142727.mb1621s60</pub-id></element-citation></ref><ref id="B120-vaccines-12-01344"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kafri</surname><given-names>T.</given-names></name>
<name><surname>van Praag</surname><given-names>H.</given-names></name>
<name><surname>Gage</surname><given-names>F.H.</given-names></name>
<name><surname>Verma</surname><given-names>I.M.</given-names></name>
</person-group><article-title>Lentiviral Vectors: Regulated Gene Expression</article-title><source>Mol. Ther.</source><year>2000</year><volume>1</volume><fpage>516</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1006/mthe.2000.0083</pub-id><pub-id pub-id-type="pmid">10933976</pub-id>
</element-citation></ref><ref id="B121-vaccines-12-01344"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiscornia</surname><given-names>G.</given-names></name>
<name><surname>Singer</surname><given-names>O.</given-names></name>
<name><surname>Verma</surname><given-names>I.M.</given-names></name>
</person-group><article-title>Production and purification of lentiviral vectors</article-title><source>Nat. Protoc.</source><year>2006</year><volume>1</volume><fpage>241</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.37</pub-id><pub-id pub-id-type="pmid">17406239</pub-id>
</element-citation></ref><ref id="B122-vaccines-12-01344"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rueckert</surname><given-names>C.</given-names></name>
<name><surname>Guzm&#x000e1;n</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Vaccines: From empirical development to rational design</article-title><source>PLoS Pathog.</source><year>2012</year><volume>8</volume><elocation-id>e1003001</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003001</pub-id><pub-id pub-id-type="pmid">23144616</pub-id>
</element-citation></ref><ref id="B123-vaccines-12-01344"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geisse</surname><given-names>S.</given-names></name>
</person-group><article-title>Reflections on more than 10 years of TGE approaches</article-title><source>Protein Expr. Purif.</source><year>2009</year><volume>64</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2008.10.017</pub-id><pub-id pub-id-type="pmid">19027070</pub-id>
</element-citation></ref><ref id="B124-vaccines-12-01344"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Dalby</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Kilzer</surname><given-names>J.M.</given-names></name>
<name><surname>Chiou</surname><given-names>H.C.</given-names></name>
</person-group><article-title>Transient transfection factors for high-level recombinant protein production in suspension cultured mammalian cells</article-title><source>Mol. Biotechnol.</source><year>2008</year><volume>39</volume><fpage>141</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1007/s12033-008-9051-x</pub-id><pub-id pub-id-type="pmid">18327552</pub-id>
</element-citation></ref><ref id="B125-vaccines-12-01344"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baldi</surname><given-names>L.</given-names></name>
<name><surname>Hacker</surname><given-names>D.L.</given-names></name>
<name><surname>Adam</surname><given-names>M.</given-names></name>
<name><surname>Wurm</surname><given-names>F.M.</given-names></name>
</person-group><article-title>Recombinant protein production by large-scale transient gene expression in mammalian cells: State of the art and future perspectives</article-title><source>Biotechnol. Lett.</source><year>2007</year><volume>29</volume><fpage>677</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1007/s10529-006-9297-y</pub-id><pub-id pub-id-type="pmid">17235486</pub-id>
</element-citation></ref><ref id="B126-vaccines-12-01344"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rozkov</surname><given-names>A.</given-names></name>
<name><surname>Larsson</surname><given-names>B.</given-names></name>
<name><surname>Gillstr&#x000f6;m</surname><given-names>S.</given-names></name>
<name><surname>Bj&#x000f6;rnestedt</surname><given-names>R.</given-names></name>
<name><surname>Schmidt</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Large-scale production of endotoxin-free plasmids for transient expression in mammalian cell culture</article-title><source>Biotechnol. Bioeng.</source><year>2008</year><volume>99</volume><fpage>557</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1002/bit.21603</pub-id><pub-id pub-id-type="pmid">17680665</pub-id>
</element-citation></ref><ref id="B127-vaccines-12-01344"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yarranton</surname><given-names>G.T.</given-names></name>
</person-group><article-title>Inducible vectors for expression in mammalian cells</article-title><source>Curr. Opin. Biotechnol.</source><year>1992</year><volume>3</volume><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1016/0958-1669(92)90078-W</pub-id><pub-id pub-id-type="pmid">1368935</pub-id>
</element-citation></ref><ref id="B128-vaccines-12-01344"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fike</surname><given-names>R.</given-names></name>
</person-group><article-title>Nutrient supplementation strategies for biopharmaceutical production, Part 3</article-title><source>Bioproc. Int.</source><year>2010</year><volume>8</volume><fpage>24</fpage><lpage>31</lpage></element-citation></ref><ref id="B129-vaccines-12-01344"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lufino</surname><given-names>M.M.P.</given-names></name>
<name><surname>Edser</surname><given-names>P.A.H.</given-names></name>
<name><surname>Wade-Martins</surname><given-names>R.</given-names></name>
</person-group><article-title>Advances in high-capacity extrachromosomal vector technology: Episomal maintenance, vector delivery, and transgene expression</article-title><source>Mol. Ther.</source><year>2008</year><volume>16</volume><fpage>1525</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.1038/mt.2008.156</pub-id><pub-id pub-id-type="pmid">18628754</pub-id>
</element-citation></ref><ref id="B130-vaccines-12-01344"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cacciatore</surname><given-names>J.J.</given-names></name>
<name><surname>Chasin</surname><given-names>L.A.</given-names></name>
<name><surname>Leonard</surname><given-names>E.F.</given-names></name>
</person-group><article-title>Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system</article-title><source>Biotechnol. Adv.</source><year>2010</year><volume>28</volume><fpage>673</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2010.04.003</pub-id><pub-id pub-id-type="pmid">20416368</pub-id>
</element-citation></ref><ref id="B131-vaccines-12-01344"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>L.M.</given-names></name>
<name><surname>Bentley</surname><given-names>C.M.</given-names></name>
<name><surname>Dickson</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Advances in animal cell recombinant protein production: GS-NS0 expression system</article-title><source>Cytotechnology</source><year>2000</year><volume>32</volume><fpage>109</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1023/A:1008170710003</pub-id><pub-id pub-id-type="pmid">19002973</pub-id>
</element-citation></ref><ref id="B132-vaccines-12-01344"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jadhav</surname><given-names>V.</given-names></name>
<name><surname>Hackl</surname><given-names>M.</given-names></name>
<name><surname>Druz</surname><given-names>A.</given-names></name>
<name><surname>Shridhar</surname><given-names>S.</given-names></name>
<name><surname>Chung</surname><given-names>C.-Y.</given-names></name>
<name><surname>Heffner</surname><given-names>K.M.</given-names></name>
<name><surname>Kreil</surname><given-names>D.P.</given-names></name>
<name><surname>Betenbaugh</surname><given-names>M.</given-names></name>
<name><surname>Shiloach</surname><given-names>J.</given-names></name>
<name><surname>Barron</surname><given-names>N.</given-names></name>
</person-group><article-title>CHO microRNA engineering is growing up: Recent successes and future challenges</article-title><source>Biotechnol. Adv.</source><year>2013</year><volume>31</volume><fpage>1501</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2013.07.007</pub-id><pub-id pub-id-type="pmid">23916872</pub-id>
</element-citation></ref><ref id="B133-vaccines-12-01344"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jefferis</surname><given-names>R.</given-names></name>
</person-group><article-title>Glycosylation as a strategy to improve antibody-based therapeutics</article-title><source>Nat. Rev. Drug Discov.</source><year>2009</year><volume>8</volume><fpage>226</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1038/nrd2804</pub-id><pub-id pub-id-type="pmid">19247305</pub-id>
</element-citation></ref><ref id="B134-vaccines-12-01344"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costa</surname><given-names>A.R.</given-names></name>
<name><surname>Rodrigues</surname><given-names>M.E.</given-names></name>
<name><surname>Henriques</surname><given-names>M.</given-names></name>
<name><surname>Oliveira</surname><given-names>R.</given-names></name>
<name><surname>Azeredo</surname><given-names>J.</given-names></name>
</person-group><article-title>Glycosylation: Impact, control and improvement during therapeutic protein production</article-title><source>Crit. Rev. Biotechnol.</source><year>2014</year><volume>34</volume><fpage>281</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.3109/07388551.2013.793649</pub-id><pub-id pub-id-type="pmid">23919242</pub-id>
</element-citation></ref><ref id="B135-vaccines-12-01344"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beck</surname><given-names>A.</given-names></name>
<name><surname>Wagner-Rousset</surname><given-names>E.</given-names></name>
<name><surname>Bussat</surname><given-names>M.-C.</given-names></name>
<name><surname>Lokteff</surname><given-names>M.</given-names></name>
<name><surname>Klinguer-Hamour</surname><given-names>C.</given-names></name>
<name><surname>Haeuw</surname><given-names>J.-F.</given-names></name>
<name><surname>Goetsch</surname><given-names>L.</given-names></name>
<name><surname>Wurch</surname><given-names>T.</given-names></name>
<name><surname>Dorsselaer</surname><given-names>A.V.</given-names></name>
<name><surname>Corva&#x000ef;a</surname><given-names>N.</given-names></name>
</person-group><article-title>Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins</article-title><source>Curr. Pharm. Biotechnol.</source><year>2008</year><volume>9</volume><fpage>482</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.2174/138920108786786411</pub-id><pub-id pub-id-type="pmid">19075687</pub-id>
</element-citation></ref><ref id="B136-vaccines-12-01344"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bosques</surname><given-names>C.J.</given-names></name>
<name><surname>Collins</surname><given-names>B.E.</given-names></name>
<name><surname>Meador</surname><given-names>J.W.</given-names></name>
<name><surname>Sarvaiya</surname><given-names>H.</given-names></name>
<name><surname>Murphy</surname><given-names>J.L.</given-names></name>
<name><surname>DelloRusso</surname><given-names>G.</given-names></name>
<name><surname>Bulik</surname><given-names>D.A.</given-names></name>
<name><surname>Hsu</surname><given-names>I.-H.</given-names></name>
<name><surname>Washburn</surname><given-names>N.</given-names></name>
<name><surname>Sipsey</surname><given-names>S.F.</given-names></name>
</person-group><article-title>Chinese hamster ovary cells can produce galactose-&#x003b1;-1, 3-galactose antigens on proteins</article-title><source>Nat. Biotechnol.</source><year>2010</year><volume>28</volume><fpage>1153</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1038/nbt1110-1153</pub-id><pub-id pub-id-type="pmid">21057479</pub-id>
</element-citation></ref><ref id="B137-vaccines-12-01344"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hills</surname><given-names>A.E.</given-names></name>
<name><surname>Patel</surname><given-names>A.</given-names></name>
<name><surname>Boyd</surname><given-names>P.</given-names></name>
<name><surname>James</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells</article-title><source>Biotechnol. Bioeng.</source><year>2001</year><volume>75</volume><fpage>239</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1002/bit.10022</pub-id><pub-id pub-id-type="pmid">11536148</pub-id>
</element-citation></ref><ref id="B138-vaccines-12-01344"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baker</surname><given-names>K.N.</given-names></name>
<name><surname>Rendall</surname><given-names>M.H.</given-names></name>
<name><surname>Hills</surname><given-names>A.E.</given-names></name>
<name><surname>Hoare</surname><given-names>M.</given-names></name>
<name><surname>Freedman</surname><given-names>R.B.</given-names></name>
<name><surname>James</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells</article-title><source>Biotechnol. Bioeng.</source><year>2001</year><volume>73</volume><fpage>188</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/bit.1051</pub-id><pub-id pub-id-type="pmid">11257601</pub-id>
</element-citation></ref><ref id="B139-vaccines-12-01344"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sordo-Puga</surname><given-names>Y.</given-names></name>
<name><surname>Su&#x000e1;rez-Pedroso</surname><given-names>M.</given-names></name>
<name><surname>Naranjo-Vald&#x000e9;z</surname><given-names>P.</given-names></name>
<name><surname>P&#x000e9;rez-P&#x000e9;rez</surname><given-names>D.</given-names></name>
<name><surname>Santana-Rodr&#x000ed;guez</surname><given-names>E.</given-names></name>
<name><surname>Sardinas-Gonzalez</surname><given-names>T.</given-names></name>
<name><surname>Mendez-Orta</surname><given-names>M.K.</given-names></name>
<name><surname>Duarte-Cano</surname><given-names>C.A.</given-names></name>
<name><surname>Estrada-Garcia</surname><given-names>M.P.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Molt&#x000f3;</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Porvac<sup>&#x000ae;</sup> Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection against Classical Swine Fever Virus</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>167</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9020167</pub-id><pub-id pub-id-type="pmid">33671399</pub-id>
</element-citation></ref><ref id="B140-vaccines-12-01344"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;rez Rubio</surname><given-names>A.</given-names></name>
<name><surname>Eiros</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Cell culture-derived flu vaccine: Present and future</article-title><source>Hum. Vaccines Immunother.</source><year>2018</year><volume>14</volume><fpage>1874</fpage><lpage>1882</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1460297</pub-id></element-citation></ref><ref id="B141-vaccines-12-01344"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Partridge</surname><given-names>J.</given-names></name>
<name><surname>Kieny</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Global production capacity of seasonal influenza vaccine in 2011</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>728</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.111</pub-id><pub-id pub-id-type="pmid">23149268</pub-id>
</element-citation></ref><ref id="B142-vaccines-12-01344"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lamb</surname><given-names>Y.N.</given-names></name>
</person-group><article-title>Cell-Based Quadrivalent Inactivated InfluenzaVirus Vaccine (Flucelvax<sup>&#x000ae;</sup> Tetra/FlucelvaxQuadrivalent<sup>&#x000ae;</sup>): A Review in the Prevention ofInfluenza</article-title><source>Drugs</source><year>2019</year><volume>79</volume><fpage>1337</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1007/s40265-019-01176-z</pub-id><pub-id pub-id-type="pmid">31372959</pub-id>
</element-citation></ref><ref id="B143-vaccines-12-01344"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bouzya</surname><given-names>B.</given-names></name>
<name><surname>Rouxel</surname><given-names>R.N.</given-names></name>
<name><surname>Sacconnay</surname><given-names>L.</given-names></name>
<name><surname>Mascolo</surname><given-names>R.</given-names></name>
<name><surname>Nols</surname><given-names>L.</given-names></name>
<name><surname>Quique</surname><given-names>S.</given-names></name>
<name><surname>Fran&#x000e7;ois</surname><given-names>L.</given-names></name>
<name><surname>Atas</surname><given-names>A.</given-names></name>
<name><surname>Warter</surname><given-names>L.</given-names></name>
<name><surname>Dezutter</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF<sub>3</sub>) vaccine in animal models</article-title><source>npj Vaccines</source><year>2023</year><volume>8</volume><fpage>143</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00729-4</pub-id><pub-id pub-id-type="pmid">37773185</pub-id>
</element-citation></ref><ref id="B144-vaccines-12-01344"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kotb</surname><given-names>S.</given-names></name>
<name><surname>Haranaka</surname><given-names>M.</given-names></name>
<name><surname>Folschweiller</surname><given-names>N.</given-names></name>
<name><surname>Nakanwagi</surname><given-names>P.</given-names></name>
<name><surname>Verheust</surname><given-names>C.</given-names></name>
<name><surname>De Schrevel</surname><given-names>N.</given-names></name>
<name><surname>David</surname><given-names>M.-P.</given-names></name>
<name><surname>Mesaros</surname><given-names>N.</given-names></name>
<name><surname>Hulstr&#x000f8;m</surname><given-names>V.</given-names></name>
</person-group><article-title>Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF<sub>3</sub>) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial</article-title><source>Respir. Investig.</source><year>2023</year><volume>61</volume><fpage>261</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.resinv.2022.11.003</pub-id><pub-id pub-id-type="pmid">36641341</pub-id>
</element-citation></ref><ref id="B145-vaccines-12-01344"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kopera</surname><given-names>E.</given-names></name>
<name><surname>Czajka</surname><given-names>H.</given-names></name>
<name><surname>Zapolnik</surname><given-names>P.</given-names></name>
<name><surname>Mazur</surname><given-names>A.</given-names></name>
</person-group><article-title>New Insights on Respiratory Syncytial Virus Prevention</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1797</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11121797</pub-id><pub-id pub-id-type="pmid">38140201</pub-id>
</element-citation></ref><ref id="B146-vaccines-12-01344"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leroux-Roels</surname><given-names>I.</given-names></name>
<name><surname>Davis</surname><given-names>M.G.</given-names></name>
<name><surname>Steenackers</surname><given-names>K.</given-names></name>
<name><surname>Essink</surname><given-names>B.</given-names></name>
<name><surname>Vandermeulen</surname><given-names>C.</given-names></name>
<name><surname>Fogarty</surname><given-names>C.</given-names></name>
<name><surname>Andrews</surname><given-names>C.P.</given-names></name>
<name><surname>Kerwin</surname><given-names>E.</given-names></name>
<name><surname>David</surname><given-names>M.-P.</given-names></name>
<name><surname>Fissette</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF<sub>3</sub>) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial</article-title><source>J. Infect. Dis.</source><year>2023</year><volume>227</volume><fpage>761</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac327</pub-id><pub-id pub-id-type="pmid">35904987</pub-id>
</element-citation></ref><ref id="B147-vaccines-12-01344"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bebia</surname><given-names>Z.</given-names></name>
<name><surname>Reyes</surname><given-names>O.</given-names></name>
<name><surname>Jeanfreau</surname><given-names>R.</given-names></name>
<name><surname>Kantele</surname><given-names>A.</given-names></name>
<name><surname>De Leon</surname><given-names>R.G.</given-names></name>
<name><surname>S&#x000e1;nchez</surname><given-names>M.G.</given-names></name>
<name><surname>Banooni</surname><given-names>P.</given-names></name>
<name><surname>Gardener</surname><given-names>G.J.</given-names></name>
<name><surname>Rasero</surname><given-names>J.L.B.</given-names></name>
<name><surname>Pardilla</surname><given-names>M.B.E.</given-names></name>
<etal/>
</person-group><article-title>Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF<sub>3</sub>) in Mothers and Their Infants: A Phase 2 Randomized Trial</article-title><source>J. Infect. Dis.</source><year>2023</year><volume>228</volume><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiad024</pub-id><pub-id pub-id-type="pmid">36722147</pub-id>
</element-citation></ref><ref id="B148-vaccines-12-01344"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fleming-Dutra</surname><given-names>K.E.</given-names></name>
</person-group><article-title>Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus&#x02013;associated lower respiratory tract disease in infants: Recommendations of the Advisory Committee on Immunization Practices&#x02014;United Stat</article-title><source>MMWR. Morb. Mortal. Wkly. Rep.</source><year>2023</year><volume>72</volume><fpage>1115</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7241e1</pub-id><pub-id pub-id-type="pmid">37824423</pub-id>
</element-citation></ref><ref id="B149-vaccines-12-01344"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Che</surname><given-names>Y.</given-names></name>
<name><surname>Gribenko</surname><given-names>A.V.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Handke</surname><given-names>L.D.</given-names></name>
<name><surname>Efferen</surname><given-names>K.S.</given-names></name>
<name><surname>Tompkins</surname><given-names>K.</given-names></name>
<name><surname>Kodali</surname><given-names>S.</given-names></name>
<name><surname>Nunez</surname><given-names>L.</given-names></name>
<name><surname>Prasad</surname><given-names>A.K.</given-names></name>
<name><surname>Phelan</surname><given-names>L.M.</given-names></name>
<etal/>
</person-group><article-title>Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine</article-title><source>Sci. Transl. Med.</source><year>2024</year><volume>15</volume><fpage>eade6422</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.ade6422</pub-id><pub-id pub-id-type="pmid">37023209</pub-id>
</element-citation></ref><ref id="B150-vaccines-12-01344"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walsh</surname><given-names>E.E.</given-names></name>
<name><surname>Falsey</surname><given-names>A.R.</given-names></name>
<name><surname>Scott</surname><given-names>D.A.</given-names></name>
<name><surname>Gurtman</surname><given-names>A.</given-names></name>
<name><surname>Zareba</surname><given-names>A.M.</given-names></name>
<name><surname>Jansen</surname><given-names>K.U.</given-names></name>
<name><surname>Gruber</surname><given-names>W.C.</given-names></name>
<name><surname>Dormitzer</surname><given-names>P.R.</given-names></name>
<name><surname>Swanson</surname><given-names>K.A.</given-names></name>
<name><surname>Radley</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>225</volume><fpage>1357</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab612</pub-id><pub-id pub-id-type="pmid">34932102</pub-id>
</element-citation></ref><ref id="B151-vaccines-12-01344"><label>151.</label><element-citation publication-type="confproc"><person-group person-group-type="author">
<name><surname>Melgar</surname><given-names>M.</given-names></name>
<name><surname>Britton</surname><given-names>A.</given-names></name>
</person-group><article-title>Evidence to Recommendations Framework: Respiratory Syncytial Virus (RSV) in Adults Pfizer bivalent RSVpreF vaccine in older adults GSK adjuvanted RSVPreF<sub>3</sub> vaccine in older adults</article-title><source>Proceedings of the ACIP Meeting</source><conf-loc>Atlanta, GA, USA</conf-loc><conf-date>21&#x02013;23 June 2023</conf-date></element-citation></ref><ref id="B152-vaccines-12-01344"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>H.</given-names></name>
<name><surname>Ren</surname><given-names>X.</given-names></name>
<name><surname>Hao</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.</given-names></name>
<name><surname>Fang</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Rong</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Efficient mucosal vaccination of a novel classical swine fever virus E2-Fc fusion protein mediated by neonatal Fc receptor</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>4574</fpage><lpage>4583</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.05.013</pub-id><pub-id pub-id-type="pmid">32417139</pub-id>
</element-citation></ref><ref id="B153-vaccines-12-01344"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bossart</surname><given-names>K.N.</given-names></name>
<name><surname>Crameri</surname><given-names>G.</given-names></name>
<name><surname>Dimitrov</surname><given-names>A.S.</given-names></name>
<name><surname>Mungall</surname><given-names>B.A.</given-names></name>
<name><surname>Feng</surname><given-names>Y.-R.</given-names></name>
<name><surname>Patch</surname><given-names>J.R.</given-names></name>
<name><surname>Choudhary</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>L.-F.</given-names></name>
<name><surname>Eaton</surname><given-names>B.T.</given-names></name>
<name><surname>Broder</surname><given-names>C.C.</given-names></name>
</person-group><article-title>Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>6690</fpage><lpage>6702</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.11.6690-6702.2005</pub-id><pub-id pub-id-type="pmid">15890907</pub-id>
</element-citation></ref><ref id="B154-vaccines-12-01344"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bossart</surname><given-names>K.N.</given-names></name>
<name><surname>Rockx</surname><given-names>B.</given-names></name>
<name><surname>Feldmann</surname><given-names>F.</given-names></name>
<name><surname>Brining</surname><given-names>D.</given-names></name>
<name><surname>Scott</surname><given-names>D.</given-names></name>
<name><surname>LaCasse</surname><given-names>R.</given-names></name>
<name><surname>Geisbert</surname><given-names>J.B.</given-names></name>
<name><surname>Feng</surname><given-names>Y.-R.</given-names></name>
<name><surname>Chan</surname><given-names>Y.-P.</given-names></name>
<name><surname>Hickey</surname><given-names>A.C.</given-names></name>
<etal/>
</person-group><article-title>A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge</article-title><source>Sci. Transl. Med.</source><year>2012</year><volume>4</volume><fpage>146ra107</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3004241</pub-id><pub-id pub-id-type="pmid">22875827</pub-id>
</element-citation></ref><ref id="B155-vaccines-12-01344"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McEachern</surname><given-names>J.A.</given-names></name>
<name><surname>Bingham</surname><given-names>J.</given-names></name>
<name><surname>Crameri</surname><given-names>G.</given-names></name>
<name><surname>Green</surname><given-names>D.J.</given-names></name>
<name><surname>Hancock</surname><given-names>T.J.</given-names></name>
<name><surname>Middleton</surname><given-names>D.</given-names></name>
<name><surname>Feng</surname><given-names>Y.-R.</given-names></name>
<name><surname>Broder</surname><given-names>C.C.</given-names></name>
<name><surname>Wang</surname><given-names>L.-F.</given-names></name>
<name><surname>Bossart</surname><given-names>K.N.</given-names></name>
</person-group><article-title>A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>3842</fpage><lpage>3852</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.05.016</pub-id><pub-id pub-id-type="pmid">18556094</pub-id>
</element-citation></ref><ref id="B156-vaccines-12-01344"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pallister</surname><given-names>J.</given-names></name>
<name><surname>Middleton</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>L.-F.</given-names></name>
<name><surname>Klein</surname><given-names>R.</given-names></name>
<name><surname>Haining</surname><given-names>J.</given-names></name>
<name><surname>Robinson</surname><given-names>R.</given-names></name>
<name><surname>Yamada</surname><given-names>M.</given-names></name>
<name><surname>White</surname><given-names>J.</given-names></name>
<name><surname>Payne</surname><given-names>J.</given-names></name>
<name><surname>Feng</surname><given-names>Y.-R.</given-names></name>
<etal/>
</person-group><article-title>A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>5623</fpage><lpage>5630</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.015</pub-id><pub-id pub-id-type="pmid">21689706</pub-id>
</element-citation></ref><ref id="B157-vaccines-12-01344"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Middleton</surname><given-names>D.</given-names></name>
<name><surname>Pallister</surname><given-names>J.</given-names></name>
<name><surname>Klein</surname><given-names>R.</given-names></name>
<name><surname>Feng</surname><given-names>Y.-R.</given-names></name>
<name><surname>Haining</surname><given-names>J.</given-names></name>
<name><surname>Arkinstall</surname><given-names>R.</given-names></name>
<name><surname>Frazer</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>J.-A.</given-names></name>
<name><surname>Edwards</surname><given-names>N.</given-names></name>
<name><surname>Wareing</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health</article-title><source>Emerg. Infect. Dis.</source><year>2014</year><volume>20</volume><fpage>372</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.3201/eid2003.131159</pub-id><pub-id pub-id-type="pmid">24572697</pub-id>
</element-citation></ref><ref id="B158-vaccines-12-01344"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pallister</surname><given-names>J.A.</given-names></name>
<name><surname>Klein</surname><given-names>R.</given-names></name>
<name><surname>Arkinstall</surname><given-names>R.</given-names></name>
<name><surname>Haining</surname><given-names>J.</given-names></name>
<name><surname>Long</surname><given-names>F.</given-names></name>
<name><surname>White</surname><given-names>J.R.</given-names></name>
<name><surname>Payne</surname><given-names>J.</given-names></name>
<name><surname>Feng</surname><given-names>Y.-R.</given-names></name>
<name><surname>Wang</surname><given-names>L.-F.</given-names></name>
<name><surname>Broder</surname><given-names>C.C.</given-names></name>
<etal/>
</person-group><article-title>Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months</article-title><source>Virol. J.</source><year>2013</year><volume>10</volume><fpage>237</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-10-237</pub-id><pub-id pub-id-type="pmid">23867060</pub-id>
</element-citation></ref><ref id="B159-vaccines-12-01344"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Young-Il</surname><given-names>K.</given-names></name>
<name><surname>Dokyun</surname><given-names>K.</given-names></name>
<name><surname>Kwang-Min</surname><given-names>Y.</given-names></name>
<name><surname>David</surname><given-names>S.H.</given-names></name>
<name><surname>Shin-Ae</surname><given-names>L.</given-names></name>
<name><surname>Casel</surname><given-names>M.A.B.</given-names></name>
<name><surname>Seung-Gyu</surname><given-names>J.</given-names></name>
<name><surname>Stephanie</surname><given-names>K.</given-names></name>
<name><surname>WooRam</surname><given-names>J.</given-names></name>
<name><surname>Chih-Jen</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets</article-title><source>MBio</source><year>2021</year><volume>12</volume><fpage>e00230-21</fpage><pub-id pub-id-type="doi">10.1128/mbio.00230-21</pub-id><pub-id pub-id-type="pmid">33653891</pub-id>
</element-citation></ref><ref id="B160-vaccines-12-01344"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kassardjian</surname><given-names>A.</given-names></name>
<name><surname>Sun</surname><given-names>E.</given-names></name>
<name><surname>Sookhoo</surname><given-names>J.</given-names></name>
<name><surname>Muthuraman</surname><given-names>K.</given-names></name>
<name><surname>Boligan</surname><given-names>K.F.</given-names></name>
<name><surname>Kucharska</surname><given-names>I.</given-names></name>
<name><surname>Rujas</surname><given-names>E.</given-names></name>
<name><surname>Jetha</surname><given-names>A.</given-names></name>
<name><surname>Branch</surname><given-names>D.R.</given-names></name>
<name><surname>Babiuk</surname><given-names>S.</given-names></name>
</person-group><article-title>Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>112391</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112391</pub-id><pub-id pub-id-type="pmid">37053069</pub-id>
</element-citation></ref><ref id="B161-vaccines-12-01344"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colgrave</surname><given-names>M.L.</given-names></name>
<name><surname>Snelling</surname><given-names>H.J.</given-names></name>
<name><surname>Shiell</surname><given-names>B.J.</given-names></name>
<name><surname>Feng</surname><given-names>Y.-R.</given-names></name>
<name><surname>Chan</surname><given-names>Y.-P.</given-names></name>
<name><surname>Bossart</surname><given-names>K.N.</given-names></name>
<name><surname>Xu</surname><given-names>K.</given-names></name>
<name><surname>Nikolov</surname><given-names>D.B.</given-names></name>
<name><surname>Broder</surname><given-names>C.C.</given-names></name>
<name><surname>Michalski</surname><given-names>W.P.</given-names></name>
</person-group><article-title>Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus</article-title><source>Glycobiology</source><year>2012</year><volume>22</volume><fpage>572</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwr180</pub-id><pub-id pub-id-type="pmid">22171062</pub-id>
</element-citation></ref><ref id="B162-vaccines-12-01344"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gst&#x000f6;ttner</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Resemann</surname><given-names>A.</given-names></name>
<name><surname>Ruben</surname><given-names>S.</given-names></name>
<name><surname>Pengelley</surname><given-names>S.</given-names></name>
<name><surname>Suckau</surname><given-names>D.</given-names></name>
<name><surname>Welsink</surname><given-names>T.</given-names></name>
<name><surname>Wuhrer</surname><given-names>M.</given-names></name>
<name><surname>Dom&#x000ed;nguez-Vega</surname><given-names>E.</given-names></name>
</person-group><article-title>Structural and Functional Characterization of SARS-CoV-2 RBD Domains Produced in Mammalian Cells</article-title><source>Anal. Chem.</source><year>2021</year><volume>93</volume><fpage>6839</fpage><lpage>6847</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.1c00893</pub-id><pub-id pub-id-type="pmid">33871970</pub-id>
</element-citation></ref><ref id="B163-vaccines-12-01344"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arbeitman</surname><given-names>C.R.</given-names></name>
<name><surname>Auge</surname><given-names>G.</given-names></name>
<name><surname>Blaustein</surname><given-names>M.</given-names></name>
<name><surname>Bredeston</surname><given-names>L.</given-names></name>
<name><surname>Corapi</surname><given-names>E.S.</given-names></name>
<name><surname>Craig</surname><given-names>P.O.</given-names></name>
<name><surname>Cossio</surname><given-names>L.A.</given-names></name>
<name><surname>Dain</surname><given-names>L.</given-names></name>
<name><surname>D&#x02019;Alessio</surname><given-names>C.</given-names></name>
<name><surname>Elias</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in <italic toggle="yes">Pichia pastoris</italic> and mammalian cells</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>21779</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-78711-6</pub-id><pub-id pub-id-type="pmid">33311634</pub-id>
</element-citation></ref><ref id="B164-vaccines-12-01344"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brindha</surname><given-names>S.</given-names></name>
<name><surname>Kuroda</surname><given-names>Y.</given-names></name>
</person-group><article-title>A Multi-Disulfide Receptor-Binding Domain (RBD) of the SARS-CoV-2 Spike Protein Expressed in <italic toggle="yes">E. coli</italic> Using a SEP-Tag Produces Antisera Interacting with the Mammalian Cell Expressed Spike (S1) Protein</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>1703</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23031703</pub-id><pub-id pub-id-type="pmid">35163624</pub-id>
</element-citation></ref><ref id="B165-vaccines-12-01344"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Merkuleva</surname><given-names>I.A.</given-names></name>
<name><surname>Shcherbakov</surname><given-names>D.N.</given-names></name>
<name><surname>Borgoyakova</surname><given-names>M.B.</given-names></name>
<name><surname>Shanshin</surname><given-names>D.V.</given-names></name>
<name><surname>Rudometov</surname><given-names>A.P.</given-names></name>
<name><surname>Karpenko</surname><given-names>L.I.</given-names></name>
<name><surname>Belenkaya</surname><given-names>S.V.</given-names></name>
<name><surname>Isaeva</surname><given-names>A.A.</given-names></name>
<name><surname>Nesmeyanova</surname><given-names>V.S.</given-names></name>
<name><surname>Kazachinskaia</surname><given-names>E.I.</given-names></name>
<etal/>
</person-group><article-title>Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>96</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10010096</pub-id><pub-id pub-id-type="pmid">35062757</pub-id>
</element-citation></ref><ref id="B166-vaccines-12-01344"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arias-Arias</surname><given-names>J.L.</given-names></name>
<name><surname>Molina-Castro</surname><given-names>S.E.</given-names></name>
<name><surname>Monturiol-Gross</surname><given-names>L.</given-names></name>
<name><surname>Lomonte</surname><given-names>B.</given-names></name>
<name><surname>Corrales-Aguilar</surname><given-names>E.</given-names></name>
</person-group><article-title>Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing</article-title><source>Biotechnol. Rep.</source><year>2023</year><volume>37</volume><elocation-id>e00780</elocation-id><pub-id pub-id-type="doi">10.1016/j.btre.2022.e00780</pub-id><pub-id pub-id-type="pmid">36619904</pub-id>
</element-citation></ref><ref id="B167-vaccines-12-01344"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>R.</given-names></name>
<name><surname>Shi</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Song</surname><given-names>P.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
</person-group><article-title>Construction of SARS-CoV-2 virus-like particles by mammalian expression system</article-title><source>Front. Bioeng. Biotechnol.</source><year>2020</year><volume>8</volume><elocation-id>862</elocation-id><pub-id pub-id-type="pmid">32850726</pub-id>
</element-citation></ref><ref id="B168-vaccines-12-01344"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garc&#x000ed;a-Cordero</surname><given-names>J.</given-names></name>
<name><surname>Mendoza-Ram&#x000ed;rez</surname><given-names>J.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Benavides</surname><given-names>D.</given-names></name>
<name><surname>Roa-Velazquez</surname><given-names>D.</given-names></name>
<name><surname>Filisola-Villase&#x000f1;or</surname><given-names>J.</given-names></name>
<name><surname>Mart&#x000ed;nez-Fr&#x000ed;as</surname><given-names>S.P.</given-names></name>
<name><surname>Sanchez-Salguero</surname><given-names>E.S.</given-names></name>
<name><surname>Miguel-Rodr&#x000ed;guez</surname><given-names>C.E.</given-names></name>
<name><surname>Maravillas Montero</surname><given-names>J.L.</given-names></name>
<name><surname>Torres-Ruiz</surname><given-names>J.J.</given-names></name>
<etal/>
</person-group><article-title>Recombinant Protein Expression and Purification of N, S1, and RBD of SARS-CoV-2 from Mammalian Cells and Their Potential Applications</article-title><source>Diagnostics</source><year>2021</year><volume>11</volume><elocation-id>1808</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics11101808</pub-id><pub-id pub-id-type="pmid">34679506</pub-id>
</element-citation></ref><ref id="B169-vaccines-12-01344"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shouval</surname><given-names>D.</given-names></name>
</person-group><article-title>Hepatitis B vaccines</article-title><source>J. Hepatol.</source><year>2003</year><volume>39</volume><issue>(Suppl. 1)</issue><fpage>S70</fpage><lpage>S76</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(03)00152-1</pub-id><pub-id pub-id-type="pmid">14708681</pub-id>
</element-citation></ref><ref id="B170-vaccines-12-01344"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bryan</surname><given-names>J.T.</given-names></name>
</person-group><article-title>Developing an HPV vaccine to prevent cervical cancer and genital warts</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>3001</fpage><lpage>3006</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.01.013</pub-id><pub-id pub-id-type="pmid">17289220</pub-id>
</element-citation></ref><ref id="B171-vaccines-12-01344"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Damasceno</surname><given-names>L.M.</given-names></name>
<name><surname>Huang</surname><given-names>C.-J.</given-names></name>
<name><surname>Batt</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Protein secretion in <italic toggle="yes">Pichia pastoris</italic> and advances in protein production</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2012</year><volume>93</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1007/s00253-011-3654-z</pub-id><pub-id pub-id-type="pmid">22057543</pub-id>
</element-citation></ref><ref id="B172-vaccines-12-01344"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeong</surname><given-names>K.J.</given-names></name>
<name><surname>Jang</surname><given-names>S.H.</given-names></name>
<name><surname>Velmurugan</surname><given-names>N.</given-names></name>
</person-group><article-title>Recombinant antibodies: Engineering and production in yeast and bacterial hosts</article-title><source>Biotechnol. J.</source><year>2011</year><volume>6</volume><fpage>16</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1002/biot.201000381</pub-id><pub-id pub-id-type="pmid">21170983</pub-id>
</element-citation></ref><ref id="B173-vaccines-12-01344"><label>173.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Cregg</surname><given-names>J.M.</given-names></name>
<name><surname>Tolstorukov</surname><given-names>I.</given-names></name>
<name><surname>Kusari</surname><given-names>A.</given-names></name>
<name><surname>Sunga</surname><given-names>J.</given-names></name>
<name><surname>Madden</surname><given-names>K.</given-names></name>
<name><surname>Chappell</surname><given-names>T.</given-names></name>
</person-group><article-title>Expression in the yeast <italic toggle="yes">Pichia pastoris</italic></article-title><source>Methods in Enzymology</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2009</year><volume>Volume 463</volume><fpage>169</fpage><lpage>189</lpage></element-citation></ref><ref id="B174-vaccines-12-01344"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jahic</surname><given-names>M.</given-names></name>
<name><surname>Veide</surname><given-names>A.</given-names></name>
<name><surname>Charoenrat</surname><given-names>T.</given-names></name>
<name><surname>Teeri</surname><given-names>T.</given-names></name>
<name><surname>Enfors</surname><given-names>S.</given-names></name>
</person-group><article-title>Process technology for production and recovery of heterologous proteins with <italic toggle="yes">Pichia pastoris</italic></article-title><source>Biotechnol. Prog.</source><year>2006</year><volume>22</volume><fpage>1465</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1021/bp060171t</pub-id><pub-id pub-id-type="pmid">17137292</pub-id>
</element-citation></ref><ref id="B175-vaccines-12-01344"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomimoto</surname><given-names>K.</given-names></name>
<name><surname>Fujita</surname><given-names>Y.</given-names></name>
<name><surname>Iwaki</surname><given-names>T.</given-names></name>
<name><surname>Chiba</surname><given-names>Y.</given-names></name>
<name><surname>Jigami</surname><given-names>Y.</given-names></name>
<name><surname>Nakayama</surname><given-names>K.</given-names></name>
<name><surname>Nakajima</surname><given-names>Y.</given-names></name>
<name><surname>Abe</surname><given-names>H.</given-names></name>
</person-group><article-title>Protease-deficient <italic toggle="yes">Saccharomyces cerevisiae</italic> strains for the synthesis of human-compatible glycoproteins</article-title><source>Biosci. Biotechnol. Biochem.</source><year>2013</year><volume>77</volume><fpage>2461</fpage><lpage>2466</lpage><pub-id pub-id-type="doi">10.1271/bbb.130588</pub-id><pub-id pub-id-type="pmid">24317067</pub-id>
</element-citation></ref><ref id="B176-vaccines-12-01344"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Celik</surname><given-names>E.</given-names></name>
<name><surname>Cal&#x00131;k</surname><given-names>P.</given-names></name>
</person-group><article-title>Production of recombinant proteins by yeast cells</article-title><source>Biotechnol. Adv.</source><year>2012</year><volume>30</volume><fpage>1108</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2011.09.011</pub-id><pub-id pub-id-type="pmid">21964262</pub-id>
</element-citation></ref><ref id="B177-vaccines-12-01344"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laurent</surname><given-names>J.M.</given-names></name>
<name><surname>Young</surname><given-names>J.H.</given-names></name>
<name><surname>Kachroo</surname><given-names>A.H.</given-names></name>
<name><surname>Marcotte</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Efforts to make and apply humanized yeast</article-title><source>Brief. Funct. Genom.</source><year>2016</year><volume>15</volume><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1093/bfgp/elv041</pub-id></element-citation></ref><ref id="B178-vaccines-12-01344"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wildt</surname><given-names>S.</given-names></name>
<name><surname>Gerngross</surname><given-names>T.U.</given-names></name>
</person-group><article-title>The humanization of N-glycosylation pathways in yeast</article-title><source>Nat. Rev. Microbiol.</source><year>2005</year><volume>3</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1087</pub-id><pub-id pub-id-type="pmid">15685223</pub-id>
</element-citation></ref><ref id="B179-vaccines-12-01344"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Shen</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Wan</surname><given-names>S.</given-names></name>
<name><surname>Qiu</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Tan</surname><given-names>H.</given-names></name>
</person-group><article-title>Humanization of yeasts for glycan-type end-products</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>930658</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.930658</pub-id><pub-id pub-id-type="pmid">35875538</pub-id>
</element-citation></ref><ref id="B180-vaccines-12-01344"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bobrowicz</surname><given-names>P.</given-names></name>
<name><surname>Davidson</surname><given-names>R.C.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Potgieter</surname><given-names>T.I.</given-names></name>
<name><surname>Nett</surname><given-names>J.H.</given-names></name>
<name><surname>Hamilton</surname><given-names>S.R.</given-names></name>
<name><surname>Stadheim</surname><given-names>T.A.</given-names></name>
<name><surname>Miele</surname><given-names>R.G.</given-names></name>
<name><surname>Bobrowicz</surname><given-names>B.</given-names></name>
<name><surname>Mitchell</surname><given-names>T.</given-names></name>
</person-group><article-title>Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast <italic toggle="yes">Pichia pastoris</italic>: Production of complex humanized glycoproteins with terminal galactose</article-title><source>Glycobiology</source><year>2004</year><volume>14</volume><fpage>757</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwh104</pub-id><pub-id pub-id-type="pmid">15190003</pub-id>
</element-citation></ref><ref id="B181-vaccines-12-01344"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>M.B.</given-names></name>
<name><surname>Bhalla</surname><given-names>P.L.</given-names></name>
</person-group><article-title>Recombinant expression systems for allergen vaccines</article-title><source>Inflamm. Allergy-Drug Targets (Formerly Curr. Drug Targets-Inflamm. Allergy)</source><year>2006</year><volume>5</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.2174/187152806775269312</pub-id></element-citation></ref><ref id="B182-vaccines-12-01344"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bernstein</surname><given-names>M.B.</given-names></name>
<name><surname>Chakraborty</surname><given-names>M.</given-names></name>
<name><surname>Wansley</surname><given-names>E.K.</given-names></name>
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Franzusoff</surname><given-names>A.</given-names></name>
<name><surname>Mostb&#x000f6;ck</surname><given-names>S.</given-names></name>
<name><surname>Sabzevari</surname><given-names>H.</given-names></name>
<name><surname>Schlom</surname><given-names>J.</given-names></name>
<name><surname>Hodge</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Recombinant <italic toggle="yes">Saccharomyces cerevisiae</italic> (yeast-CEA) as a potent activator of murine dendritic cells</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>509</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.11.033</pub-id><pub-id pub-id-type="pmid">18155327</pub-id>
</element-citation></ref><ref id="B183-vaccines-12-01344"><label>183.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Munson</surname><given-names>S.</given-names></name>
<name><surname>Parker</surname><given-names>J.</given-names></name>
<name><surname>King</surname><given-names>T.H.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Kelley</surname><given-names>V.</given-names></name>
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Borges</surname><given-names>V.</given-names></name>
<name><surname>Franzusoff</surname><given-names>A.</given-names></name>
</person-group><article-title>Coupling innate and adaptive immunity with yeast-based cancer immunotherapy</article-title><source>Cancer Vaccines and Tumor Immunity</source><publisher-name>John Wiley &#x00026; Sons, Inc.</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2008</year><fpage>131</fpage><lpage>149</lpage></element-citation></ref><ref id="B184-vaccines-12-01344"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Remondo</surname><given-names>C.</given-names></name>
<name><surname>Cereda</surname><given-names>V.</given-names></name>
<name><surname>Mostb&#x000f6;ck</surname><given-names>S.</given-names></name>
<name><surname>Sabzevari</surname><given-names>H.</given-names></name>
<name><surname>Franzusoff</surname><given-names>A.</given-names></name>
<name><surname>Schlom</surname><given-names>J.</given-names></name>
<name><surname>Tsang</surname><given-names>K.-Y.</given-names></name>
</person-group><article-title>Human dendritic cell maturation and activation by a heat-killed recombinant yeast (<italic toggle="yes">Saccharomyces cerevisiae</italic>) vector encoding carcinoembryonic antigen</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>987</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.12.002</pub-id><pub-id pub-id-type="pmid">19110021</pub-id>
</element-citation></ref><ref id="B185-vaccines-12-01344"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ueno</surname><given-names>K.</given-names></name>
<name><surname>Okawara</surname><given-names>A.</given-names></name>
<name><surname>Yamagoe</surname><given-names>S.</given-names></name>
<name><surname>Naka</surname><given-names>T.</given-names></name>
<name><surname>Umeyama</surname><given-names>T.</given-names></name>
<name><surname>Utena-Abe</surname><given-names>Y.</given-names></name>
<name><surname>Tarumoto</surname><given-names>N.</given-names></name>
<name><surname>Niimi</surname><given-names>M.</given-names></name>
<name><surname>Ohno</surname><given-names>H.</given-names></name>
<name><surname>Doe</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>The mannan of Candida albicans lacking &#x003b2;-1,2-linked oligomannosides increases the production of inflammatory cytokines by dendritic cells</article-title><source>Med. Mycol.</source><year>2013</year><volume>51</volume><fpage>385</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.3109/13693786.2012.733892</pub-id><pub-id pub-id-type="pmid">23101887</pub-id>
</element-citation></ref><ref id="B186-vaccines-12-01344"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roohvand</surname><given-names>F.</given-names></name>
<name><surname>Shokri</surname><given-names>M.</given-names></name>
<name><surname>Abdollahpour-Alitappeh</surname><given-names>M.</given-names></name>
<name><surname>Ehsani</surname><given-names>P.</given-names></name>
</person-group><article-title>Biomedical applications of yeast- a patent view, part one: Yeasts as workhorses for the production of therapeutics and vaccines</article-title><source>Expert Opin. Ther. Pat.</source><year>2017</year><volume>27</volume><fpage>929</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1080/13543776.2017.1339789</pub-id><pub-id pub-id-type="pmid">28608761</pub-id>
</element-citation></ref><ref id="B187-vaccines-12-01344"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schellenbacher</surname><given-names>C.</given-names></name>
<name><surname>Roden</surname><given-names>R.B.S.</given-names></name>
<name><surname>Kirnbauer</surname><given-names>R.</given-names></name>
</person-group><article-title>Developments in L2-based human papillomavirus (HPV) vaccines</article-title><source>Virus Res.</source><year>2017</year><volume>231</volume><fpage>166</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2016.11.020</pub-id><pub-id pub-id-type="pmid">27889616</pub-id>
</element-citation></ref><ref id="B188-vaccines-12-01344"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Yao</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Bai</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Xia</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
</person-group><article-title>Production of Recombinant Human Papillomavirus Type 52 L1 Protein in <italic toggle="yes">Hansenula polymorpha</italic> Formed Virus-Like Particles</article-title><source>J. Microbiol. Biotechnol.</source><year>2015</year><volume>25</volume><fpage>936</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.4014/jmb.1412.12027</pub-id><pub-id pub-id-type="pmid">25639723</pub-id>
</element-citation></ref><ref id="B189-vaccines-12-01344"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caetano</surname><given-names>K.A.A.</given-names></name>
<name><surname>Del-Rios</surname><given-names>N.H.A.</given-names></name>
<name><surname>Pinheiro</surname><given-names>R.S.</given-names></name>
<name><surname>Bergamaschi</surname><given-names>F.P.R.</given-names></name>
<name><surname>Carneiro</surname><given-names>M.A.D.S.</given-names></name>
<name><surname>Teles</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Low Immunogenicity of Recombinant Hepatitis B Vaccine Derived from <italic toggle="yes">Hansenula polymorpha</italic> in Adults Aged Over 40 Years</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2017</year><volume>96</volume><fpage>118</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.16-0475</pub-id><pub-id pub-id-type="pmid">27799647</pub-id>
</element-citation></ref><ref id="B190-vaccines-12-01344"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>P.</given-names></name>
<name><surname>Du</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Hao</surname><given-names>X.</given-names></name>
<name><surname>Dong</surname><given-names>B.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
</person-group><article-title>High-level expression and immunogenicity of porcine circovirus type 2b capsid protein without nuclear localization signal expressed in <italic toggle="yes">Hansenula polymorpha</italic></article-title><source>Biologicals</source><year>2018</year><volume>51</volume><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2017.11.003</pub-id><pub-id pub-id-type="pmid">29225046</pub-id>
</element-citation></ref><ref id="B191-vaccines-12-01344"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramasamy</surname><given-names>V.</given-names></name>
<name><surname>Arora</surname><given-names>U.</given-names></name>
<name><surname>Shukla</surname><given-names>R.</given-names></name>
<name><surname>Poddar</surname><given-names>A.</given-names></name>
<name><surname>Shanmugam</surname><given-names>R.K.</given-names></name>
<name><surname>White</surname><given-names>L.J.</given-names></name>
<name><surname>Mattocks</surname><given-names>M.M.</given-names></name>
<name><surname>Raut</surname><given-names>R.</given-names></name>
<name><surname>Perween</surname><given-names>A.</given-names></name>
<name><surname>Tyagi</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice</article-title><source>PLoS Negl. Trop. Dis.</source><year>2018</year><volume>12</volume><elocation-id>e0006191</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0006191</pub-id><pub-id pub-id-type="pmid">29309412</pub-id>
</element-citation></ref><ref id="B192-vaccines-12-01344"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajpoot</surname><given-names>R.K.</given-names></name>
<name><surname>Shukla</surname><given-names>R.</given-names></name>
<name><surname>Arora</surname><given-names>U.</given-names></name>
<name><surname>Swaminathan</surname><given-names>S.</given-names></name>
<name><surname>Khanna</surname><given-names>N.</given-names></name>
</person-group><article-title>Dengue envelope-based &#x0201c;four-in-one&#x0201d; virus-like particles produced using <italic toggle="yes">Pichia pastoris</italic> induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>8643</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-26904-5</pub-id><pub-id pub-id-type="pmid">29872153</pub-id>
</element-citation></ref><ref id="B193-vaccines-12-01344"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>Z.</given-names></name>
<name><surname>Fang</surname><given-names>D.</given-names></name>
<name><surname>Fu</surname><given-names>C.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<name><surname>He</surname><given-names>Z.</given-names></name>
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Jiang</surname><given-names>L.</given-names></name>
</person-group><article-title>Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: Immunological properties</article-title><source>BMC Microbiol.</source><year>2014</year><volume>14</volume><elocation-id>233</elocation-id><pub-id pub-id-type="doi">10.1186/s12866-014-0233-3</pub-id><pub-id pub-id-type="pmid">25520151</pub-id>
</element-citation></ref><ref id="B194-vaccines-12-01344"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poddar</surname><given-names>A.</given-names></name>
<name><surname>Ramasamy</surname><given-names>V.</given-names></name>
<name><surname>Shukla</surname><given-names>R.</given-names></name>
<name><surname>Rajpoot</surname><given-names>R.K.</given-names></name>
<name><surname>Arora</surname><given-names>U.</given-names></name>
<name><surname>Jain</surname><given-names>S.K.</given-names></name>
<name><surname>Swaminathan</surname><given-names>S.</given-names></name>
<name><surname>Khanna</surname><given-names>N.</given-names></name>
</person-group><article-title>Virus-like particles derived from <italic toggle="yes">Pichia pastoris</italic>-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies</article-title><source>BMC Biotechnol.</source><year>2016</year><volume>16</volume><elocation-id>50</elocation-id><pub-id pub-id-type="doi">10.1186/s12896-016-0280-y</pub-id><pub-id pub-id-type="pmid">27301568</pub-id>
</element-citation></ref><ref id="B195-vaccines-12-01344"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khetarpal</surname><given-names>N.</given-names></name>
<name><surname>Shukla</surname><given-names>R.</given-names></name>
<name><surname>Rajpoot</surname><given-names>R.K.</given-names></name>
<name><surname>Poddar</surname><given-names>A.</given-names></name>
<name><surname>Pal</surname><given-names>M.</given-names></name>
<name><surname>Swaminathan</surname><given-names>S.</given-names></name>
<name><surname>Arora</surname><given-names>U.</given-names></name>
<name><surname>Khanna</surname><given-names>N.</given-names></name>
</person-group><article-title>Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from <italic toggle="yes">Pichia pastoris</italic> are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2017</year><volume>96</volume><fpage>126</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.16-0503</pub-id><pub-id pub-id-type="pmid">27821688</pub-id>
</element-citation></ref><ref id="B196-vaccines-12-01344"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Dai</surname><given-names>W.</given-names></name>
<name><surname>Xie</surname><given-names>J.</given-names></name>
<name><surname>Ye</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Gong</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Enterovirus D68 virus-like particles expressed in <italic toggle="yes">Pichia pastoris</italic> potently induce neutralizing antibody responses and confer protection against lethal viral infection in mice</article-title><source>Emerg. Microbes Infect.</source><year>2018</year><volume>7</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1038/s41426-017-0005-x</pub-id><pub-id pub-id-type="pmid">29323105</pub-id>
</element-citation></ref><ref id="B197-vaccines-12-01344"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zahid</surname><given-names>M.</given-names></name>
<name><surname>L&#x000fc;nsdorf</surname><given-names>H.</given-names></name>
<name><surname>Rinas</surname><given-names>U.</given-names></name>
</person-group><article-title>Assessing stability and assembly of the hepatitis B surface antigen into virus-like particles during down-stream processing</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>3739</fpage><lpage>3745</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.05.066</pub-id><pub-id pub-id-type="pmid">26079614</pub-id>
</element-citation></ref><ref id="B198-vaccines-12-01344"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fazlalipour</surname><given-names>M.</given-names></name>
<name><surname>Keyvani</surname><given-names>H.</given-names></name>
<name><surname>Monavari</surname><given-names>S.H.R.</given-names></name>
<name><surname>Mollaie</surname><given-names>H.R.</given-names></name>
</person-group><article-title>Expression, Purification and Immunogenic Description of a Hepatitis C Virus Recombinant CoreE1E2 Protein Expressed by Yeast <italic toggle="yes">Pichia pastoris</italic></article-title><source>Jundishapur J. Microbiol.</source><year>2015</year><volume>8</volume><elocation-id>e17157</elocation-id><pub-id pub-id-type="doi">10.5812/jjm.8(4)2015.17157</pub-id><pub-id pub-id-type="pmid">26034544</pub-id>
</element-citation></ref><ref id="B199-vaccines-12-01344"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bredell</surname><given-names>H.</given-names></name>
<name><surname>Smith</surname><given-names>J.J.</given-names></name>
<name><surname>G&#x000f6;rgens</surname><given-names>J.F.</given-names></name>
<name><surname>van Zyl</surname><given-names>W.H.</given-names></name>
</person-group><article-title>Expression of unique chimeric human papilloma virus type 16 (HPV-16) L1-L2 proteins in <italic toggle="yes">Pichia pastoris</italic> and <italic toggle="yes">Hansenula polymorpha</italic></article-title><source>Yeast</source><year>2018</year><volume>35</volume><fpage>519</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1002/yea.3318</pub-id><pub-id pub-id-type="pmid">29709079</pub-id>
</element-citation></ref><ref id="B200-vaccines-12-01344"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>G.</given-names></name>
<name><surname>Glueck</surname><given-names>R.</given-names></name>
<name><surname>Rishi</surname><given-names>N.</given-names></name>
</person-group><article-title>Physicochemical characterization and immunological properties of <italic toggle="yes">Pichia pastoris</italic> based HPV16L1 and 18L1 virus like particles</article-title><source>Biologicals</source><year>2017</year><volume>46</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2016.12.002</pub-id><pub-id pub-id-type="pmid">28012703</pub-id>
</element-citation></ref><ref id="B201-vaccines-12-01344"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Athmaram</surname><given-names>T.N.</given-names></name>
<name><surname>Singh</surname><given-names>A.K.</given-names></name>
<name><surname>Saraswat</surname><given-names>S.</given-names></name>
<name><surname>Srivastava</surname><given-names>S.</given-names></name>
<name><surname>Misra</surname><given-names>P.</given-names></name>
<name><surname>Kameswara Rao</surname><given-names>M.</given-names></name>
<name><surname>Gopalan</surname><given-names>N.</given-names></name>
<name><surname>Rao</surname><given-names>P.V.L.</given-names></name>
</person-group><article-title>A simple <italic toggle="yes">Pichia pastoris</italic> fermentation and downstream processing strategy for making recombinant pandemic Swine Origin Influenza a virus Hemagglutinin protein</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2013</year><volume>40</volume><fpage>245</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1007/s10295-012-1220-z</pub-id><pub-id pub-id-type="pmid">23247902</pub-id>
</element-citation></ref><ref id="B202-vaccines-12-01344"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.-C.</given-names></name>
<name><surname>Liao</surname><given-names>H.-Y.</given-names></name>
<name><surname>Zhang</surname><given-names>J.-Y.</given-names></name>
<name><surname>Cheng</surname><given-names>T.-J.R.</given-names></name>
<name><surname>Wong</surname><given-names>C.-H.</given-names></name>
</person-group><article-title>Development of a universal influenza vaccine using hemagglutinin stem protein produced from <italic toggle="yes">Pichia pastoris</italic></article-title><source>Virology</source><year>2019</year><volume>526</volume><fpage>125</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2018.10.005</pub-id><pub-id pub-id-type="pmid">30388628</pub-id>
</element-citation></ref><ref id="B203-vaccines-12-01344"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pietrzak</surname><given-names>M.</given-names></name>
<name><surname>Macio&#x00142;a</surname><given-names>A.</given-names></name>
<name><surname>Zdanowski</surname><given-names>K.</given-names></name>
<name><surname>Protas-Klukowska</surname><given-names>A.M.</given-names></name>
<name><surname>Olszewska</surname><given-names>M.</given-names></name>
<name><surname>&#x0015a;mietanka</surname><given-names>K.</given-names></name>
<name><surname>Minta</surname><given-names>Z.</given-names></name>
<name><surname>Szewczyk</surname><given-names>B.</given-names></name>
<name><surname>Kopera</surname><given-names>E.</given-names></name>
</person-group><article-title>An avian influenza H5N1 virus vaccine candidate based on the extracellular domain produced in yeast system as subviral particles protects chickens from lethal challenge</article-title><source>Antivir. Res.</source><year>2016</year><volume>133</volume><fpage>242</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.08.001</pub-id><pub-id pub-id-type="pmid">27498036</pub-id>
</element-citation></ref><ref id="B204-vaccines-12-01344"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>C.-Y.</given-names></name>
<name><surname>Wu</surname><given-names>C.-W.</given-names></name>
<name><surname>Lin</surname><given-names>G.-J.</given-names></name>
<name><surname>Lee</surname><given-names>W.-C.</given-names></name>
<name><surname>Chien</surname><given-names>M.-S.</given-names></name>
<name><surname>Huang</surname><given-names>C.</given-names></name>
</person-group><article-title>Enhancing expression of the classical swine fever virus glycoprotein E2 in yeast and its application to a blocking ELISA</article-title><source>J. Biotechnol.</source><year>2014</year><volume>174</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2014.01.007</pub-id><pub-id pub-id-type="pmid">24468422</pub-id>
</element-citation></ref><ref id="B205-vaccines-12-01344"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>G.-J.</given-names></name>
<name><surname>Deng</surname><given-names>M.-C.</given-names></name>
<name><surname>Chen</surname><given-names>Z.-W.</given-names></name>
<name><surname>Liu</surname><given-names>T.-Y.</given-names></name>
<name><surname>Wu</surname><given-names>C.-W.</given-names></name>
<name><surname>Cheng</surname><given-names>C.-Y.</given-names></name>
<name><surname>Chien</surname><given-names>M.-S.</given-names></name>
<name><surname>Huang</surname><given-names>C.</given-names></name>
</person-group><article-title>Yeast expressed classical swine fever E2 subunit vaccine candidate provides complete protection against lethal challenge infection and prevents horizontal virus transmission</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>2336</fpage><lpage>2341</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.01.051</pub-id><pub-id pub-id-type="pmid">22300723</pub-id>
</element-citation></ref><ref id="B206-vaccines-12-01344"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saraswat</surname><given-names>S.</given-names></name>
<name><surname>Athmaram</surname><given-names>T.N.</given-names></name>
<name><surname>Parida</surname><given-names>M.</given-names></name>
<name><surname>Agarwal</surname><given-names>A.</given-names></name>
<name><surname>Saha</surname><given-names>A.</given-names></name>
<name><surname>Dash</surname><given-names>P.K.</given-names></name>
</person-group><article-title>Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004782</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004782</pub-id><pub-id pub-id-type="pmid">27399001</pub-id>
</element-citation></ref><ref id="B207-vaccines-12-01344"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zang</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Gu</surname><given-names>C.</given-names></name>
<name><surname>Yi</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Xu</surname><given-names>S.</given-names></name>
<name><surname>Hu</surname><given-names>G.</given-names></name>
<name><surname>Du</surname><given-names>S.</given-names></name>
<name><surname>Yin</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection</article-title><source>Cell Discov.</source><year>2021</year><volume>7</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1038/s41421-021-00315-9</pub-id><pub-id pub-id-type="pmid">34408130</pub-id>
</element-citation></ref><ref id="B208-vaccines-12-01344"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Lee</surname><given-names>J.Y.</given-names></name>
<name><surname>Kang</surname><given-names>H.A.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Park</surname><given-names>E.-J.</given-names></name>
<name><surname>Kim</surname><given-names>H.-J.</given-names></name>
</person-group><article-title>Oral immunization with whole yeast producing viral capsid antigen provokes a stronger humoral immune response than purified viral capsid antigen</article-title><source>Lett. Appl. Microbiol.</source><year>2014</year><volume>58</volume><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1111/lam.12188</pub-id><pub-id pub-id-type="pmid">24251903</pub-id>
</element-citation></ref><ref id="B209-vaccines-12-01344"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hadiji-Abbes</surname><given-names>N.</given-names></name>
<name><surname>Martin</surname><given-names>M.</given-names></name>
<name><surname>Benzina</surname><given-names>W.</given-names></name>
<name><surname>Karray-Hakim</surname><given-names>H.</given-names></name>
<name><surname>Gergely</surname><given-names>C.</given-names></name>
<name><surname>Gargouri</surname><given-names>A.</given-names></name>
<name><surname>Mokdad-Gargouri</surname><given-names>R.</given-names></name>
</person-group><article-title>Extraction and purification of hepatitis B virus-like M particles from a recombinant <italic toggle="yes">Saccharomyces cerevisiae</italic> strain using alumina powder</article-title><source>J. Virol. Methods</source><year>2013</year><volume>187</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2012.09.023</pub-id><pub-id pub-id-type="pmid">23059550</pub-id>
</element-citation></ref><ref id="B210-vaccines-12-01344"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pleckaityte</surname><given-names>M.</given-names></name>
<name><surname>Bremer</surname><given-names>C.M.</given-names></name>
<name><surname>Gedvilaite</surname><given-names>A.</given-names></name>
<name><surname>Kucinskaite-Kodze</surname><given-names>I.</given-names></name>
<name><surname>Glebe</surname><given-names>D.</given-names></name>
<name><surname>Zvirbliene</surname><given-names>A.</given-names></name>
</person-group><article-title>Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen</article-title><source>BMC Biotechnol.</source><year>2015</year><volume>15</volume><elocation-id>85</elocation-id><pub-id pub-id-type="doi">10.1186/s12896-015-0203-3</pub-id><pub-id pub-id-type="pmid">26370129</pub-id>
</element-citation></ref><ref id="B211-vaccines-12-01344"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>King</surname><given-names>T.H.</given-names></name>
<name><surname>Kemmler</surname><given-names>C.B.</given-names></name>
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Mann</surname><given-names>D.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Coeshott</surname><given-names>C.</given-names></name>
<name><surname>Gehring</surname><given-names>A.J.</given-names></name>
<name><surname>Bertoletti</surname><given-names>A.</given-names></name>
<name><surname>Ho</surname><given-names>Z.Z.</given-names></name>
<name><surname>Delaney</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e101904</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0101904</pub-id><pub-id pub-id-type="pmid">25051027</pub-id>
</element-citation></ref><ref id="B212-vaccines-12-01344"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>Yan</surname><given-names>B.</given-names></name>
<name><surname>Song</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Cui</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Liang</surname><given-names>X.</given-names></name>
</person-group><article-title>Antibody response to revaccination among adult non-responders to primary Hepatitis B vaccination in China</article-title><source>Hum. Vaccines Immunother.</source><year>2015</year><volume>11</volume><fpage>2716</fpage><lpage>2722</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1045172</pub-id><pub-id pub-id-type="pmid">26252481</pub-id>
</element-citation></ref><ref id="B213-vaccines-12-01344"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaggar</surname><given-names>A.</given-names></name>
<name><surname>Coeshott</surname><given-names>C.</given-names></name>
<name><surname>Apelian</surname><given-names>D.</given-names></name>
<name><surname>Rodell</surname><given-names>T.</given-names></name>
<name><surname>Armstrong</surname><given-names>B.R.</given-names></name>
<name><surname>Shen</surname><given-names>G.</given-names></name>
<name><surname>Subramanian</surname><given-names>G.M.</given-names></name>
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
</person-group><article-title>Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>4925</fpage><lpage>4931</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.07.027</pub-id><pub-id pub-id-type="pmid">25045824</pub-id>
</element-citation></ref><ref id="B214-vaccines-12-01344"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>T.</given-names></name>
<name><surname>Xianyu</surname><given-names>L.</given-names></name>
<name><surname>Lyu</surname><given-names>S.</given-names></name>
</person-group><article-title>Monoclonal neutralizing antibodies against EV71 screened from mice immunized with yeast-produced virus-like particles</article-title><source>Virol. Sin.</source><year>2015</year><volume>30</volume><fpage>208</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1007/s12250-015-3573-8</pub-id><pub-id pub-id-type="pmid">26040893</pub-id>
</element-citation></ref><ref id="B215-vaccines-12-01344"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Xiao</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Pang</surname><given-names>L.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Cen</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>B.B.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Sheng</surname><given-names>W.</given-names></name>
</person-group><article-title>EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge</article-title><source>BMC Res. Notes</source><year>2016</year><volume>9</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.1186/s13104-015-1780-x</pub-id><pub-id pub-id-type="pmid">26809443</pub-id>
</element-citation></ref><ref id="B216-vaccines-12-01344"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Penkert</surname><given-names>R.R.</given-names></name>
<name><surname>Young</surname><given-names>N.S.</given-names></name>
<name><surname>Surman</surname><given-names>S.L.</given-names></name>
<name><surname>Sealy</surname><given-names>R.E.</given-names></name>
<name><surname>Rosch</surname><given-names>J.</given-names></name>
<name><surname>Dormitzer</surname><given-names>P.R.</given-names></name>
<name><surname>Settembre</surname><given-names>E.C.</given-names></name>
<name><surname>Chandramouli</surname><given-names>S.</given-names></name>
<name><surname>Wong</surname><given-names>S.</given-names></name>
<name><surname>Hankins</surname><given-names>J.S.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Saccharomyces cerevisiae</italic>-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>3615</fpage><lpage>3620</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.022</pub-id><pub-id pub-id-type="pmid">28554503</pub-id>
</element-citation></ref><ref id="B217-vaccines-12-01344"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chandramouli</surname><given-names>S.</given-names></name>
<name><surname>Medina-Selby</surname><given-names>A.</given-names></name>
<name><surname>Coit</surname><given-names>D.</given-names></name>
<name><surname>Schaefer</surname><given-names>M.</given-names></name>
<name><surname>Spencer</surname><given-names>T.</given-names></name>
<name><surname>Brito</surname><given-names>L.A.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Otten</surname><given-names>G.</given-names></name>
<name><surname>Mandl</surname><given-names>C.W.</given-names></name>
<name><surname>Mason</surname><given-names>P.W.</given-names></name>
<etal/>
</person-group><article-title>Generation of a parvovirus B19 vaccine candidate</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>3872</fpage><lpage>3878</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.06.062</pub-id><pub-id pub-id-type="pmid">23827313</pub-id>
</element-citation></ref><ref id="B218-vaccines-12-01344"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>N.-L.</given-names></name>
<name><surname>Kim</surname><given-names>J.-M.</given-names></name>
<name><surname>Park</surname><given-names>J.-A.</given-names></name>
<name><surname>Park</surname><given-names>S.-M.</given-names></name>
<name><surname>Jang</surname><given-names>Y.-S.</given-names></name>
<name><surname>Yang</surname><given-names>M.-S.</given-names></name>
<name><surname>Kim</surname><given-names>D.-H.</given-names></name>
</person-group><article-title>Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and <italic toggle="yes">Saccharomyces cerevisiae</italic></article-title><source>Protein Expr. Purif.</source><year>2013</year><volume>88</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2013.01.009</pub-id><pub-id pub-id-type="pmid">23376461</pub-id>
</element-citation></ref><ref id="B219-vaccines-12-01344"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Yao</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Xie</surname><given-names>J.</given-names></name>
<name><surname>Shi</surname><given-names>X.</given-names></name>
<name><surname>Xiang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
</person-group><article-title>Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto-and heterologous viruses</article-title><source>J. Biol. Chem.</source><year>2018</year><volume>293</volume><fpage>830</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.816447</pub-id><pub-id pub-id-type="pmid">29187598</pub-id>
</element-citation></ref><ref id="B220-vaccines-12-01344"><label>220.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Sablon</surname><given-names>E.</given-names></name>
<name><surname>Van Broekhoven</surname><given-names>A.</given-names></name>
<name><surname>Bosman</surname><given-names>F.</given-names></name>
<name><surname>Depla</surname><given-names>E.</given-names></name>
<name><surname>Deschamps</surname><given-names>G.</given-names></name>
</person-group><article-title>Constructs and Methods for Expression of Recombinant HCV Envelope Proteins</article-title><source>U.S. Patent</source><patent>7,314,925</patent><day>1</day><month>January</month><year>2008</year></element-citation></ref><ref id="B221-vaccines-12-01344"><label>221.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name><surname>Evans</surname><given-names>J.D.</given-names></name>
<name><surname>Beatty</surname><given-names>N.M.</given-names></name>
</person-group><article-title>Yeast Expression of Flavivirus Virus-Like Particles and Use Thereof</article-title><source>U.S. Patent</source><patent>4/241,530</patent><day>7</day><month>August</month><year>2014</year></element-citation></ref><ref id="B222-vaccines-12-01344"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Gong</surname><given-names>Y.</given-names></name>
<name><surname>Gan</surname><given-names>C.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
</person-group><article-title>A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1011484</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1011484</pub-id><pub-id pub-id-type="pmid">36439096</pub-id>
</element-citation></ref><ref id="B223-vaccines-12-01344"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pino</surname><given-names>M.</given-names></name>
<name><surname>Abid</surname><given-names>T.</given-names></name>
<name><surname>Pereira Ribeiro</surname><given-names>S.</given-names></name>
<name><surname>Edara</surname><given-names>V.V.</given-names></name>
<name><surname>Floyd</surname><given-names>K.</given-names></name>
<name><surname>Smith</surname><given-names>J.C.</given-names></name>
<name><surname>Latif</surname><given-names>M.B.</given-names></name>
<name><surname>Pacheco-Sanchez</surname><given-names>G.</given-names></name>
<name><surname>Dutta</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates</article-title><source>Sci. Immunol.</source><year>2021</year><volume>6</volume><fpage>eabh3634</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abh3634</pub-id><pub-id pub-id-type="pmid">34266981</pub-id>
</element-citation></ref><ref id="B224-vaccines-12-01344"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pollet</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>W.-H.</given-names></name>
<name><surname>Versteeg</surname><given-names>L.</given-names></name>
<name><surname>Keegan</surname><given-names>B.</given-names></name>
<name><surname>Zhan</surname><given-names>B.</given-names></name>
<name><surname>Wei</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Kundu</surname><given-names>R.</given-names></name>
<name><surname>Adhikari</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice</article-title><source>Hum. Vaccines Immunother.</source><year>2021</year><volume>17</volume><fpage>2356</fpage><lpage>2366</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.1901545</pub-id></element-citation></ref><ref id="B225-vaccines-12-01344"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W.-H.</given-names></name>
<name><surname>Pollet</surname><given-names>J.</given-names></name>
<name><surname>Strych</surname><given-names>U.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Kundu</surname><given-names>R.T.</given-names></name>
<name><surname>Versteeg</surname><given-names>L.</given-names></name>
<name><surname>Villar</surname><given-names>M.J.</given-names></name>
<name><surname>Adhikari</surname><given-names>R.</given-names></name>
<name><surname>Wei</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate</article-title><source>Protein Expr. Purif.</source><year>2022</year><volume>190</volume><fpage>106003</fpage><pub-id pub-id-type="doi">10.1016/j.pep.2021.106003</pub-id><pub-id pub-id-type="pmid">34688919</pub-id>
</element-citation></ref><ref id="B226-vaccines-12-01344"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W.-H.</given-names></name>
<name><surname>Du</surname><given-names>L.</given-names></name>
<name><surname>Chag</surname><given-names>S.M.</given-names></name>
<name><surname>Ma</surname><given-names>C.</given-names></name>
<name><surname>Tricoche</surname><given-names>N.</given-names></name>
<name><surname>Tao</surname><given-names>X.</given-names></name>
<name><surname>Seid</surname><given-names>C.A.</given-names></name>
<name><surname>Hudspeth</surname><given-names>E.M.</given-names></name>
<name><surname>Lustigman</surname><given-names>S.</given-names></name>
<name><surname>Tseng</surname><given-names>C.-T.K.</given-names></name>
<etal/>
</person-group><article-title>Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate</article-title><source>Hum. Vaccines Immunother.</source><year>2014</year><volume>10</volume><fpage>648</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.4161/hv.27464</pub-id></element-citation></ref><ref id="B227-vaccines-12-01344"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>L.</given-names></name>
<name><surname>Zheng</surname><given-names>T.</given-names></name>
<name><surname>Xu</surname><given-names>K.</given-names></name>
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>E.</given-names></name>
<name><surname>An</surname><given-names>Y.</given-names></name>
<name><surname>Cheng</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
</person-group><article-title>A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>722</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.035</pub-id><pub-id pub-id-type="pmid">32645327</pub-id>
</element-citation></ref><ref id="B228-vaccines-12-01344"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thak</surname><given-names>E.J.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>D.-J.</given-names></name>
<name><surname>Kim</surname><given-names>J.Y.</given-names></name>
<name><surname>Kang</surname><given-names>H.A.</given-names></name>
</person-group><article-title>Structural analysis of N-/O-glycans assembled on proteins in yeasts</article-title><source>J. Microbiol.</source><year>2018</year><volume>56</volume><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s12275-018-7468-x</pub-id><pub-id pub-id-type="pmid">29299842</pub-id>
</element-citation></ref><ref id="B229-vaccines-12-01344"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamilton</surname><given-names>S.R.</given-names></name>
<name><surname>Cook</surname><given-names>W.J.</given-names></name>
<name><surname>Gomathinayagam</surname><given-names>S.</given-names></name>
<name><surname>Burnina</surname><given-names>I.</given-names></name>
<name><surname>Bukowski</surname><given-names>J.</given-names></name>
<name><surname>Hopkins</surname><given-names>D.</given-names></name>
<name><surname>Schwartz</surname><given-names>S.</given-names></name>
<name><surname>Du</surname><given-names>M.</given-names></name>
<name><surname>Sharkey</surname><given-names>N.J.</given-names></name>
<name><surname>Bobrowicz</surname><given-names>P.</given-names></name>
</person-group><article-title>Production of sialylated O-linked glycans in <italic toggle="yes">Pichia pastoris</italic></article-title><source>Glycobiology</source><year>2013</year><volume>23</volume><fpage>1192</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwt056</pub-id><pub-id pub-id-type="pmid">23893788</pub-id>
</element-citation></ref><ref id="B230-vaccines-12-01344"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shajahan</surname><given-names>A.</given-names></name>
<name><surname>Supekar</surname><given-names>N.T.</given-names></name>
<name><surname>Gleinich</surname><given-names>A.S.</given-names></name>
<name><surname>Azadi</surname><given-names>P.</given-names></name>
</person-group><article-title>Deducing the N-and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2</article-title><source>Glycobiology</source><year>2020</year><volume>30</volume><fpage>981</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwaa042</pub-id><pub-id pub-id-type="pmid">32363391</pub-id>
</element-citation></ref><ref id="B231-vaccines-12-01344"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>H.-Y.</given-names></name>
<name><surname>Han</surname><given-names>J.-F.</given-names></name>
<name><surname>Qin</surname><given-names>C.-F.</given-names></name>
<name><surname>Chen</surname><given-names>R.</given-names></name>
</person-group><article-title>Virus-like particles for enterovirus 71 produced from <italic toggle="yes">Saccharomyces cerevisiae</italic> potently elicits protective immune responses in mice</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>3281</fpage><lpage>3287</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.05.019</pub-id><pub-id pub-id-type="pmid">23726823</pub-id>
</element-citation></ref><ref id="B232-vaccines-12-01344"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>H.-Y.</given-names></name>
<name><surname>Han</surname><given-names>J.-F.</given-names></name>
<name><surname>Deng</surname><given-names>Y.-Q.</given-names></name>
<name><surname>Li</surname><given-names>Y.-X.</given-names></name>
<name><surname>Zhu</surname><given-names>S.-Y.</given-names></name>
<name><surname>He</surname><given-names>Y.-L.</given-names></name>
<name><surname>Qin</surname><given-names>E.-D.</given-names></name>
<name><surname>Chen</surname><given-names>R.</given-names></name>
<name><surname>Qin</surname><given-names>C.-F.</given-names></name>
</person-group><article-title>Virus-like particles produced in <italic toggle="yes">Saccharomyces cerevisiae</italic> elicit protective immunity against Coxsackievirus A16 in mice</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2013</year><volume>97</volume><fpage>10445</fpage><lpage>10452</lpage><pub-id pub-id-type="doi">10.1007/s00253-013-5257-3</pub-id><pub-id pub-id-type="pmid">24085395</pub-id>
</element-citation></ref><ref id="B233-vaccines-12-01344"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bill</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Recombinant protein subunit vaccine synthesis in microbes: A role for yeast?</article-title><source>J. Pharm. Pharmacol.</source><year>2015</year><volume>67</volume><fpage>319</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1111/jphp.12353</pub-id><pub-id pub-id-type="pmid">25556638</pub-id>
</element-citation></ref><ref id="B234-vaccines-12-01344"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name>
<name><surname>Paz-Maldonado</surname><given-names>L.M.T.</given-names></name>
<name><surname>Soria-Guerra</surname><given-names>R.E.</given-names></name>
</person-group><article-title>Chlamydomonas reinhardtii as a viable platform for the production of recombinant proteins: Current status and perspectives</article-title><source>Plant Cell Rep.</source><year>2012</year><volume>31</volume><fpage>479</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1007/s00299-011-1186-8</pub-id><pub-id pub-id-type="pmid">22080228</pub-id>
</element-citation></ref><ref id="B235-vaccines-12-01344"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lauersen</surname><given-names>K.J.</given-names></name>
<name><surname>Kruse</surname><given-names>O.</given-names></name>
<name><surname>Berger</surname><given-names>H.</given-names></name>
<name><surname>Mussgnug</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Efficient recombinant protein production and secretion from nuclear transgenes in Chlamydomonas reinhardtii</article-title><source>J. Biotechnol.</source><year>2013</year><volume>167</volume><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2012.10.010</pub-id><pub-id pub-id-type="pmid">23099045</pub-id>
</element-citation></ref><ref id="B236-vaccines-12-01344"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guti&#x000e9;rrez</surname><given-names>S.</given-names></name>
<name><surname>Lauersen</surname><given-names>K.J.</given-names></name>
</person-group><article-title>Gene delivery technologies with applications in microalgal genetic engineering</article-title><source>Biology</source><year>2021</year><volume>10</volume><elocation-id>265</elocation-id><pub-id pub-id-type="doi">10.3390/biology10040265</pub-id><pub-id pub-id-type="pmid">33810286</pub-id>
</element-citation></ref><ref id="B237-vaccines-12-01344"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lanigan</surname><given-names>T.M.</given-names></name>
<name><surname>Kopera</surname><given-names>H.C.</given-names></name>
<name><surname>Saunders</surname><given-names>T.L.</given-names></name>
</person-group><article-title>Principles of genetic engineering</article-title><source>Genes</source><year>2020</year><volume>11</volume><elocation-id>291</elocation-id><pub-id pub-id-type="doi">10.3390/genes11030291</pub-id><pub-id pub-id-type="pmid">32164255</pub-id>
</element-citation></ref><ref id="B238-vaccines-12-01344"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>H.-C.</given-names></name>
<name><surname>Long</surname><given-names>J.R.</given-names></name>
<name><surname>Yaghi</surname><given-names>O.M.</given-names></name>
</person-group><article-title>Introduction to metal&#x02013;organic frameworks</article-title><source>Chem. Rev.</source><year>2012</year><volume>112</volume><fpage>673</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1021/cr300014x</pub-id><pub-id pub-id-type="pmid">22280456</pub-id>
</element-citation></ref><ref id="B239-vaccines-12-01344"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>S.</given-names></name>
<name><surname>Almeida</surname><given-names>A.J.</given-names></name>
<name><surname>Vale</surname><given-names>N.</given-names></name>
</person-group><article-title>Combination of cell-penetrating peptides with nanoparticles for therapeutic application: A review</article-title><source>Biomolecules</source><year>2019</year><volume>9</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.3390/biom9010022</pub-id><pub-id pub-id-type="pmid">30634689</pub-id>
</element-citation></ref><ref id="B240-vaccines-12-01344"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gregory</surname><given-names>J.A.</given-names></name>
<name><surname>Topol</surname><given-names>A.B.</given-names></name>
<name><surname>Doerner</surname><given-names>D.Z.</given-names></name>
<name><surname>Mayfield</surname><given-names>S.</given-names></name>
</person-group><article-title>Alga-Produced Cholera Toxin-Pfs25 Fusion Proteins as Oral Vaccines</article-title><source>Appl. Environ. Microbiol.</source><year>2013</year><volume>79</volume><fpage>3917</fpage><lpage>3925</lpage><pub-id pub-id-type="doi">10.1128/AEM.00714-13</pub-id><pub-id pub-id-type="pmid">23603678</pub-id>
</element-citation></ref><ref id="B241-vaccines-12-01344"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dreesen</surname><given-names>I.A.J.</given-names></name>
<name><surname>Hamri</surname><given-names>G.C.-E.</given-names></name>
<name><surname>Fussenegger</surname><given-names>M.</given-names></name>
</person-group><article-title>Heat-stable oral alga-based vaccine protects mice from Staphylococcus aureus infection</article-title><source>J. Biotechnol.</source><year>2010</year><volume>145</volume><fpage>273</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2009.12.006</pub-id><pub-id pub-id-type="pmid">19995584</pub-id>
</element-citation></ref><ref id="B242-vaccines-12-01344"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Specht</surname><given-names>E.</given-names></name>
<name><surname>Mayfield</surname><given-names>S.</given-names></name>
</person-group><article-title>Algae-based oral recombinant vaccines</article-title><source>Front. Microbiol.</source><year>2014</year><volume>5</volume><elocation-id>60</elocation-id><comment>Available online: <ext-link xlink:href="https://www.frontiersin.org/article/10.3389/fmicb.2014.00060" ext-link-type="uri">https://www.frontiersin.org/article/10.3389/fmicb.2014.00060</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-01">(accessed on 1 June 2024)</date-in-citation><pub-id pub-id-type="doi">10.3389/fmicb.2014.00060</pub-id><pub-id pub-id-type="pmid">24596570</pub-id>
</element-citation></ref><ref id="B243-vaccines-12-01344"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x000f6;ssl</surname><given-names>A.G.</given-names></name>
<name><surname>Waheed</surname><given-names>M.T.</given-names></name>
</person-group><article-title>Chloroplast-derived vaccines against human diseases: Achievements, challenges and scopes</article-title><source>Plant Biotechnol. J.</source><year>2011</year><volume>9</volume><fpage>527</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2011.00615.x</pub-id><pub-id pub-id-type="pmid">21447052</pub-id>
</element-citation></ref><ref id="B244-vaccines-12-01344"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franklin</surname><given-names>S.</given-names></name>
<name><surname>Ngo</surname><given-names>B.</given-names></name>
<name><surname>Efuet</surname><given-names>E.</given-names></name>
<name><surname>Mayfield</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Development of a GFP reporter gene for Chlamydomonas reinhardtii chloroplast</article-title><source>Plant J.</source><year>2002</year><volume>30</volume><fpage>733</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1046/j.1365-313X.2002.01319.x</pub-id><pub-id pub-id-type="pmid">12061904</pub-id>
</element-citation></ref><ref id="B245-vaccines-12-01344"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mayfield</surname><given-names>S.P.</given-names></name>
<name><surname>Franklin</surname><given-names>S.E.</given-names></name>
<name><surname>Lerner</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Expression and assembly of a fully active antibody in algae</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>438</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1073/pnas.0237108100</pub-id><pub-id pub-id-type="pmid">12522151</pub-id>
</element-citation></ref><ref id="B246-vaccines-12-01344"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Butinar</surname><given-names>L.</given-names></name>
<name><surname>Sonjak</surname><given-names>S.</given-names></name>
<name><surname>Zalar</surname><given-names>P.</given-names></name>
<name><surname>Plemenita&#x00161;</surname><given-names>A.</given-names></name>
<name><surname>Gunde-Cimerman</surname><given-names>N.</given-names></name>
</person-group><article-title>Melanized halophilic fungi are eukaryotic members of microbial communities in hypersaline waters of solar salterns</article-title><source>Bot. Mar.</source><year>2005</year><volume>48</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1515/BOT.2005.007</pub-id></element-citation></ref><ref id="B247-vaccines-12-01344"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ben-Amotz</surname><given-names>A.</given-names></name>
<name><surname>Avron</surname><given-names>M.</given-names></name>
</person-group><article-title>The biotechnology of cultivating the halotolerant algaDunaliella</article-title><source>Trends Biotechnol.</source><year>1990</year><volume>8</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/0167-7799(90)90152-N</pub-id></element-citation></ref><ref id="B248-vaccines-12-01344"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qin</surname><given-names>S.</given-names></name>
<name><surname>Lin</surname><given-names>H.</given-names></name>
<name><surname>Jiang</surname><given-names>P.</given-names></name>
</person-group><article-title>Advances in genetic engineering of marine algae</article-title><source>Biotechnol. Adv.</source><year>2012</year><volume>30</volume><fpage>1602</fpage><lpage>1613</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2012.05.004</pub-id><pub-id pub-id-type="pmid">22634258</pub-id>
</element-citation></ref><ref id="B249-vaccines-12-01344"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Georgianna</surname><given-names>D.R.</given-names></name>
<name><surname>Mayfield</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Exploiting diversity and synthetic biology for the production of algal biofuels</article-title><source>Nature</source><year>2012</year><volume>488</volume><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1038/nature11479</pub-id><pub-id pub-id-type="pmid">22895338</pub-id>
</element-citation></ref><ref id="B250-vaccines-12-01344"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ducat</surname><given-names>D.C.</given-names></name>
<name><surname>Way</surname><given-names>J.C.</given-names></name>
<name><surname>Silver</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Engineering cyanobacteria to generate high-value products</article-title><source>Trends Biotechnol.</source><year>2011</year><volume>29</volume><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2010.12.003</pub-id><pub-id pub-id-type="pmid">21211860</pub-id>
</element-citation></ref><ref id="B251-vaccines-12-01344"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gong</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Gao</surname><given-names>H.</given-names></name>
</person-group><article-title>Microalgae as platforms for production of recombinant proteins and valuable compounds: Progress and prospects</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2011</year><volume>38</volume><fpage>1879</fpage><lpage>1890</lpage><pub-id pub-id-type="doi">10.1007/s10295-011-1032-6</pub-id><pub-id pub-id-type="pmid">21882013</pub-id>
</element-citation></ref><ref id="B252-vaccines-12-01344"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berndt</surname><given-names>A.J.</given-names></name>
<name><surname>Smalley</surname><given-names>T.N.</given-names></name>
<name><surname>Ren</surname><given-names>B.</given-names></name>
<name><surname>Simkovsky</surname><given-names>R.</given-names></name>
<name><surname>Badary</surname><given-names>A.</given-names></name>
<name><surname>Sproles</surname><given-names>A.E.</given-names></name>
<name><surname>Fields</surname><given-names>F.J.</given-names></name>
<name><surname>Torres-Tiji</surname><given-names>Y.</given-names></name>
<name><surname>Heredia</surname><given-names>V.</given-names></name>
<name><surname>Mayfield</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><elocation-id>e0257089</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0257089</pub-id><pub-id pub-id-type="pmid">34793485</pub-id>
</element-citation></ref><ref id="B253-vaccines-12-01344"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Govea-Alonso</surname><given-names>D.O.</given-names></name>
<name><surname>Malla</surname><given-names>A.</given-names></name>
<name><surname>Bola&#x000f1;os-Mart&#x000ed;nez</surname><given-names>O.C.</given-names></name>
<name><surname>Vimolmangkang</surname><given-names>S.</given-names></name>
<name><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name>
</person-group><article-title>An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><elocation-id>1298</elocation-id><pub-id pub-id-type="doi">10.3390/ph15101298</pub-id><pub-id pub-id-type="pmid">36297410</pub-id>
</element-citation></ref><ref id="B254-vaccines-12-01344"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malla</surname><given-names>A.</given-names></name>
<name><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name>
<name><surname>Phoolcharoen</surname><given-names>W.</given-names></name>
<name><surname>Vimolmangkang</surname><given-names>S.</given-names></name>
</person-group><article-title>Efficient transient expression of recombinant proteins using DNA viral vectors in freshwater microalgal species</article-title><source>Front. Plant Sci.</source><year>2021</year><volume>12</volume><elocation-id>650820</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2021.650820</pub-id><pub-id pub-id-type="pmid">33897742</pub-id>
</element-citation></ref><ref id="B255-vaccines-12-01344"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Slattery</surname><given-names>S.S.</given-names></name>
<name><surname>Giguere</surname><given-names>D.J.</given-names></name>
<name><surname>Stuckless</surname><given-names>E.E.</given-names></name>
<name><surname>Shrestha</surname><given-names>A.</given-names></name>
<name><surname>Briere</surname><given-names>L.-A.K.</given-names></name>
<name><surname>Galbraith</surname><given-names>A.</given-names></name>
<name><surname>Reaume</surname><given-names>S.</given-names></name>
<name><surname>Boyko</surname><given-names>X.</given-names></name>
<name><surname>Say</surname><given-names>H.H.</given-names></name>
<name><surname>Browne</surname><given-names>T.S.</given-names></name>
<etal/>
</person-group><article-title>Phosphate-regulated expression of the SARS-CoV-2 receptor-binding domain in the diatom Phaeodactylum tricornutum for pandemic diagnostics</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>7010</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-11053-7</pub-id><pub-id pub-id-type="pmid">35487958</pub-id>
</element-citation></ref><ref id="B256-vaccines-12-01344"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gimpel</surname><given-names>J.A.</given-names></name>
<name><surname>Hyun</surname><given-names>J.S.</given-names></name>
<name><surname>Schoepp</surname><given-names>N.G.</given-names></name>
<name><surname>Mayfield</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Production of recombinant proteins in microalgae at pilot greenhouse scale</article-title><source>Biotechnol. Bioeng.</source><year>2015</year><volume>112</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1002/bit.25357</pub-id><pub-id pub-id-type="pmid">25116083</pub-id>
</element-citation></ref><ref id="B257-vaccines-12-01344"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rattanapisit</surname><given-names>K.</given-names></name>
<name><surname>Shanmugaraj</surname><given-names>B.</given-names></name>
<name><surname>Manopwisedjaroen</surname><given-names>S.</given-names></name>
<name><surname>Purwono</surname><given-names>P.B.</given-names></name>
<name><surname>Siriwattananon</surname><given-names>K.</given-names></name>
<name><surname>Khorattanakulchai</surname><given-names>N.</given-names></name>
<name><surname>Hanittinan</surname><given-names>O.</given-names></name>
<name><surname>Boonyayothin</surname><given-names>W.</given-names></name>
<name><surname>Thitithanyanont</surname><given-names>A.</given-names></name>
<name><surname>Smith</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in <italic toggle="yes">Nicotiana benthamiana</italic></article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>17698</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-74904-1</pub-id><pub-id pub-id-type="pmid">33077899</pub-id>
</element-citation></ref><ref id="B258-vaccines-12-01344"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yusibov</surname><given-names>V.</given-names></name>
<name><surname>Rabindran</surname><given-names>S.</given-names></name>
</person-group><article-title>Recent progress in the development of plant derived vaccines</article-title><source>Expert Rev. Vaccines</source><year>2008</year><volume>7</volume><fpage>1173</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1586/14760584.7.8.1173</pub-id><pub-id pub-id-type="pmid">18844592</pub-id>
</element-citation></ref><ref id="B259-vaccines-12-01344"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yusibov</surname><given-names>V.</given-names></name>
<name><surname>Streatfield</surname><given-names>S.J.</given-names></name>
<name><surname>Kushnir</surname><given-names>N.</given-names></name>
</person-group><article-title>Clinical development of plant-produced recombinant pharmaceuticals: Vaccines, antibodies and beyond</article-title><source>Hum. Vaccines</source><year>2011</year><volume>7</volume><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.4161/hv.7.3.14207</pub-id><pub-id pub-id-type="pmid">21346417</pub-id>
</element-citation></ref><ref id="B260-vaccines-12-01344"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Egelkrout</surname><given-names>E.</given-names></name>
<name><surname>Hayden</surname><given-names>C.</given-names></name>
<name><surname>Fake</surname><given-names>G.</given-names></name>
<name><surname>Keener</surname><given-names>T.</given-names></name>
<name><surname>Arruda</surname><given-names>P.</given-names></name>
<name><surname>Saltzman</surname><given-names>R.</given-names></name>
<name><surname>Walker</surname><given-names>J.</given-names></name>
<name><surname>Howard</surname><given-names>J.</given-names></name>
</person-group><article-title>Oral delivery of maize-produced porcine epidemic diarrhea virus spike protein elicits neutralizing antibodies in pigs</article-title><source>Plant Cell. Tissue Organ Cult.</source><year>2020</year><volume>142</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/s11240-020-01835-0</pub-id><pub-id pub-id-type="pmid">32394992</pub-id>
</element-citation></ref><ref id="B261-vaccines-12-01344"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hayden</surname><given-names>C.A.</given-names></name>
<name><surname>Egelkrout</surname><given-names>E.M.</given-names></name>
<name><surname>Moscoso</surname><given-names>A.M.</given-names></name>
<name><surname>Enrique</surname><given-names>C.</given-names></name>
<name><surname>Keener</surname><given-names>T.K.</given-names></name>
<name><surname>Jimenez-Flores</surname><given-names>R.</given-names></name>
<name><surname>Wong</surname><given-names>J.C.</given-names></name>
<name><surname>Howard</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Production of highly concentrated, heat-stable hepatitis B surface antigen in maize</article-title><source>Plant Biotechnol. J.</source><year>2012</year><volume>10</volume><fpage>979</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2012.00727.x</pub-id><pub-id pub-id-type="pmid">22816734</pub-id>
</element-citation></ref><ref id="B262-vaccines-12-01344"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hayden</surname><given-names>C.A.</given-names></name>
<name><surname>Smith</surname><given-names>E.M.</given-names></name>
<name><surname>Turner</surname><given-names>D.D.</given-names></name>
<name><surname>Keener</surname><given-names>T.K.</given-names></name>
<name><surname>Wong</surname><given-names>J.C.</given-names></name>
<name><surname>Walker</surname><given-names>J.H.</given-names></name>
<name><surname>Tizard</surname><given-names>I.R.</given-names></name>
<name><surname>Jimenez-Flores</surname><given-names>R.</given-names></name>
<name><surname>Howard</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Supercritical fluid extraction provides an enhancement to the immune response for orally-delivered hepatitis B surface antigen</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>1240</fpage><lpage>1246</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.01.037</pub-id><pub-id pub-id-type="pmid">24486361</pub-id>
</element-citation></ref><ref id="B263-vaccines-12-01344"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shahid</surname><given-names>N.</given-names></name>
<name><surname>Daniell</surname><given-names>H.</given-names></name>
</person-group><article-title>Plant-based oral vaccines against zoonotic and non-zoonotic diseases</article-title><source>Plant Biotechnol. J.</source><year>2016</year><volume>14</volume><fpage>2079</fpage><lpage>2099</lpage><pub-id pub-id-type="doi">10.1111/pbi.12604</pub-id><pub-id pub-id-type="pmid">27442628</pub-id>
</element-citation></ref><ref id="B264-vaccines-12-01344"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gehl</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Serek</surname><given-names>M.</given-names></name>
</person-group><article-title>An efficient protocol for Agrobacterium-mediated transformation and regeneration of Campanula medium (<italic toggle="yes">Canterbury bells</italic>) based on leaf disc explants</article-title><source>Plant Cell Tissue Organ Cult.</source><year>2020</year><volume>140</volume><fpage>635</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1007/s11240-019-01758-5</pub-id></element-citation></ref><ref id="B265-vaccines-12-01344"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ariga</surname><given-names>H.</given-names></name>
<name><surname>Toki</surname><given-names>S.</given-names></name>
<name><surname>Ishibashi</surname><given-names>K.</given-names></name>
</person-group><article-title>Potato virus X vector-mediated DNA-free genome editing in plants</article-title><source>Plant Cell Physiol.</source><year>2020</year><volume>61</volume><fpage>1946</fpage><lpage>1953</lpage><pub-id pub-id-type="doi">10.1093/pcp/pcaa123</pub-id><pub-id pub-id-type="pmid">32991731</pub-id>
</element-citation></ref><ref id="B266-vaccines-12-01344"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>R.B.</given-names></name>
<name><surname>Abranches</surname><given-names>R.</given-names></name>
<name><surname>Fischer</surname><given-names>R.</given-names></name>
<name><surname>Sack</surname><given-names>M.</given-names></name>
<name><surname>Holland</surname><given-names>T.</given-names></name>
</person-group><article-title>Putting the spotlight back on plant suspension cultures</article-title><source>Front. Plant Sci.</source><year>2016</year><volume>7</volume><elocation-id>297</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2016.00297</pub-id><pub-id pub-id-type="pmid">27014320</pub-id>
</element-citation></ref><ref id="B267-vaccines-12-01344"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kolotilin</surname><given-names>I.</given-names></name>
<name><surname>Topp</surname><given-names>E.</given-names></name>
<name><surname>Cox</surname><given-names>E.</given-names></name>
<name><surname>Devriendt</surname><given-names>B.</given-names></name>
<name><surname>Conrad</surname><given-names>U.</given-names></name>
<name><surname>Joensuu</surname><given-names>J.</given-names></name>
<name><surname>St&#x000f6;ger</surname><given-names>E.</given-names></name>
<name><surname>Warzecha</surname><given-names>H.</given-names></name>
<name><surname>McAllister</surname><given-names>T.</given-names></name>
<name><surname>Potter</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Plant-based solutions for veterinary immunotherapeutics and prophylactics</article-title><source>Vet. Res.</source><year>2014</year><volume>45</volume><fpage>117</fpage><pub-id pub-id-type="doi">10.1186/s13567-014-0117-4</pub-id><pub-id pub-id-type="pmid">25559098</pub-id>
</element-citation></ref><ref id="B268-vaccines-12-01344"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Floss</surname><given-names>D.M.</given-names></name>
<name><surname>Falkenburg</surname><given-names>D.</given-names></name>
<name><surname>Conrad</surname><given-names>U.</given-names></name>
</person-group><article-title>Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: An overview</article-title><source>Transgenic Res.</source><year>2007</year><volume>16</volume><fpage>315</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1007/s11248-007-9095-x</pub-id><pub-id pub-id-type="pmid">17436059</pub-id>
</element-citation></ref><ref id="B269-vaccines-12-01344"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oh</surname><given-names>Y.</given-names></name>
<name><surname>Park</surname><given-names>Y.</given-names></name>
<name><surname>Choi</surname><given-names>B.-H.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Gu</surname><given-names>S.</given-names></name>
<name><surname>Park</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>J.-K.</given-names></name>
<name><surname>Sohn</surname><given-names>E.-J.</given-names></name>
</person-group><article-title>Field Application of a New CSF Vaccine Based on Plant-Produced Recombinant E2 Marker Proteins on Pigs in Areas with Two Different Control Strategies</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>537</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9060537</pub-id><pub-id pub-id-type="pmid">34063818</pub-id>
</element-citation></ref><ref id="B270-vaccines-12-01344"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Landry</surname><given-names>N.</given-names></name>
<name><surname>Pillet</surname><given-names>S.</given-names></name>
<name><surname>Favre</surname><given-names>D.</given-names></name>
<name><surname>Poulin</surname><given-names>J.-F.</given-names></name>
<name><surname>Tr&#x000e9;panier</surname><given-names>S.</given-names></name>
<name><surname>Yassine-Diab</surname><given-names>B.</given-names></name>
<name><surname>Ward</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Influenza virus-like particle vaccines made in <italic toggle="yes">Nicotiana benthamiana</italic> elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens</article-title><source>Clin. Immunol.</source><year>2014</year><volume>154</volume><fpage>164</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2014.08.003</pub-id><pub-id pub-id-type="pmid">25128897</pub-id>
</element-citation></ref><ref id="B271-vaccines-12-01344"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pillet</surname><given-names>S.</given-names></name>
<name><surname>Racine</surname><given-names>T.</given-names></name>
<name><surname>Nfon</surname><given-names>C.</given-names></name>
<name><surname>Di Lenardo</surname><given-names>T.Z.</given-names></name>
<name><surname>Babiuk</surname><given-names>S.</given-names></name>
<name><surname>Ward</surname><given-names>B.J.</given-names></name>
<name><surname>Kobinger</surname><given-names>G.P.</given-names></name>
<name><surname>Landry</surname><given-names>N.</given-names></name>
</person-group><article-title>Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>6282</fpage><lpage>6289</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.065</pub-id><pub-id pub-id-type="pmid">26432915</pub-id>
</element-citation></ref><ref id="B272-vaccines-12-01344"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shoji</surname><given-names>Y.</given-names></name>
<name><surname>Chichester</surname><given-names>J.A.</given-names></name>
<name><surname>Jones</surname><given-names>M.</given-names></name>
<name><surname>Manceva</surname><given-names>S.D.</given-names></name>
<name><surname>Damon</surname><given-names>E.</given-names></name>
<name><surname>Mett</surname><given-names>V.</given-names></name>
<name><surname>Musiychuk</surname><given-names>K.</given-names></name>
<name><surname>Bi</surname><given-names>H.</given-names></name>
<name><surname>Farrance</surname><given-names>C.</given-names></name>
<name><surname>Shamloul</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza</article-title><source>Hum. Vaccines</source><year>2011</year><volume>7</volume><issue>(Suppl. 1)</issue><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.4161/hv.7.0.14561</pub-id><pub-id pub-id-type="pmid">21266846</pub-id>
</element-citation></ref><ref id="B273-vaccines-12-01344"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>T.</given-names></name>
<name><surname>O&#x02019;Kennedy</surname><given-names>M.M.</given-names></name>
<name><surname>Wandrag</surname><given-names>D.B.R.</given-names></name>
<name><surname>Adeyemi</surname><given-names>M.</given-names></name>
<name><surname>Abolnik</surname><given-names>C.</given-names></name>
</person-group><article-title>Efficacy of a plant-produced virus-like particle vaccine in chickens challenged with Influenza A H6N2 virus</article-title><source>Plant Biotechnol. J.</source><year>2020</year><volume>18</volume><fpage>502</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1111/pbi.13219</pub-id><pub-id pub-id-type="pmid">31350931</pub-id>
</element-citation></ref><ref id="B274-vaccines-12-01344"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sepotokele</surname><given-names>K.M.</given-names></name>
<name><surname>O&#x02019;Kennedy</surname><given-names>M.M.</given-names></name>
<name><surname>Wandrag</surname><given-names>D.B.R.</given-names></name>
<name><surname>Abolnik</surname><given-names>C.</given-names></name>
</person-group><article-title>Optimization of infectious bronchitis virus-like particle expression in <italic toggle="yes">Nicotiana benthamiana</italic> as potential poultry vaccines</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0288970</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0288970</pub-id><pub-id pub-id-type="pmid">37471377</pub-id>
</element-citation></ref><ref id="B275-vaccines-12-01344"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siriwattananon</surname><given-names>K.</given-names></name>
<name><surname>Manopwisedjaroen</surname><given-names>S.</given-names></name>
<name><surname>Shanmugaraj</surname><given-names>B.</given-names></name>
<name><surname>Rattanapisit</surname><given-names>K.</given-names></name>
<name><surname>Phumiamorn</surname><given-names>S.</given-names></name>
<name><surname>Sapsutthipas</surname><given-names>S.</given-names></name>
<name><surname>Trisiriwanich</surname><given-names>S.</given-names></name>
<name><surname>Prompetchara</surname><given-names>E.</given-names></name>
<name><surname>Ketloy</surname><given-names>C.</given-names></name>
<name><surname>Buranapraditkun</surname><given-names>S.</given-names></name>
</person-group><article-title>Plant-produced receptor-binding domain of SARS-CoV-2 elicits potent neutralizing responses in mice and non-human primates</article-title><source>Front. Plant Sci.</source><year>2021</year><volume>12</volume><elocation-id>682953</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2021.682953</pub-id><pub-id pub-id-type="pmid">34054909</pub-id>
</element-citation></ref><ref id="B276-vaccines-12-01344"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Kang</surname><given-names>H.</given-names></name>
<name><surname>Park</surname><given-names>M.</given-names></name>
<name><surname>Min</surname><given-names>K.</given-names></name>
<name><surname>Kim</surname><given-names>N.H.</given-names></name>
<name><surname>Gu</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>J.K.</given-names></name>
<name><surname>An</surname><given-names>D.-J.</given-names></name>
<name><surname>Choe</surname><given-names>S.</given-names></name>
</person-group><article-title>A classical swine fever virus E2 fusion protein produced in plants elicits a neutralizing humoral immune response in mice and pigs</article-title><source>Biotechnol. Lett.</source><year>2020</year><volume>42</volume><fpage>1247</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1007/s10529-020-02892-3</pub-id><pub-id pub-id-type="pmid">32323080</pub-id>
</element-citation></ref><ref id="B277-vaccines-12-01344"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamamoto</surname><given-names>T.</given-names></name>
<name><surname>Hoshikawa</surname><given-names>K.</given-names></name>
<name><surname>Ezura</surname><given-names>K.</given-names></name>
<name><surname>Okazawa</surname><given-names>R.</given-names></name>
<name><surname>Fujita</surname><given-names>S.</given-names></name>
<name><surname>Takaoka</surname><given-names>M.</given-names></name>
<name><surname>Mason</surname><given-names>H.S.</given-names></name>
<name><surname>Ezura</surname><given-names>H.</given-names></name>
<name><surname>Miura</surname><given-names>K.</given-names></name>
</person-group><article-title>Improvement of the transient expression system for production of recombinant proteins in plants</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>4755</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-23024-y</pub-id><pub-id pub-id-type="pmid">29555968</pub-id>
</element-citation></ref><ref id="B278-vaccines-12-01344"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garabagi</surname><given-names>F.</given-names></name>
<name><surname>McLean</surname><given-names>M.D.</given-names></name>
<name><surname>Hall</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Transient and stable expression of antibodies in Nicotiana species</article-title><source>Methods Mol. Biol.</source><year>2012</year><volume>907</volume><fpage>389</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-974-7_23</pub-id><pub-id pub-id-type="pmid">22907365</pub-id>
</element-citation></ref><ref id="B279-vaccines-12-01344"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Darveau</surname><given-names>R.P.</given-names></name>
<name><surname>Chilton</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Naturally occurring low biological reactivity lipopolysaccharides as vaccine adjuvants</article-title><source>Expert Rev. Vaccines</source><year>2013</year><volume>12</volume><fpage>707</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1586/14760584.2013.811181</pub-id><pub-id pub-id-type="pmid">23885813</pub-id>
</element-citation></ref><ref id="B280-vaccines-12-01344"><label>280.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Global Biodefense Staff</collab>
</person-group><article-title>DARPA Hits Milestone in Plant-Based Vaccines for Pandemics</article-title><source>Glob. Biodefense</source><comment>Available online: <ext-link xlink:href="https://globalbiodefense.com/2012/07/28/darpa-program-hits-milestone-in-plant-based-vaccines-for-pandemics/" ext-link-type="uri">https://globalbiodefense.com/2012/07/28/darpa-program-hits-milestone-in-plant-based-vaccines-for-pandemics/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-03">(accessed on 3 June 2020)</date-in-citation></element-citation></ref><ref id="B281-vaccines-12-01344"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Potera</surname><given-names>C.</given-names></name>
</person-group><article-title>Vaccine Manufacturing Gets Boost from Tobacco Plants</article-title><source>Genet. Eng. Biotechnol. News</source><year>2012</year><volume>32</volume><fpage>8</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1089/gen.32.6.02</pub-id></element-citation></ref><ref id="B282-vaccines-12-01344"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shin</surname><given-names>Y.-J.</given-names></name>
<name><surname>K&#x000f6;nig-Beihammer</surname><given-names>J.</given-names></name>
<name><surname>Vavra</surname><given-names>U.</given-names></name>
<name><surname>Schwestka</surname><given-names>J.</given-names></name>
<name><surname>Kienzl</surname><given-names>N.F.</given-names></name>
<name><surname>Klausberger</surname><given-names>M.</given-names></name>
<name><surname>Laurent</surname><given-names>E.</given-names></name>
<name><surname>Gr&#x000fc;nwald-Gruber</surname><given-names>C.</given-names></name>
<name><surname>Vierlinger</surname><given-names>K.</given-names></name>
<name><surname>Hofner</surname><given-names>M.</given-names></name>
</person-group><article-title>N-glycosylation of the SARS-CoV-2 receptor binding domain is important for functional expression in plants</article-title><source>Front. Plant Sci.</source><year>2021</year><volume>12</volume><elocation-id>689104</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2021.689104</pub-id><pub-id pub-id-type="pmid">34211491</pub-id>
</element-citation></ref><ref id="B283-vaccines-12-01344"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makatsa</surname><given-names>M.S.</given-names></name>
<name><surname>Tincho</surname><given-names>M.B.</given-names></name>
<name><surname>Wendoh</surname><given-names>J.M.</given-names></name>
<name><surname>Ismail</surname><given-names>S.D.</given-names></name>
<name><surname>Nesamari</surname><given-names>R.</given-names></name>
<name><surname>Pera</surname><given-names>F.</given-names></name>
<name><surname>De Beer</surname><given-names>S.</given-names></name>
<name><surname>David</surname><given-names>A.</given-names></name>
<name><surname>Jugwanth</surname><given-names>S.</given-names></name>
<name><surname>Gededzha</surname><given-names>M.P.</given-names></name>
</person-group><article-title>SARS-CoV-2 antigens expressed in plants detect antibody responses in COVID-19 patients</article-title><source>Front. Plant Sci.</source><year>2021</year><volume>12</volume><elocation-id>589940</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2021.589940</pub-id><pub-id pub-id-type="pmid">33868324</pub-id>
</element-citation></ref><ref id="B284-vaccines-12-01344"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>J.</given-names></name>
<name><surname>Zahmanova</surname><given-names>G.</given-names></name>
<name><surname>Minkov</surname><given-names>I.</given-names></name>
<name><surname>Lomonossoff</surname><given-names>G.P.</given-names></name>
</person-group><article-title>Plant-based expression and characterization of SARS-CoV-2 virus-like particles presenting a native spike protein</article-title><source>Plant Biotechnol. J.</source><year>2022</year><volume>20</volume><fpage>1363</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1111/pbi.13813</pub-id><pub-id pub-id-type="pmid">35325498</pub-id>
</element-citation></ref><ref id="B285-vaccines-12-01344"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Capell</surname><given-names>T.</given-names></name>
<name><surname>Twyman</surname><given-names>R.M.</given-names></name>
<name><surname>Armario-Najera</surname><given-names>V.</given-names></name>
<name><surname>Ma</surname><given-names>J.K.-C.</given-names></name>
<name><surname>Schillberg</surname><given-names>S.</given-names></name>
<name><surname>Christou</surname><given-names>P.</given-names></name>
</person-group><article-title>Potential applications of plant biotechnology against SARS-CoV-2</article-title><source>Trends Plant Sci.</source><year>2020</year><volume>25</volume><fpage>635</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/j.tplants.2020.04.009</pub-id><pub-id pub-id-type="pmid">32371057</pub-id>
</element-citation></ref><ref id="B286-vaccines-12-01344"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maharjan</surname><given-names>P.M.</given-names></name>
<name><surname>Cheon</surname><given-names>J.</given-names></name>
<name><surname>Jung</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Song</surname><given-names>M.</given-names></name>
<name><surname>Jeong</surname><given-names>G.U.</given-names></name>
<name><surname>Kwon</surname><given-names>Y.</given-names></name>
<name><surname>Shim</surname><given-names>B.</given-names></name>
<name><surname>Choe</surname><given-names>S.</given-names></name>
</person-group><article-title>Plant-expressed receptor binding domain of the SARS-CoV-2 spike protein elicits Humoral immunity in mice</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>978</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9090978</pub-id><pub-id pub-id-type="pmid">34579215</pub-id>
</element-citation></ref><ref id="B287-vaccines-12-01344"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moon</surname><given-names>K.-B.</given-names></name>
<name><surname>Jeon</surname><given-names>J.-H.</given-names></name>
<name><surname>Choi</surname><given-names>H.</given-names></name>
<name><surname>Park</surname><given-names>J.-S.</given-names></name>
<name><surname>Park</surname><given-names>S.-J.</given-names></name>
<name><surname>Lee</surname><given-names>H.-J.</given-names></name>
<name><surname>Park</surname><given-names>J.M.</given-names></name>
<name><surname>Cho</surname><given-names>H.S.</given-names></name>
<name><surname>Moon</surname><given-names>J.S.</given-names></name>
<name><surname>Oh</surname><given-names>H.</given-names></name>
</person-group><article-title>Construction of SARS-CoV-2 virus-like particles in plant</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>1005</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-04883-y</pub-id><pub-id pub-id-type="pmid">35046461</pub-id>
</element-citation></ref><ref id="B288-vaccines-12-01344"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gregorio</surname><given-names>N.E.</given-names></name>
<name><surname>Levine</surname><given-names>M.Z.</given-names></name>
<name><surname>Oza</surname><given-names>J.P.</given-names></name>
</person-group><article-title>A User&#x02019;s Guide to Cell-Free Protein Synthesis</article-title><source>Methods Protoc.</source><year>2019</year><volume>2</volume><elocation-id>24</elocation-id><pub-id pub-id-type="doi">10.3390/mps2010024</pub-id><pub-id pub-id-type="pmid">31164605</pub-id>
</element-citation></ref><ref id="B289-vaccines-12-01344"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>X.</given-names></name>
<name><surname>Hong</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Cell-free protein synthesis for producing &#x02018;difficult-to-express&#x02019; proteins</article-title><source>Biochem. Eng. J.</source><year>2018</year><volume>138</volume><fpage>156</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.bej.2018.07.013</pub-id></element-citation></ref><ref id="B290-vaccines-12-01344"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosenblum</surname><given-names>G.</given-names></name>
<name><surname>Cooperman</surname><given-names>B.S.</given-names></name>
</person-group><article-title>Engine out of the chassis: Cell-free protein synthesis and its uses</article-title><source>FEBS Lett.</source><year>2014</year><volume>588</volume><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2013.10.016</pub-id><pub-id pub-id-type="pmid">24161673</pub-id>
</element-citation></ref><ref id="B291-vaccines-12-01344"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bretthauer</surname><given-names>R.K.</given-names></name>
<name><surname>Marcus</surname><given-names>L.</given-names></name>
<name><surname>Chaloupka</surname><given-names>J.</given-names></name>
<name><surname>Halvorson</surname><given-names>H.O.</given-names></name>
<name><surname>Bock</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Amino acid incorporation into protein by cell-free extracts of yeast</article-title><source>Biochemistry</source><year>1963</year><volume>2</volume><fpage>1079</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1021/bi00905a029</pub-id><pub-id pub-id-type="pmid">14087363</pub-id>
</element-citation></ref><ref id="B292-vaccines-12-01344"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zubay</surname><given-names>G.</given-names></name>
</person-group><article-title>In Vitro Synthesis of Protein in Microbial Systems</article-title><source>Annu. Rev. Genet.</source><year>1973</year><volume>7</volume><fpage>267</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1146/annurev.ge.07.120173.001411</pub-id><pub-id pub-id-type="pmid">4593305</pub-id>
</element-citation></ref><ref id="B293-vaccines-12-01344"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shin</surname><given-names>J.</given-names></name>
<name><surname>Noireaux</surname><given-names>V.</given-names></name>
</person-group><article-title>An <italic toggle="yes">E. coli</italic> Cell-Free Expression Toolbox: Application to Synthetic Gene Circuits and Artificial Cells</article-title><source>ACS Synth. Biol.</source><year>2012</year><volume>1</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1021/sb200016s</pub-id><pub-id pub-id-type="pmid">23651008</pub-id>
</element-citation></ref><ref id="B294-vaccines-12-01344"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>P.</given-names></name>
<name><surname>Thomas</surname><given-names>C.J.</given-names></name>
<name><surname>Sprang</surname><given-names>S.R.</given-names></name>
<name><surname>Tall</surname><given-names>G.G.</given-names></name>
</person-group><article-title>Molecular chaperoning function of Ric-8 is to fold nascent heterotrimeric G protein &#x003b1; subunits</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>3794</fpage><lpage>3799</lpage><pub-id pub-id-type="doi">10.1073/pnas.1220943110</pub-id><pub-id pub-id-type="pmid">23431197</pub-id>
</element-citation></ref><ref id="B295-vaccines-12-01344"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Gu</surname><given-names>L.</given-names></name>
<name><surname>Aach</surname><given-names>J.</given-names></name>
<name><surname>Church</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Improved Cell-Free RNA and Protein Synthesis System</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e106232</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0106232</pub-id><pub-id pub-id-type="pmid">25180701</pub-id>
</element-citation></ref><ref id="B296-vaccines-12-01344"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tinafar</surname><given-names>A.</given-names></name>
<name><surname>Jaenes</surname><given-names>K.</given-names></name>
<name><surname>Pardee</surname><given-names>K.</given-names></name>
</person-group><article-title>Synthetic Biology Goes Cell-Free</article-title><source>BMC Biol.</source><year>2019</year><volume>17</volume><elocation-id>64</elocation-id><pub-id pub-id-type="doi">10.1186/s12915-019-0685-x</pub-id><pub-id pub-id-type="pmid">31395057</pub-id>
</element-citation></ref><ref id="B297-vaccines-12-01344"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>M.T.</given-names></name>
<name><surname>Berkheimer</surname><given-names>S.D.</given-names></name>
<name><surname>Werner</surname><given-names>C.J.</given-names></name>
<name><surname>Bundy</surname><given-names>B.C.</given-names></name>
</person-group><article-title>Lyophilized <italic toggle="yes">Escherichia coli</italic>-based cell-free systems for robust, high-density, long-term storage</article-title><source>Biotechniques</source><year>2014</year><volume>56</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.2144/000114158</pub-id><pub-id pub-id-type="pmid">24724844</pub-id>
</element-citation></ref><ref id="B298-vaccines-12-01344"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pardee</surname><given-names>K.</given-names></name>
<name><surname>Slomovic</surname><given-names>S.</given-names></name>
<name><surname>Nguyen</surname><given-names>P.Q.</given-names></name>
<name><surname>Lee</surname><given-names>J.W.</given-names></name>
<name><surname>Donghia</surname><given-names>N.</given-names></name>
<name><surname>Burrill</surname><given-names>D.</given-names></name>
<name><surname>Ferrante</surname><given-names>T.</given-names></name>
<name><surname>McSorley</surname><given-names>F.R.</given-names></name>
<name><surname>Furuta</surname><given-names>Y.</given-names></name>
<name><surname>Vernet</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Portable, On-Demand Biomolecular Manufacturing</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>248</fpage><lpage>259.e12</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.013</pub-id><pub-id pub-id-type="pmid">27662092</pub-id>
</element-citation></ref><ref id="B299-vaccines-12-01344"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stech</surname><given-names>M.</given-names></name>
<name><surname>Quast</surname><given-names>R.B.</given-names></name>
<name><surname>Sachse</surname><given-names>R.</given-names></name>
<name><surname>Schulze</surname><given-names>C.</given-names></name>
<name><surname>W&#x000fc;stenhagen</surname><given-names>D.A.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>A Continuous-Exchange Cell-Free Protein Synthesis System Based on Extracts from Cultured Insect Cells</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e96635</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0096635</pub-id><pub-id pub-id-type="pmid">24804975</pub-id>
</element-citation></ref><ref id="B300-vaccines-12-01344"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Emileh</surname><given-names>A.</given-names></name>
<name><surname>Brideau</surname><given-names>N.</given-names></name>
<name><surname>Britton</surname><given-names>J.</given-names></name>
</person-group><article-title>Cell-free reactions in continuous manufacturing systems</article-title><source>Curr. Opin. Green Sustain. Chem.</source><year>2020</year><volume>25</volume><fpage>100380</fpage><pub-id pub-id-type="doi">10.1016/j.cogsc.2020.100380</pub-id></element-citation></ref><ref id="B301-vaccines-12-01344"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quast</surname><given-names>R.B.</given-names></name>
<name><surname>Kortt</surname><given-names>O.</given-names></name>
<name><surname>Henkel</surname><given-names>J.</given-names></name>
<name><surname>Dondapati</surname><given-names>S.K.</given-names></name>
<name><surname>W&#x000fc;stenhagen</surname><given-names>D.A.</given-names></name>
<name><surname>Stech</surname><given-names>M.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>Automated production of functional membrane proteins using eukaryotic cell-free translation systems</article-title><source>J. Biotechnol.</source><year>2015</year><volume>203</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2015.03.015</pub-id><pub-id pub-id-type="pmid">25828454</pub-id>
</element-citation></ref><ref id="B302-vaccines-12-01344"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silverman</surname><given-names>A.D.</given-names></name>
<name><surname>Karim</surname><given-names>A.S.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Cell-free gene expression: An expanded repertoire of applications</article-title><source>Nat. Rev. Genet.</source><year>2020</year><volume>21</volume><fpage>151</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/s41576-019-0186-3</pub-id><pub-id pub-id-type="pmid">31780816</pub-id>
</element-citation></ref><ref id="B303-vaccines-12-01344"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dopp</surname><given-names>B.J.L.</given-names></name>
<name><surname>Tamiev</surname><given-names>D.D.</given-names></name>
<name><surname>Reuel</surname><given-names>N.F.</given-names></name>
</person-group><article-title>Cell-free supplement mixtures: Elucidating the history and biochemical utility of additives used to support in vitro protein synthesis in <italic toggle="yes">E. coli</italic> extract</article-title><source>Biotechnol. Adv.</source><year>2019</year><volume>37</volume><fpage>246</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2018.12.006</pub-id><pub-id pub-id-type="pmid">30572024</pub-id>
</element-citation></ref><ref id="B304-vaccines-12-01344"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carlson</surname><given-names>E.D.</given-names></name>
<name><surname>Gan</surname><given-names>R.</given-names></name>
<name><surname>Hodgman</surname><given-names>C.E.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Cell-free protein synthesis: Applications come of age</article-title><source>Biotechnol. Adv.</source><year>2012</year><volume>30</volume><fpage>1185</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2011.09.016</pub-id><pub-id pub-id-type="pmid">22008973</pub-id>
</element-citation></ref><ref id="B305-vaccines-12-01344"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chiao</surname><given-names>A.C.</given-names></name>
<name><surname>Murray</surname><given-names>R.M.</given-names></name>
<name><surname>Sun</surname><given-names>Z.Z.</given-names></name>
</person-group><article-title>Development of prokaryotic cell-free systems for synthetic biology</article-title><source>bioRxiv</source><year>2016</year><elocation-id>48710</elocation-id><pub-id pub-id-type="doi">10.1101/048710</pub-id></element-citation></ref><ref id="B306-vaccines-12-01344"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>W.C.</given-names></name>
<name><surname>Patel</surname><given-names>K.G.</given-names></name>
<name><surname>Wong</surname><given-names>H.E.</given-names></name>
<name><surname>Swartz</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Simplifying and streamlining <italic toggle="yes">Escherichia coli</italic>-based cell-free protein synthesis</article-title><source>Biotechnol. Prog.</source><year>2012</year><volume>28</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1002/btpr.1509</pub-id><pub-id pub-id-type="pmid">22275217</pub-id>
</element-citation></ref><ref id="B307-vaccines-12-01344"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caschera</surname><given-names>F.</given-names></name>
<name><surname>Noireaux</surname><given-names>V.</given-names></name>
</person-group><article-title>Synthesis of 2.3 mg/ml of protein with an all <italic toggle="yes">Escherichia coli</italic> cell-free transcription&#x02013;translation system</article-title><source>Biochimie</source><year>2014</year><volume>99</volume><fpage>162</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2013.11.025</pub-id><pub-id pub-id-type="pmid">24326247</pub-id>
</element-citation></ref><ref id="B308-vaccines-12-01344"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Des Soye</surname><given-names>B.J.</given-names></name>
<name><surname>Davidson</surname><given-names>S.R.</given-names></name>
<name><surname>Weinstock</surname><given-names>M.T.</given-names></name>
<name><surname>Gibson</surname><given-names>D.G.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Establishing a High-Yielding Cell-Free Protein Synthesis Platform Derived from Vibrio natriegens</article-title><source>ACS Synth. Biol.</source><year>2018</year><volume>7</volume><fpage>2245</fpage><lpage>2255</lpage><pub-id pub-id-type="doi">10.1021/acssynbio.8b00252</pub-id><pub-id pub-id-type="pmid">30107122</pub-id>
</element-citation></ref><ref id="B309-vaccines-12-01344"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>W.-Q.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Translation Related Factors Improve the Productivity of a Streptomyces-Based Cell-Free Protein Synthesis System</article-title><source>ACS Synth. Biol.</source><year>2020</year><volume>9</volume><fpage>1221</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1021/acssynbio.0c00140</pub-id><pub-id pub-id-type="pmid">32330385</pub-id>
</element-citation></ref><ref id="B310-vaccines-12-01344"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelwick</surname><given-names>R.</given-names></name>
<name><surname>Webb</surname><given-names>A.J.</given-names></name>
<name><surname>MacDonald</surname><given-names>J.T.</given-names></name>
<name><surname>Freemont</surname><given-names>P.S.</given-names></name>
</person-group><article-title>Development of a Bacillus subtilis cell-free transcription-translation system for prototyping regulatory elements</article-title><source>Metab. Eng.</source><year>2016</year><volume>38</volume><fpage>370</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2016.09.008</pub-id><pub-id pub-id-type="pmid">27697563</pub-id>
</element-citation></ref><ref id="B311-vaccines-12-01344"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moore</surname><given-names>S.J.</given-names></name>
<name><surname>MacDonald</surname><given-names>J.T.</given-names></name>
<name><surname>Wienecke</surname><given-names>S.</given-names></name>
<name><surname>Ishwarbhai</surname><given-names>A.</given-names></name>
<name><surname>Tsipa</surname><given-names>A.</given-names></name>
<name><surname>Aw</surname><given-names>R.</given-names></name>
<name><surname>Kylilis</surname><given-names>N.</given-names></name>
<name><surname>Bell</surname><given-names>D.J.</given-names></name>
<name><surname>McClymont</surname><given-names>D.W.</given-names></name>
<name><surname>Jensen</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Rapid acquisition and model-based analysis of cell-free transcription&#x02013;translation reactions from nonmodel bacteria</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>E4340</fpage><lpage>E4349</lpage><pub-id pub-id-type="doi">10.1073/pnas.1715806115</pub-id><pub-id pub-id-type="pmid">29666238</pub-id>
</element-citation></ref><ref id="B312-vaccines-12-01344"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Development of a Pseudomonas putida cell-free protein synthesis platform for rapid screening of gene regulatory elements</article-title><source>Synth. Biol.</source><year>2018</year><volume>3</volume><elocation-id>ysy003</elocation-id><pub-id pub-id-type="doi">10.1093/synbio/ysy003</pub-id></element-citation></ref><ref id="B313-vaccines-12-01344"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tran</surname><given-names>K.</given-names></name>
<name><surname>Gurramkonda</surname><given-names>C.</given-names></name>
<name><surname>Cooper</surname><given-names>M.A.</given-names></name>
<name><surname>Pilli</surname><given-names>M.</given-names></name>
<name><surname>Taris</surname><given-names>J.E.</given-names></name>
<name><surname>Selock</surname><given-names>N.</given-names></name>
<name><surname>Han</surname><given-names>T.-C.</given-names></name>
<name><surname>Tolosa</surname><given-names>M.</given-names></name>
<name><surname>Zuber</surname><given-names>A.</given-names></name>
<name><surname>Pe&#x000f1;alber-Johnstone</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Cell-free production of a therapeutic protein: Expression, purification, and characterization of recombinant streptokinase using a CHO lysate</article-title><source>Biotechnol. Bioeng.</source><year>2018</year><volume>115</volume><fpage>92</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1002/bit.26439</pub-id><pub-id pub-id-type="pmid">28843001</pub-id>
</element-citation></ref><ref id="B314-vaccines-12-01344"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>R.W.</given-names></name>
<name><surname>Majewska</surname><given-names>N.I.</given-names></name>
<name><surname>Chen</surname><given-names>C.X.</given-names></name>
<name><surname>Albanetti</surname><given-names>T.E.</given-names></name>
<name><surname>Jimenez</surname><given-names>R.B.C.</given-names></name>
<name><surname>Schmelzer</surname><given-names>A.E.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
<name><surname>Roy</surname><given-names>V.</given-names></name>
</person-group><article-title>Development of a CHO-Based Cell-Free Platform for Synthesis of Active Monoclonal Antibodies</article-title><source>ACS Synth. Biol.</source><year>2017</year><volume>6</volume><fpage>1370</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1021/acssynbio.7b00001</pub-id><pub-id pub-id-type="pmid">28350472</pub-id>
</element-citation></ref><ref id="B315-vaccines-12-01344"><label>315.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
</person-group><article-title>Host-regulated Hepatitis B Virus Capsid Assembly in a Mammalian Cell-free System</article-title><source>Bio-protocol</source><year>2018</year><volume>8</volume><elocation-id>e2813</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.2813</pub-id><pub-id pub-id-type="pmid">29770355</pub-id>
</element-citation></ref><ref id="B316-vaccines-12-01344"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kopniczky</surname><given-names>M.B.</given-names></name>
<name><surname>Canavan</surname><given-names>C.</given-names></name>
<name><surname>McClymont</surname><given-names>D.W.</given-names></name>
<name><surname>Crone</surname><given-names>M.A.</given-names></name>
<name><surname>Suckling</surname><given-names>L.</given-names></name>
<name><surname>Goetzmann</surname><given-names>B.</given-names></name>
<name><surname>Siciliano</surname><given-names>V.</given-names></name>
<name><surname>MacDonald</surname><given-names>J.T.</given-names></name>
<name><surname>Jensen</surname><given-names>K.</given-names></name>
<name><surname>Freemont</surname><given-names>P.S.</given-names></name>
</person-group><article-title>Cell-Free Protein Synthesis as a Prototyping Platform for Mammalian Synthetic Biology</article-title><source>ACS Synth. Biol.</source><year>2020</year><volume>9</volume><fpage>144</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1021/acssynbio.9b00437</pub-id><pub-id pub-id-type="pmid">31899623</pub-id>
</element-citation></ref><ref id="B317-vaccines-12-01344"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ezure</surname><given-names>T.</given-names></name>
<name><surname>Suzuki</surname><given-names>T.</given-names></name>
<name><surname>Higashide</surname><given-names>S.</given-names></name>
<name><surname>Shintani</surname><given-names>E.</given-names></name>
<name><surname>Endo</surname><given-names>K.</given-names></name>
<name><surname>Kobayashi</surname><given-names>S.</given-names></name>
<name><surname>Shikata</surname><given-names>M.</given-names></name>
<name><surname>Ito</surname><given-names>M.</given-names></name>
<name><surname>Tanimizu</surname><given-names>K.</given-names></name>
<name><surname>Nishimura</surname><given-names>O.</given-names></name>
</person-group><article-title>Cell-Free Protein Synthesis System Prepared from Insect Cells by Freeze-Thawing</article-title><source>Biotechnol. Prog.</source><year>2006</year><volume>22</volume><fpage>1570</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1021/bp060110v</pub-id><pub-id pub-id-type="pmid">17137303</pub-id>
</element-citation></ref><ref id="B318-vaccines-12-01344"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ezure</surname><given-names>T.</given-names></name>
<name><surname>Suzuki</surname><given-names>T.</given-names></name>
<name><surname>Shikata</surname><given-names>M.</given-names></name>
<name><surname>Ito</surname><given-names>M.</given-names></name>
<name><surname>Ando</surname><given-names>E.</given-names></name>
</person-group><article-title>A cell-free protein synthesis system from insect cells</article-title><source>Methods Mol. Biol.</source><year>2010</year><volume>607</volume><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1007/978-1-60327-331-2_4</pub-id><pub-id pub-id-type="pmid">20204846</pub-id>
</element-citation></ref><ref id="B319-vaccines-12-01344"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harbers</surname><given-names>M.</given-names></name>
</person-group><article-title>Wheat germ systems for cell-free protein expression</article-title><source>FEBS Lett.</source><year>2014</year><volume>588</volume><fpage>2762</fpage><lpage>2773</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2014.05.061</pub-id><pub-id pub-id-type="pmid">24931374</pub-id>
</element-citation></ref><ref id="B320-vaccines-12-01344"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buntru</surname><given-names>M.</given-names></name>
<name><surname>Vogel</surname><given-names>S.</given-names></name>
<name><surname>Stoff</surname><given-names>K.</given-names></name>
<name><surname>Spiegel</surname><given-names>H.</given-names></name>
<name><surname>Schillberg</surname><given-names>S.</given-names></name>
</person-group><article-title>A versatile coupled cell-free transcription&#x02013;translation system based on tobacco BY-2 cell lysates</article-title><source>Biotechnol. Bioeng.</source><year>2015</year><volume>112</volume><fpage>867</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1002/bit.25502</pub-id><pub-id pub-id-type="pmid">25421615</pub-id>
</element-citation></ref><ref id="B321-vaccines-12-01344"><label>321.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Nomoto</surname><given-names>M.</given-names></name>
<name><surname>Tada</surname><given-names>Y.</given-names></name>
</person-group><article-title>Cell-free protein synthesis of plant transcription factors</article-title><source>Methods in Molecular Biology</source><publisher-name>Humana Press Inc.</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2018</year><volume>Volume 1830</volume><fpage>337</fpage><lpage>349</lpage></element-citation></ref><ref id="B322-vaccines-12-01344"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zemella</surname><given-names>A.</given-names></name>
<name><surname>Thoring</surname><given-names>L.</given-names></name>
<name><surname>Hoffmeister</surname><given-names>C.</given-names></name>
<name><surname>&#x00160;amal&#x000ed;kov&#x000e1;</surname><given-names>M.</given-names></name>
<name><surname>Ehren</surname><given-names>P.</given-names></name>
<name><surname>W&#x000fc;stenhagen</surname><given-names>D.A.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>Cell-free protein synthesis as a novel tool for directed glycoengineering of active erythropoietin</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>8514</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-26936-x</pub-id><pub-id pub-id-type="pmid">29867209</pub-id>
</element-citation></ref><ref id="B323-vaccines-12-01344"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burgenson</surname><given-names>D.</given-names></name>
<name><surname>Gurramkonda</surname><given-names>C.</given-names></name>
<name><surname>Pilli</surname><given-names>M.</given-names></name>
<name><surname>Ge</surname><given-names>X.</given-names></name>
<name><surname>Andar</surname><given-names>A.</given-names></name>
<name><surname>Kostov</surname><given-names>Y.</given-names></name>
<name><surname>Tolosa</surname><given-names>L.</given-names></name>
<name><surname>Rao</surname><given-names>G.</given-names></name>
</person-group><article-title>Rapid recombinant protein expression in cell-free extracts from human blood</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>9569</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-27846-8</pub-id><pub-id pub-id-type="pmid">29934577</pub-id>
</element-citation></ref><ref id="B324-vaccines-12-01344"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Kwon</surname><given-names>Y.-C.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Establishing a high yielding streptomyces-based cell-free protein synthesis system</article-title><source>Biotechnol. Bioeng.</source><year>2017</year><volume>114</volume><fpage>1343</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1002/bit.26253</pub-id><pub-id pub-id-type="pmid">28112394</pub-id>
</element-citation></ref><ref id="B325-vaccines-12-01344"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buntru</surname><given-names>M.</given-names></name>
<name><surname>Vogel</surname><given-names>S.</given-names></name>
<name><surname>Spiegel</surname><given-names>H.</given-names></name>
<name><surname>Schillberg</surname><given-names>S.</given-names></name>
</person-group><article-title>Tobacco BY-2 cell-free lysate: An alternative and highly-productive plant-based in vitro translation system</article-title><source>BMC Biotechnol.</source><year>2014</year><volume>14</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6750-14-37</pub-id><pub-id pub-id-type="pmid">24886601</pub-id>
</element-citation></ref><ref id="B326-vaccines-12-01344"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kovtun</surname><given-names>O.</given-names></name>
<name><surname>Mureev</surname><given-names>S.</given-names></name>
<name><surname>Jung</surname><given-names>W.</given-names></name>
<name><surname>Kubala</surname><given-names>M.H.</given-names></name>
<name><surname>Johnston</surname><given-names>W.</given-names></name>
<name><surname>Alexandrov</surname><given-names>K.</given-names></name>
</person-group><article-title>Leishmania cell-free protein expression system</article-title><source>Methods</source><year>2011</year><volume>55</volume><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2011.06.006</pub-id><pub-id pub-id-type="pmid">21704167</pub-id>
</element-citation></ref><ref id="B327-vaccines-12-01344"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>C.</given-names></name>
<name><surname>Dasgupta</surname><given-names>A.</given-names></name>
<name><surname>Shen</surname><given-names>L.</given-names></name>
<name><surname>Bell-Pedersen</surname><given-names>D.</given-names></name>
<name><surname>Sachs</surname><given-names>M.S.</given-names></name>
</person-group><article-title>The cell free protein synthesis system from the model filamentous fungus Neurospora crassa</article-title><source>Methods</source><year>2018</year><volume>137</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2017.12.003</pub-id><pub-id pub-id-type="pmid">29294368</pub-id>
</element-citation></ref><ref id="B328-vaccines-12-01344"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gan</surname><given-names>R.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
</person-group><article-title>A combined cell-free transcription-translation system from <italic toggle="yes">Saccharomyces cerevisiae</italic> for rapid and robust protein synthe</article-title><source>Biotechnol. J.</source><year>2014</year><volume>9</volume><fpage>641</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1002/biot.201300545</pub-id><pub-id pub-id-type="pmid">24677809</pub-id>
</element-citation></ref><ref id="B329-vaccines-12-01344"><label>329.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaroentomeechai</surname><given-names>T.</given-names></name>
<name><surname>Stark</surname><given-names>J.C.</given-names></name>
<name><surname>Natarajan</surname><given-names>A.</given-names></name>
<name><surname>Glasscock</surname><given-names>C.J.</given-names></name>
<name><surname>Yates</surname><given-names>L.E.</given-names></name>
<name><surname>Hsu</surname><given-names>K.J.</given-names></name>
<name><surname>Mrksich</surname><given-names>M.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
<name><surname>DeLisa</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Single-pot glycoprotein biosynthesis using a cell-free transcription-translation system enriched with glycosylation machinery</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>2686</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05110-x</pub-id><pub-id pub-id-type="pmid">30002445</pub-id>
</element-citation></ref><ref id="B330-vaccines-12-01344"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>R.W.</given-names></name>
<name><surname>Des Soye</surname><given-names>B.J.</given-names></name>
<name><surname>Kwon</surname><given-names>Y.-C.</given-names></name>
<name><surname>Kay</surname><given-names>J.</given-names></name>
<name><surname>Davis</surname><given-names>R.G.</given-names></name>
<name><surname>Thomas</surname><given-names>P.M.</given-names></name>
<name><surname>Majewska</surname><given-names>N.I.</given-names></name>
<name><surname>Chen</surname><given-names>C.X.</given-names></name>
<name><surname>Marcum</surname><given-names>R.D.</given-names></name>
<name><surname>Weiss</surname><given-names>M.G.</given-names></name>
<etal/>
</person-group><article-title>Cell-free protein synthesis from genomically recoded bacteria enables multisite incorporation of noncanonical amino acids</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>1203</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-03469-5</pub-id><pub-id pub-id-type="pmid">29572528</pub-id>
</element-citation></ref><ref id="B331-vaccines-12-01344"><label>331.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shinoda</surname><given-names>T.</given-names></name>
<name><surname>Shinya</surname><given-names>N.</given-names></name>
<name><surname>Ito</surname><given-names>K.</given-names></name>
<name><surname>Ishizuka-Katsura</surname><given-names>Y.</given-names></name>
<name><surname>Ohsawa</surname><given-names>N.</given-names></name>
<name><surname>Terada</surname><given-names>T.</given-names></name>
<name><surname>Hirata</surname><given-names>K.</given-names></name>
<name><surname>Kawano</surname><given-names>Y.</given-names></name>
<name><surname>Yamamoto</surname><given-names>M.</given-names></name>
<name><surname>Tomita</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Cell-free methods to produce structurally intact mammalian membrane proteins</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>30442</elocation-id><pub-id pub-id-type="doi">10.1038/srep30442</pub-id><pub-id pub-id-type="pmid">27465719</pub-id>
</element-citation></ref><ref id="B332-vaccines-12-01344"><label>332.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Focke</surname><given-names>P.J.</given-names></name>
<name><surname>Hein</surname><given-names>C.</given-names></name>
<name><surname>Hoffmann</surname><given-names>B.</given-names></name>
<name><surname>Matulef</surname><given-names>K.</given-names></name>
<name><surname>Bernhard</surname><given-names>F.</given-names></name>
<name><surname>D&#x000f6;tsch</surname><given-names>V.</given-names></name>
<name><surname>Valiyaveetil</surname><given-names>F.I.</given-names></name>
</person-group><article-title>Combining in Vitro Folding with Cell Free Protein Synthesis for Membrane Protein Expression</article-title><source>Biochemistry</source><year>2016</year><volume>55</volume><fpage>4212</fpage><lpage>4219</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.6b00488</pub-id><pub-id pub-id-type="pmid">27384110</pub-id>
</element-citation></ref><ref id="B333-vaccines-12-01344"><label>333.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baumann</surname><given-names>A.</given-names></name>
<name><surname>Kerruth</surname><given-names>S.</given-names></name>
<name><surname>Fitter</surname><given-names>J.</given-names></name>
<name><surname>B&#x000fc;ldt</surname><given-names>G.</given-names></name>
<name><surname>Heberle</surname><given-names>J.</given-names></name>
<name><surname>Schlesinger</surname><given-names>R.</given-names></name>
<name><surname>Ataka</surname><given-names>K.</given-names></name>
</person-group><article-title>In-Situ Observation of Membrane Protein Folding during Cell-Free Expression</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0151051</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0151051</pub-id><pub-id pub-id-type="pmid">26978519</pub-id>
</element-citation></ref><ref id="B334-vaccines-12-01344"><label>334.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fogeron</surname><given-names>M.-L.</given-names></name>
<name><surname>Badillo</surname><given-names>A.</given-names></name>
<name><surname>Penin</surname><given-names>F.</given-names></name>
<name><surname>B&#x000f6;ckmann</surname><given-names>A.</given-names></name>
</person-group><article-title>Wheat Germ Cell-Free Overexpression for the Production of Membrane Proteins</article-title><source>Methods Mol. Biol.</source><year>2017</year><volume>1635</volume><fpage>91</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7151-0_5</pub-id><pub-id pub-id-type="pmid">28755365</pub-id>
</element-citation></ref><ref id="B335-vaccines-12-01344"><label>335.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Junge</surname><given-names>F.</given-names></name>
<name><surname>Haberstock</surname><given-names>S.</given-names></name>
<name><surname>Roos</surname><given-names>C.</given-names></name>
<name><surname>Stefer</surname><given-names>S.</given-names></name>
<name><surname>Proverbio</surname><given-names>D.</given-names></name>
<name><surname>D&#x000f6;tsch</surname><given-names>V.</given-names></name>
<name><surname>Bernhard</surname><given-names>F.</given-names></name>
</person-group><article-title>Advances in cell-free protein synthesis for the functional and structural analysis of membrane proteins</article-title><source>New Biotechnol.</source><year>2011</year><volume>28</volume><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.nbt.2010.07.002</pub-id><pub-id pub-id-type="pmid">20637904</pub-id>
</element-citation></ref><ref id="B336-vaccines-12-01344"><label>336.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>R.</given-names></name>
<name><surname>Noireaux</surname><given-names>V.</given-names></name>
</person-group><article-title>Quantitative modeling of transcription and translation of an all-<italic toggle="yes">E. coli</italic> cell-free system</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>11980</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-48468-8</pub-id><pub-id pub-id-type="pmid">31427623</pub-id>
</element-citation></ref><ref id="B337-vaccines-12-01344"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>R.</given-names></name>
<name><surname>Maxwell</surname><given-names>C.S.</given-names></name>
<name><surname>Collins</surname><given-names>S.P.</given-names></name>
<name><surname>Jacobsen</surname><given-names>T.</given-names></name>
<name><surname>Luo</surname><given-names>M.L.</given-names></name>
<name><surname>Begemann</surname><given-names>M.B.</given-names></name>
<name><surname>Gray</surname><given-names>B.N.</given-names></name>
<name><surname>January</surname><given-names>E.</given-names></name>
<name><surname>Singer</surname><given-names>A.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Rapid and Scalable Characterization of CRISPR Technologies Using an <italic toggle="yes">E. coli</italic> Cell-Free Transcription-Translation System</article-title><source>Mol. Cell</source><year>2018</year><volume>69</volume><fpage>146</fpage><lpage>157.e3</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.12.007</pub-id><pub-id pub-id-type="pmid">29304331</pub-id>
</element-citation></ref><ref id="B338-vaccines-12-01344"><label>338.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Des Soye</surname><given-names>B.J.</given-names></name>
<name><surname>Gerbasi</surname><given-names>V.R.</given-names></name>
<name><surname>Thomas</surname><given-names>P.M.</given-names></name>
<name><surname>Kelleher</surname><given-names>N.L.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
</person-group><article-title>A Highly Productive, One-Pot Cell-Free Protein Synthesis Platform Based on Genomically Recoded <italic toggle="yes">Escherichia coli</italic></article-title><source>Cell Chem. Biol.</source><year>2019</year><volume>26</volume><fpage>1743</fpage><lpage>1754.e9</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2019.10.008</pub-id><pub-id pub-id-type="pmid">31706984</pub-id>
</element-citation></ref><ref id="B339-vaccines-12-01344"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vilkhovoy</surname><given-names>M.</given-names></name>
<name><surname>Horvath</surname><given-names>N.</given-names></name>
<name><surname>Shih</surname><given-names>C.-H.</given-names></name>
<name><surname>Wayman</surname><given-names>J.A.</given-names></name>
<name><surname>Calhoun</surname><given-names>K.</given-names></name>
<name><surname>Swartz</surname><given-names>J.</given-names></name>
<name><surname>Varner</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Sequence Specific Modeling of <italic toggle="yes">E. coli</italic> Cell-Free Protein Synthesis</article-title><source>ACS Synth. Biol.</source><year>2018</year><volume>7</volume><fpage>1844</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1021/acssynbio.7b00465</pub-id><pub-id pub-id-type="pmid">29944340</pub-id>
</element-citation></ref><ref id="B340-vaccines-12-01344"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hodgman</surname><given-names>C.E.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Optimized extract preparation methods and reaction conditions for improved yeast cell-free protein synthesis</article-title><source>Biotechnol. Bioeng.</source><year>2013</year><volume>110</volume><fpage>2643</fpage><lpage>2654</lpage><pub-id pub-id-type="doi">10.1002/bit.24942</pub-id><pub-id pub-id-type="pmid">23832321</pub-id>
</element-citation></ref><ref id="B341-vaccines-12-01344"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hodgman</surname><given-names>C.E.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Characterizing IGR IRES-mediated translation initiation for use in yeast cell-free protein synthesis</article-title><source>New Biotechnol.</source><year>2014</year><volume>31</volume><fpage>499</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1016/j.nbt.2014.07.001</pub-id><pub-id pub-id-type="pmid">25017988</pub-id>
</element-citation></ref><ref id="B342-vaccines-12-01344"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choudhury</surname><given-names>A.</given-names></name>
<name><surname>Hodgman</surname><given-names>C.E.</given-names></name>
<name><surname>Anderson</surname><given-names>M.J.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Evaluating fermentation effects on cell growth and crude extract metabolic activity for improved yeast cell-free protein synthesis</article-title><source>Biochem. Eng. J.</source><year>2014</year><volume>91</volume><fpage>140</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.bej.2014.07.014</pub-id></element-citation></ref><ref id="B343-vaccines-12-01344"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miura</surname><given-names>K.</given-names></name>
<name><surname>Tachibana</surname><given-names>M.</given-names></name>
<name><surname>Takashima</surname><given-names>E.</given-names></name>
<name><surname>Morita</surname><given-names>M.</given-names></name>
<name><surname>Kanoi</surname><given-names>B.N.</given-names></name>
<name><surname>Nagaoka</surname><given-names>H.</given-names></name>
<name><surname>Baba</surname><given-names>M.</given-names></name>
<name><surname>Torii</surname><given-names>M.</given-names></name>
<name><surname>Ishino</surname><given-names>T.</given-names></name>
<name><surname>Tsuboi</surname><given-names>T.</given-names></name>
</person-group><article-title>Malaria transmission-blocking vaccines: Wheat germ cell-free technology can accelerate vaccine development</article-title><source>Expert Rev. Vaccines</source><year>2019</year><volume>18</volume><fpage>1017</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1080/14760584.2019.1674145</pub-id><pub-id pub-id-type="pmid">31566026</pub-id>
</element-citation></ref><ref id="B344-vaccines-12-01344"><label>344.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Das Gupta</surname><given-names>M.</given-names></name>
<name><surname>Flaskamp</surname><given-names>Y.</given-names></name>
<name><surname>Roentgen</surname><given-names>R.</given-names></name>
<name><surname>Juergens</surname><given-names>H.</given-names></name>
<name><surname>Armero-Gimenez</surname><given-names>J.</given-names></name>
<name><surname>Albrecht</surname><given-names>F.</given-names></name>
<name><surname>Hemmerich</surname><given-names>J.</given-names></name>
<name><surname>Arfi</surname><given-names>Z.A.</given-names></name>
<name><surname>Neuser</surname><given-names>J.</given-names></name>
<name><surname>Spiegel</surname><given-names>H.</given-names></name>
</person-group><article-title>Scaling eukaryotic cell-free protein synthesis achieved with the versatile and high-yielding tobacco BY-2 cell lysate</article-title><source>Biotechnol. Bioeng.</source><year>2023</year><volume>120</volume><fpage>2890</fpage><lpage>2906</lpage><pub-id pub-id-type="doi">10.1002/bit.28461</pub-id><pub-id pub-id-type="pmid">37376851</pub-id>
</element-citation></ref><ref id="B345-vaccines-12-01344"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zemella</surname><given-names>A.</given-names></name>
<name><surname>Thoring</surname><given-names>L.</given-names></name>
<name><surname>Hoffmeister</surname><given-names>C.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>Cell-Free Protein Synthesis: Pros and Cons of Prokaryotic and Eukaryotic Systems</article-title><source>Chembiochem</source><year>2015</year><volume>16</volume><fpage>2420</fpage><lpage>2431</lpage><pub-id pub-id-type="doi">10.1002/cbic.201500340</pub-id><pub-id pub-id-type="pmid">26478227</pub-id>
</element-citation></ref><ref id="B346-vaccines-12-01344"><label>346.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kubick</surname><given-names>S.</given-names></name>
<name><surname>Schacherl</surname><given-names>J.</given-names></name>
<name><surname>Fleischer-Notter</surname><given-names>H.</given-names></name>
<name><surname>Royall</surname><given-names>E.</given-names></name>
<name><surname>Roberts</surname><given-names>L.O.</given-names></name>
<name><surname>Stiege</surname><given-names>W.</given-names></name>
</person-group><article-title>In Vitro Translation in an Insect-Based Cell-Free System</article-title><source>Cell-Free Protein Expression</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2003</year><fpage>209</fpage><lpage>217</lpage></element-citation></ref><ref id="B347-vaccines-12-01344"><label>347.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thoring</surname><given-names>L.</given-names></name>
<name><surname>Dondapati</surname><given-names>S.K.</given-names></name>
<name><surname>Stech</surname><given-names>M.</given-names></name>
<name><surname>W&#x000fc;stenhagen</surname><given-names>D.A.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>High-yield production of &#x0201c;difficult-to-express&#x0201d; proteins in a continuous exchange cell-free system based on CHO cell lysates</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>11710</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-12188-8</pub-id><pub-id pub-id-type="pmid">28916746</pub-id>
</element-citation></ref><ref id="B348-vaccines-12-01344"><label>348.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thoring</surname><given-names>L.</given-names></name>
<name><surname>W&#x000fc;stenhagen</surname><given-names>D.A.</given-names></name>
<name><surname>Borowiak</surname><given-names>M.</given-names></name>
<name><surname>Stech</surname><given-names>M.</given-names></name>
<name><surname>Sonnabend</surname><given-names>A.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>Cell-Free Systems Based on CHO Cell Lysates: Optimization Strategies, Synthesis of &#x0201c;Difficult-to-Express&#x0201d; Proteins and Future Perspectives</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0163670</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0163670</pub-id><pub-id pub-id-type="pmid">27684475</pub-id>
</element-citation></ref><ref id="B349-vaccines-12-01344"><label>349.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Br&#x000f6;del</surname><given-names>A.K.</given-names></name>
<name><surname>Sonnabend</surname><given-names>A.</given-names></name>
<name><surname>Roberts</surname><given-names>L.O.</given-names></name>
<name><surname>Stech</surname><given-names>M.</given-names></name>
<name><surname>W&#x000fc;stenhagen</surname><given-names>D.A.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>IRES-Mediated Translation of Membrane Proteins and Glycoproteins in Eukaryotic Cell-Free Systems</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e82234</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0082234</pub-id><pub-id pub-id-type="pmid">24376523</pub-id>
</element-citation></ref><ref id="B350-vaccines-12-01344"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burgenson</surname><given-names>D.</given-names></name>
<name><surname>Linton</surname><given-names>J.</given-names></name>
<name><surname>Ge</surname><given-names>X.</given-names></name>
<name><surname>Kostov</surname><given-names>Y.</given-names></name>
<name><surname>Tolosa</surname><given-names>L.</given-names></name>
<name><surname>Szeto</surname><given-names>G.L.</given-names></name>
<name><surname>Rao</surname><given-names>G.</given-names></name>
</person-group><article-title>A Cell-Free Protein Expression System Derived from Human Primary Peripheral Blood Mononuclear Cells</article-title><source>ACS Synth. Biol.</source><year>2020</year><volume>9</volume><fpage>2188</fpage><lpage>2196</lpage><pub-id pub-id-type="doi">10.1021/acssynbio.0c00256</pub-id><pub-id pub-id-type="pmid">32698572</pub-id>
</element-citation></ref><ref id="B351-vaccines-12-01344"><label>351.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Welsh</surname><given-names>J.P.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>X.-S.</given-names></name>
<name><surname>Greenberg</surname><given-names>H.B.</given-names></name>
<name><surname>Swartz</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens</article-title><source>Biotechnol. Bioeng.</source><year>2012</year><volume>109</volume><fpage>2962</fpage><lpage>2969</lpage><pub-id pub-id-type="doi">10.1002/bit.24581</pub-id><pub-id pub-id-type="pmid">22729608</pub-id>
</element-citation></ref><ref id="B352-vaccines-12-01344"><label>352.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Welsh</surname><given-names>J.P.</given-names></name>
<name><surname>Swartz</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>125</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1073/pnas.1308701110</pub-id><pub-id pub-id-type="pmid">24344259</pub-id>
</element-citation></ref><ref id="B353-vaccines-12-01344"><label>353.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheng</surname><given-names>J.</given-names></name>
<name><surname>Lei</surname><given-names>S.</given-names></name>
<name><surname>Yuan</surname><given-names>L.</given-names></name>
<name><surname>Feng</surname><given-names>X.</given-names></name>
</person-group><article-title>Cell-free protein synthesis of norovirus virus-like particles</article-title><source>RSC Adv.</source><year>2017</year><volume>7</volume><fpage>28837</fpage><lpage>28840</lpage><pub-id pub-id-type="doi">10.1039/C7RA03742B</pub-id></element-citation></ref><ref id="B354-vaccines-12-01344"><label>354.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brito</surname><given-names>L.A.</given-names></name>
<name><surname>Singh</surname><given-names>M.</given-names></name>
</person-group><article-title>Acceptable levels of endotoxin in vaccine formulations during preclinical research</article-title><source>J. Pharm. Sci.</source><year>2011</year><volume>100</volume><fpage>34</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1002/jps.22267</pub-id><pub-id pub-id-type="pmid">20575063</pub-id>
</element-citation></ref><ref id="B355-vaccines-12-01344"><label>355.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamaoka</surname><given-names>Y.</given-names></name>
<name><surname>Matsuyama</surname><given-names>S.</given-names></name>
<name><surname>Fukushi</surname><given-names>S.</given-names></name>
<name><surname>Matsunaga</surname><given-names>S.</given-names></name>
<name><surname>Matsushima</surname><given-names>Y.</given-names></name>
<name><surname>Kuroyama</surname><given-names>H.</given-names></name>
<name><surname>Kimura</surname><given-names>H.</given-names></name>
<name><surname>Takeda</surname><given-names>M.</given-names></name>
<name><surname>Chimuro</surname><given-names>T.</given-names></name>
<name><surname>Ryo</surname><given-names>A.</given-names></name>
</person-group><article-title>Development of Monoclonal Antibody and Diagnostic Test for Middle East Respiratory Syndrome Coronavirus Using Cell-Free Synthesized Nucleocapsid Antigen</article-title><source>Front. Microbiol.</source><year>2016</year><volume>7</volume><elocation-id>509</elocation-id><comment>Available online: <ext-link xlink:href="https://www.frontiersin.org/article/10.3389/fmicb.2016.00509" ext-link-type="uri">https://www.frontiersin.org/article/10.3389/fmicb.2016.00509</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-05">(accessed on 5 June 2024)</date-in-citation><pub-id pub-id-type="doi">10.3389/fmicb.2016.00509</pub-id><pub-id pub-id-type="pmid">27148198</pub-id>
</element-citation></ref><ref id="B356-vaccines-12-01344"><label>356.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spice</surname><given-names>A.J.</given-names></name>
<name><surname>Aw</surname><given-names>R.</given-names></name>
<name><surname>Bracewell</surname><given-names>D.G.</given-names></name>
<name><surname>Polizzi</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Synthesis and Assembly of Hepatitis B Virus-Like Particles in a <italic toggle="yes">Pichia pastoris</italic> Cell-Free System</article-title><source>Front. Bioeng. Biotechnol.</source><year>2020</year><volume>8</volume><elocation-id>72</elocation-id><comment>Available online: <ext-link xlink:href="https://www.frontiersin.org/article/10.3389/fbioe.2020.00072" ext-link-type="uri">https://www.frontiersin.org/article/10.3389/fbioe.2020.00072</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-05">(accessed on 5 June 2024)</date-in-citation><pub-id pub-id-type="doi">10.3389/fbioe.2020.00072</pub-id><pub-id pub-id-type="pmid">32117947</pub-id>
</element-citation></ref><ref id="B357-vaccines-12-01344"><label>357.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamaoka</surname><given-names>Y.</given-names></name>
<name><surname>Jeremiah</surname><given-names>S.S.</given-names></name>
<name><surname>Funabashi</surname><given-names>R.</given-names></name>
<name><surname>Miyakawa</surname><given-names>K.</given-names></name>
<name><surname>Morita</surname><given-names>T.</given-names></name>
<name><surname>Mihana</surname><given-names>Y.</given-names></name>
<name><surname>Kato</surname><given-names>H.</given-names></name>
<name><surname>Ryo</surname><given-names>A.</given-names></name>
</person-group><article-title>Characterization and Utilization of Disulfide-Bonded SARS-CoV-2 Receptor Binding Domain of Spike Protein Synthesized by Wheat Germ Cell-Free Production System</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>1461</elocation-id><pub-id pub-id-type="doi">10.3390/v14071461</pub-id><pub-id pub-id-type="pmid">35891441</pub-id>
</element-citation></ref><ref id="B358-vaccines-12-01344"><label>358.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takai</surname><given-names>K.</given-names></name>
<name><surname>Sawasaki</surname><given-names>T.</given-names></name>
<name><surname>Endo</surname><given-names>Y.</given-names></name>
</person-group><article-title>The wheat-germ cell-free expression system</article-title><source>Curr. Pharm. Biotechnol.</source><year>2010</year><volume>11</volume><fpage>272</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.2174/138920110791111933</pub-id><pub-id pub-id-type="pmid">20210744</pub-id>
</element-citation></ref><ref id="B359-vaccines-12-01344"><label>359.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>J.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Kaur</surname><given-names>J.</given-names></name>
</person-group><article-title>Strategies for optimization of heterologous protein expression in <italic toggle="yes">E. coli</italic>: Roadblocks and reinforcements</article-title><source>Int. J. Biol. Macromol.</source><year>2018</year><volume>106</volume><fpage>803</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2017.08.080</pub-id><pub-id pub-id-type="pmid">28830778</pub-id>
</element-citation></ref><ref id="B360-vaccines-12-01344"><label>360.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Dondapati</surname><given-names>S.K.</given-names></name>
<name><surname>W&#x000fc;stenhagen</surname><given-names>D.A.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>Functional Analysis of Membrane Proteins Produced by Cell-Free Translation</article-title><source>Protein Engineering: Methods and Protocols</source><person-group person-group-type="editor">
<name><surname>Bornscheuer</surname><given-names>U.T.</given-names></name>
<name><surname>H&#x000f6;hne</surname><given-names>M.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2018</year><fpage>171</fpage><lpage>186</lpage></element-citation></ref><ref id="B361-vaccines-12-01344"><label>361.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Venkat</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Gan</surname><given-names>Q.</given-names></name>
<name><surname>Fan</surname><given-names>C.</given-names></name>
</person-group><article-title>The Application of Cell-Free Protein Synthesis in Genetic Code Expansion for Post-translational Modifications</article-title><source>Front. Pharmacol.</source><year>2019</year><volume>10</volume><elocation-id>248</elocation-id><comment>Available online: <ext-link xlink:href="https://www.frontiersin.org/article/10.3389/fphar.2019.00248" ext-link-type="uri">https://www.frontiersin.org/article/10.3389/fphar.2019.00248</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-05">(accessed on 5 June 2024)</date-in-citation><pub-id pub-id-type="doi">10.3389/fphar.2019.00248</pub-id><pub-id pub-id-type="pmid">30949051</pub-id>
</element-citation></ref><ref id="B362-vaccines-12-01344"><label>362.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Karim</surname><given-names>A.S.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Chapter Two&#x02014;Cell-Free Synthetic Biology for Pathway Prototyping</article-title><source>Enzymes in Synthetic Biology</source><person-group person-group-type="editor">
<name><surname>Scrutton</surname><given-names>N.</given-names></name>
</person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2018</year><volume>Volume 608</volume><fpage>31</fpage><lpage>57</lpage></element-citation></ref><ref id="B363-vaccines-12-01344"><label>363.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bundy</surname><given-names>B.C.</given-names></name>
<name><surname>Hunt</surname><given-names>J.P.</given-names></name>
<name><surname>Jewett</surname><given-names>M.C.</given-names></name>
<name><surname>Swartz</surname><given-names>J.R.</given-names></name>
<name><surname>Wood</surname><given-names>D.W.</given-names></name>
<name><surname>Frey</surname><given-names>D.D.</given-names></name>
<name><surname>Rao</surname><given-names>G.</given-names></name>
</person-group><article-title>Cell-free biomanufacturing</article-title><source>Curr. Opin. Chem. Eng.</source><year>2018</year><volume>22</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.coche.2018.10.003</pub-id></element-citation></ref><ref id="B364-vaccines-12-01344"><label>364.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Cell-free synthetic biology: Engineering in an open world</article-title><source>Synth. Syst. Biotechnol.</source><year>2017</year><volume>2</volume><fpage>23</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.synbio.2017.02.003</pub-id><pub-id pub-id-type="pmid">29062958</pub-id>
</element-citation></ref><ref id="B365-vaccines-12-01344"><label>365.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adiga</surname><given-names>R.</given-names></name>
<name><surname>Al-Adhami</surname><given-names>M.</given-names></name>
<name><surname>Andar</surname><given-names>A.</given-names></name>
<name><surname>Borhani</surname><given-names>S.</given-names></name>
<name><surname>Brown</surname><given-names>S.</given-names></name>
<name><surname>Burgenson</surname><given-names>D.</given-names></name>
<name><surname>Cooper</surname><given-names>M.A.</given-names></name>
<name><surname>Deldari</surname><given-names>S.</given-names></name>
<name><surname>Frey</surname><given-names>D.D.</given-names></name>
<name><surname>Ge</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Point-of-care production of therapeutic proteins of good-manufacturing-practice quality</article-title><source>Nat. Biomed. Eng.</source><year>2018</year><volume>2</volume><fpage>675</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1038/s41551-018-0259-1</pub-id><pub-id pub-id-type="pmid">31015674</pub-id>
</element-citation></ref><ref id="B366-vaccines-12-01344"><label>366.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maghodia</surname><given-names>A.B.</given-names></name>
<name><surname>Geisler</surname><given-names>C.</given-names></name>
<name><surname>Jarvis</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Characterization of an Sf-rhabdovirus-negative <italic toggle="yes">Spodoptera frugiperda</italic> cell line as an alternative host for recombinant protein production in the baculovirus-insect cell system</article-title><source>Protein Expr. Purif.</source><year>2016</year><volume>122</volume><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2016.02.014</pub-id><pub-id pub-id-type="pmid">26923062</pub-id>
</element-citation></ref><ref id="B367-vaccines-12-01344"><label>367.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sonnabend</surname><given-names>A.</given-names></name>
<name><surname>Spahn</surname><given-names>V.</given-names></name>
<name><surname>Stech</surname><given-names>M.</given-names></name>
<name><surname>Zemella</surname><given-names>A.</given-names></name>
<name><surname>Stein</surname><given-names>C.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>Production of G protein-coupled receptors in an insect-based cell-free system</article-title><source>Biotechnol. Bioeng.</source><year>2017</year><volume>114</volume><fpage>2328</fpage><lpage>2338</lpage><pub-id pub-id-type="doi">10.1002/bit.26346</pub-id><pub-id pub-id-type="pmid">28574582</pub-id>
</element-citation></ref><ref id="B368-vaccines-12-01344"><label>368.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stech</surname><given-names>M.</given-names></name>
<name><surname>Merk</surname><given-names>H.</given-names></name>
<name><surname>Schenk</surname><given-names>J.A.</given-names></name>
<name><surname>St&#x000f6;cklein</surname><given-names>W.F.M.</given-names></name>
<name><surname>W&#x000fc;stenhagen</surname><given-names>D.A.</given-names></name>
<name><surname>Micheel</surname><given-names>B.</given-names></name>
<name><surname>Duschl</surname><given-names>C.</given-names></name>
<name><surname>Bier</surname><given-names>F.F.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>Production of functional antibody fragments in a vesicle-based eukaryotic cell-free translation system</article-title><source>J. Biotechnol.</source><year>2012</year><volume>164</volume><fpage>220</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2012.08.020</pub-id><pub-id pub-id-type="pmid">22982167</pub-id>
</element-citation></ref><ref id="B369-vaccines-12-01344"><label>369.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Merk</surname><given-names>H.</given-names></name>
<name><surname>Gless</surname><given-names>C.</given-names></name>
<name><surname>Maertens</surname><given-names>B.</given-names></name>
<name><surname>Gerrits</surname><given-names>M.</given-names></name>
<name><surname>Stiege</surname><given-names>W.</given-names></name>
</person-group><article-title>Cell-free synthesis of functional and endotoxin-free antibody Fab fragments by translocation into microsomes</article-title><source>Biotechniques</source><year>2012</year><volume>53</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.2144/0000113904</pub-id><pub-id pub-id-type="pmid">22963477</pub-id>
</element-citation></ref><ref id="B370-vaccines-12-01344"><label>370.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lai</surname><given-names>T.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Ng</surname><given-names>S.</given-names></name>
</person-group><article-title>Advances in Mammalian Cell Line Development Technologies for Recombinant Protein Production</article-title><source>Pharmaceuticals</source><year>2013</year><volume>6</volume><fpage>579</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.3390/ph6050579</pub-id><pub-id pub-id-type="pmid">24276168</pub-id>
</element-citation></ref><ref id="B371-vaccines-12-01344"><label>371.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.Y.</given-names></name>
<name><surname>Kim</surname><given-names>Y.-G.</given-names></name>
<name><surname>Lee</surname><given-names>G.M.</given-names></name>
</person-group><article-title>CHO cells in biotechnology for production of recombinant proteins: Current state and further potential</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2012</year><volume>93</volume><fpage>917</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1007/s00253-011-3758-5</pub-id><pub-id pub-id-type="pmid">22159888</pub-id>
</element-citation></ref><ref id="B372-vaccines-12-01344"><label>372.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Br&#x000f6;del</surname><given-names>A.K.</given-names></name>
<name><surname>Sonnabend</surname><given-names>A.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>Cell-free protein expression based on extracts from CHO cells</article-title><source>Biotechnol. Bioeng.</source><year>2014</year><volume>111</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1002/bit.25013</pub-id><pub-id pub-id-type="pmid">24018795</pub-id>
</element-citation></ref><ref id="B373-vaccines-12-01344"><label>373.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sachse</surname><given-names>R.</given-names></name>
<name><surname>Dondapati</surname><given-names>S.K.</given-names></name>
<name><surname>Fenz</surname><given-names>S.F.</given-names></name>
<name><surname>Schmidt</surname><given-names>T.</given-names></name>
<name><surname>Kubick</surname><given-names>S.</given-names></name>
</person-group><article-title>Membrane protein synthesis in cell-free systems: From bio-mimetic systems to bio-membranes</article-title><source>FEBS Lett.</source><year>2014</year><volume>588</volume><fpage>2774</fpage><lpage>2781</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2014.06.007</pub-id><pub-id pub-id-type="pmid">24931371</pub-id>
</element-citation></ref><ref id="B374-vaccines-12-01344"><label>374.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cole</surname><given-names>S.D.</given-names></name>
<name><surname>Beabout</surname><given-names>K.</given-names></name>
<name><surname>Turner</surname><given-names>K.B.</given-names></name>
<name><surname>Smith</surname><given-names>Z.K.</given-names></name>
<name><surname>Funk</surname><given-names>V.L.</given-names></name>
<name><surname>Harbaugh</surname><given-names>S.V.</given-names></name>
<name><surname>Liem</surname><given-names>A.T.</given-names></name>
<name><surname>Roth</surname><given-names>P.A.</given-names></name>
<name><surname>Geier</surname><given-names>B.A.</given-names></name>
<name><surname>Emanuel</surname><given-names>P.A.</given-names></name>
<etal/>
</person-group><article-title>Quantification of Interlaboratory Cell-Free Protein Synthesis Variability</article-title><source>ACS Synth. Biol.</source><year>2019</year><volume>8</volume><fpage>2080</fpage><lpage>2091</lpage><pub-id pub-id-type="doi">10.1021/acssynbio.9b00178</pub-id><pub-id pub-id-type="pmid">31386355</pub-id>
</element-citation></ref><ref id="B375-vaccines-12-01344"><label>375.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chizzolini</surname><given-names>F.</given-names></name>
<name><surname>Forlin</surname><given-names>M.</given-names></name>
<name><surname>Yeh Mart&#x000ed;n</surname><given-names>N.</given-names></name>
<name><surname>Berloffa</surname><given-names>G.</given-names></name>
<name><surname>Cecchi</surname><given-names>D.</given-names></name>
<name><surname>Mansy</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Cell-Free Translation Is More Variable than Transcription</article-title><source>ACS Synth. Biol.</source><year>2017</year><volume>6</volume><fpage>638</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1021/acssynbio.6b00250</pub-id><pub-id pub-id-type="pmid">28100049</pub-id>
</element-citation></ref><ref id="B376-vaccines-12-01344"><label>376.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dopp</surname><given-names>J.L.</given-names></name>
<name><surname>Reuel</surname><given-names>N.F.</given-names></name>
</person-group><article-title>Process optimization for scalable <italic toggle="yes">E. coli</italic> extract preparation for cell-free protein synthesis</article-title><source>Biochem. Eng. J.</source><year>2018</year><volume>138</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.bej.2018.06.021</pub-id></element-citation></ref><ref id="B377-vaccines-12-01344"><label>377.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dopp</surname><given-names>J.L.</given-names></name>
<name><surname>Jo</surname><given-names>Y.R.</given-names></name>
<name><surname>Reuel</surname><given-names>N.F.</given-names></name>
</person-group><article-title>Methods to reduce variability in E. Coli-based cell-free protein expression experiments</article-title><source>Synth. Syst. Biotechnol.</source><year>2019</year><volume>4</volume><fpage>204</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.synbio.2019.10.003</pub-id><pub-id pub-id-type="pmid">31750411</pub-id>
</element-citation></ref><ref id="B378-vaccines-12-01344"><label>378.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Bai</surname><given-names>L.</given-names></name>
<name><surname>Fan</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>E.</given-names></name>
</person-group><article-title>Expression systems and species used for transgenic animal bioreactors</article-title><source>Biomed Res. Int.</source><year>2013</year><volume>2013</volume><elocation-id>580463</elocation-id><pub-id pub-id-type="doi">10.1155/2013/580463</pub-id><pub-id pub-id-type="pmid">23586046</pub-id>
</element-citation></ref><ref id="B379-vaccines-12-01344"><label>379.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shepelev</surname><given-names>M.V.</given-names></name>
<name><surname>Kalinichenko</surname><given-names>S.V.</given-names></name>
<name><surname>Deykin</surname><given-names>A.V.</given-names></name>
<name><surname>Korobko</surname><given-names>I.V.</given-names></name>
</person-group><article-title>Production of Recombinant Proteins in the Milk of Transgenic Animals: Current State and Prospects</article-title><source>Acta Naturae</source><year>2018</year><volume>10</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.32607/20758251-2018-10-3-40-47</pub-id><pub-id pub-id-type="pmid">30397525</pub-id>
</element-citation></ref><ref id="B380-vaccines-12-01344"><label>380.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pollock</surname><given-names>D.P.</given-names></name>
<name><surname>Kutzko</surname><given-names>J.P.</given-names></name>
<name><surname>Birck-Wilson</surname><given-names>E.</given-names></name>
<name><surname>Williams</surname><given-names>J.L.</given-names></name>
<name><surname>Echelard</surname><given-names>Y.</given-names></name>
<name><surname>Meade</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Transgenic milk as a method for the production of recombinant antibodies</article-title><source>J. Immunol. Methods</source><year>1999</year><volume>231</volume><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/S0022-1759(99)00151-9</pub-id><pub-id pub-id-type="pmid">10648934</pub-id>
</element-citation></ref><ref id="B381-vaccines-12-01344"><label>381.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meade</surname><given-names>H.M.</given-names></name>
<name><surname>Echelard</surname><given-names>Y.</given-names></name>
<name><surname>Ziomek</surname><given-names>C.A.</given-names></name>
<name><surname>Young</surname><given-names>M.W.</given-names></name>
<name><surname>Harvey</surname><given-names>M.</given-names></name>
<name><surname>Cole</surname><given-names>E.S.</given-names></name>
<name><surname>Groet</surname><given-names>S.</given-names></name>
<name><surname>Smith</surname><given-names>T.E.</given-names></name>
<name><surname>Curling</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Expression of Recombinant Proteins in the Milk of Transgenic Animals</article-title><source>Gene Expr. Syst.</source><year>1999</year><volume>10</volume><fpage>399</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/B978-012253840-7/50015-8</pub-id></element-citation></ref><ref id="B382-vaccines-12-01344"><label>382.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lillico</surname><given-names>S.G.</given-names></name>
<name><surname>Sherman</surname><given-names>A.</given-names></name>
<name><surname>McGrew</surname><given-names>M.J.</given-names></name>
<name><surname>Robertson</surname><given-names>C.D.</given-names></name>
<name><surname>Smith</surname><given-names>J.</given-names></name>
<name><surname>Haslam</surname><given-names>C.</given-names></name>
<name><surname>Barnard</surname><given-names>P.</given-names></name>
<name><surname>Radcliffe</surname><given-names>P.A.</given-names></name>
<name><surname>Mitrophanous</surname><given-names>K.A.</given-names></name>
<name><surname>Elliot</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Oviduct-specific expression of two therapeutic proteins in transgenic hens</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>1771</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1073/pnas.0610401104</pub-id><pub-id pub-id-type="pmid">17259305</pub-id>
</element-citation></ref><ref id="B383-vaccines-12-01344"><label>383.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kerr</surname><given-names>D.E.</given-names></name>
<name><surname>Liang</surname><given-names>F.</given-names></name>
<name><surname>Bondioli</surname><given-names>K.R.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Kreibich</surname><given-names>G.</given-names></name>
<name><surname>Wall</surname><given-names>R.J.</given-names></name>
<name><surname>Sun</surname><given-names>T.-T.</given-names></name>
</person-group><article-title>The bladder as a bioreactor: Urothelium production and secretion of growth hormone into urine</article-title><source>Nat. Biotechnol.</source><year>1998</year><volume>16</volume><fpage>75</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1038/nbt0198-75</pub-id><pub-id pub-id-type="pmid">9447598</pub-id>
</element-citation></ref><ref id="B384-vaccines-12-01344"><label>384.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dyck</surname><given-names>M.K.</given-names></name>
<name><surname>Lacroix</surname><given-names>D.</given-names></name>
<name><surname>Pothier</surname><given-names>F.</given-names></name>
<name><surname>Sirard</surname><given-names>M.-A.</given-names></name>
</person-group><article-title>Making recombinant proteins in animals&#x02013;different systems, different applications</article-title><source>TRENDS Biotechnol.</source><year>2003</year><volume>21</volume><fpage>394</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/S0167-7799(03)00190-2</pub-id><pub-id pub-id-type="pmid">12948672</pub-id>
</element-citation></ref><ref id="B385-vaccines-12-01344"><label>385.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>CHRENEK</surname><given-names>P.P.</given-names></name>
<name><surname>Makarevich</surname><given-names>A.V.</given-names></name>
<name><surname>Pivko</surname><given-names>J.</given-names></name>
<name><surname>Bulla</surname><given-names>J.</given-names></name>
</person-group><article-title>Transgenic farm animal production and application</article-title><source>Slovak J. Anim. Sci.</source><year>2010</year><volume>43</volume><fpage>45</fpage><lpage>49</lpage></element-citation></ref><ref id="B386-vaccines-12-01344"><label>386.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>H.-L.</given-names></name>
<name><surname>Huang</surname><given-names>J.-Y.</given-names></name>
<name><surname>Chu</surname><given-names>T.-W.</given-names></name>
<name><surname>Tsai</surname><given-names>T.-C.</given-names></name>
<name><surname>Hung</surname><given-names>C.-M.</given-names></name>
<name><surname>Lin</surname><given-names>C.-C.</given-names></name>
<name><surname>Liu</surname><given-names>F.-C.</given-names></name>
<name><surname>Wang</surname><given-names>L.-C.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-J.</given-names></name>
<name><surname>Lin</surname><given-names>M.-F.</given-names></name>
<etal/>
</person-group><article-title>Expression of VP1 protein in the milk of transgenic mice: A potential oral vaccine protects against enterovirus 71 infection</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>2882</fpage><lpage>2889</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.03.041</pub-id><pub-id pub-id-type="pmid">18450335</pub-id>
</element-citation></ref><ref id="B387-vaccines-12-01344"><label>387.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakade</surname><given-names>S.</given-names></name>
<name><surname>Tsubota</surname><given-names>T.</given-names></name>
<name><surname>Sakane</surname><given-names>Y.</given-names></name>
<name><surname>Kume</surname><given-names>S.</given-names></name>
<name><surname>Sakamoto</surname><given-names>N.</given-names></name>
<name><surname>Obara</surname><given-names>M.</given-names></name>
<name><surname>Daimon</surname><given-names>T.</given-names></name>
<name><surname>Sezutsu</surname><given-names>H.</given-names></name>
<name><surname>Yamamoto</surname><given-names>T.</given-names></name>
<name><surname>Sakuma</surname><given-names>T.</given-names></name>
</person-group><article-title>Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>5560</fpage><pub-id pub-id-type="doi">10.1038/ncomms6560</pub-id><pub-id pub-id-type="pmid">25410609</pub-id>
</element-citation></ref><ref id="B388-vaccines-12-01344"><label>388.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cristea</surname><given-names>S.</given-names></name>
<name><surname>Freyvert</surname><given-names>Y.</given-names></name>
<name><surname>Santiago</surname><given-names>Y.</given-names></name>
<name><surname>Holmes</surname><given-names>M.C.</given-names></name>
<name><surname>Urnov</surname><given-names>F.D.</given-names></name>
<name><surname>Gregory</surname><given-names>P.D.</given-names></name>
<name><surname>Cost</surname><given-names>G.J.</given-names></name>
</person-group><article-title>In vivo cleavage of transgene donors promotes nuclease-mediated targeted integration</article-title><source>Biotechnol. Bioeng.</source><year>2013</year><volume>110</volume><fpage>871</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1002/bit.24733</pub-id><pub-id pub-id-type="pmid">23042119</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01344-f001"><label>Figure 1</label><caption><p>Molecular cloning overview.</p></caption><graphic xlink:href="vaccines-12-01344-g001" position="float"/></fig><fig position="float" id="vaccines-12-01344-f002"><label>Figure 2</label><caption><p>Bacterial expression system.</p></caption><graphic xlink:href="vaccines-12-01344-g002" position="float"/></fig><fig position="float" id="vaccines-12-01344-f003"><label>Figure 3</label><caption><p>Insect cell (baculovirus) expression system.</p></caption><graphic xlink:href="vaccines-12-01344-g003" position="float"/></fig><fig position="float" id="vaccines-12-01344-f004"><label>Figure 4</label><caption><p>Mammalian expression system.</p></caption><graphic xlink:href="vaccines-12-01344-g004" position="float"/></fig><fig position="float" id="vaccines-12-01344-f005"><label>Figure 5</label><caption><p>Yeast expression system.</p></caption><graphic xlink:href="vaccines-12-01344-g005" position="float"/></fig><fig position="float" id="vaccines-12-01344-f006"><label>Figure 6</label><caption><p>Algal expression system.</p></caption><graphic xlink:href="vaccines-12-01344-g006" position="float"/></fig><fig position="float" id="vaccines-12-01344-f007"><label>Figure 7</label><caption><p>Plant expression system.</p></caption><graphic xlink:href="vaccines-12-01344-g007" position="float"/></fig><fig position="float" id="vaccines-12-01344-f008"><label>Figure 8</label><caption><p>Cell-free expression system.</p></caption><graphic xlink:href="vaccines-12-01344-g008" position="float"/></fig><table-wrap position="float" id="vaccines-12-01344-t001"><object-id pub-id-type="pii">vaccines-12-01344-t001_Table 1</object-id><label>Table 1</label><caption><p>In-development viral vaccines produced using <italic toggle="yes">E. coli</italic> expression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Findings</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Foot and mouth disease virus</td><td align="center" valign="middle" rowspan="1" colspan="1">VP0, VP1 and VP3 VLPs</td><td align="center" valign="middle" rowspan="1" colspan="1">Demonstrated protection in guinea pigs, swine and cattle. Local mucosal and systemic immune responses in mice via IN immunization.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B43-vaccines-12-01344" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-12-01344" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-12-01344" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-12-01344" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protected mice and pigs from challenge.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-vaccines-12-01344" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACAM-FLU-A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I clinical trials.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-vaccines-12-01344" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-12-01344" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-12-01344" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porcine circovirus type 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCV2-Cap VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine demonstrating efficacy in piglets.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-vaccines-12-01344" ref-type="bibr">51</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porcine parvovirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PPV-VP2 VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Demonstrated efficacy in piglets.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-vaccines-12-01344" ref-type="bibr">51</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dual-adjuvanted RBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Demonstrated robust neutralizing antibody response in mice.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-vaccines-12-01344" ref-type="bibr">52</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01344-t002"><object-id pub-id-type="pii">vaccines-12-01344-t002_Table 2</object-id><label>Table 2</label><caption><p>Licenced BEVS-expressed vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Manufacturer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Classical swine fever virus</td><td align="center" valign="middle" rowspan="1" colspan="1">Porcilis<sup>&#x000ae;</sup> Pesti</td><td align="center" valign="middle" rowspan="1" colspan="1">E2</td><td align="center" valign="middle" rowspan="1" colspan="1">MSD Animal Health (Rahway, NJ, USA)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B90-vaccines-12-01344" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BAYOVAC CSF E2<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayer/Pfizer Animal Health (Leverkusen, Germany)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human papillomavirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cevarix<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GlaxoSmithKline (Mississauga, ON, Canada)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-vaccines-12-01344" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flublok<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein Sciences Corporation <break/>(Meriden, CT, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-vaccines-12-01344" ref-type="bibr">92</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Porcine circovirus type 2</td><td align="center" valign="middle" rowspan="1" colspan="1">Circumvent<sup>&#x000ae;</sup> PCV</td><td align="center" valign="middle" rowspan="1" colspan="1">G2</td><td align="center" valign="middle" rowspan="1" colspan="1">Merck Animal Health (Rahway, NJ, USA)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B93-vaccines-12-01344" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ingelvac CircoFLEX<sup>&#x000ae;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">ORF2</td><td align="center" valign="middle" rowspan="1" colspan="1">Boehringer Ingelheim Vetmedica <break/>(Duluth, GA, USA)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B94-vaccines-12-01344" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porcilis<sup>&#x000ae;</sup> PCV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ORF2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSD Animal Health (Rahway, NJ, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-vaccines-12-01344" ref-type="bibr">95</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01344-t003"><object-id pub-id-type="pii">vaccines-12-01344-t003_Table 3</object-id><label>Table 3</label><caption><p>In-development BEVS-expressed vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Application</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chikungunya virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV-S27 structural polyprotein (C, E3, E2, 6K, E1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine preventing viremia and inflammation in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-vaccines-12-01344" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chikungunya virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E1 and E2 proteins</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine demonstrating protection in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-vaccines-12-01344" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Classical swine fever virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E2 protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine demonstrating protective immunity in pigs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-vaccines-12-01344" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ebolavirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GP and VP40 VLPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine demonstrating protection in guinea pigs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-vaccines-12-01344" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epizootic hemorrhagic disease virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP2 protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine preventing clinical disease or viremia in deer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-vaccines-12-01344" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA, NA and M1 VLPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine demonstrating protection in pigs against pH1N1 and in chickens against H6N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-vaccines-12-01344" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-12-01344" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lassa virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycoprotein (GP)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine eliciting high antibody titres in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-vaccines-12-01344" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rift Valley fever virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gn and Gc Glycoproteins</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine demonstrating complete protection in sheep</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-vaccines-12-01344" ref-type="bibr">103</xref>,<xref rid="B104-vaccines-12-01344" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine demonstrating protection in NHPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-vaccines-12-01344" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-12-01344" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zika virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E80 and EDIII proteins</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine demonstrating protection in mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-vaccines-12-01344" ref-type="bibr">89</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01344-t004"><object-id pub-id-type="pii">vaccines-12-01344-t004_Table 4</object-id><label>Table 4</label><caption><p>Licenced mammalian cell-expressed viral antigens.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Line</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Manufacturer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Classical swine fever</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porvac<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HEK 293</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E2-CD154</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The Centre for Genetic Engineering and Biotechnology (CIGB) (Havana, Cuba)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-vaccines-12-01344" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dengue virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dengvaxia<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vero</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">preM and E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sanofi Pasteur (Val de Reuil<break/>France)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B13-vaccines-12-01344" ref-type="bibr">13</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A (H1N1) 2009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Celvapan<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vero</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Whole virion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baxter (Orth an der Donau Austria)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-12-01344" ref-type="bibr">140</xref>,<xref rid="B141-vaccines-12-01344" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A (trivalent)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flucelvax<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDCK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA and NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Novartis Vaccines and Diagnostics (Basel, Switzerland)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B12-vaccines-12-01344" ref-type="bibr">12</xref>,<xref rid="B142-vaccines-12-01344" ref-type="bibr">142</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A (trivalent)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preflucel<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vero</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baxter (Orth an der Donau Austria)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-vaccines-12-01344" ref-type="bibr">11</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza H5N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Celvapan<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vero</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Whole virion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baxter (Orth an der Donau Austria)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-12-01344" ref-type="bibr">140</xref>,<xref rid="B141-vaccines-12-01344" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory syncytial virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AREXEVY<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSVPreF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GlaxoSmithKline (London, UK)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-vaccines-12-01344" ref-type="bibr">143</xref>,<xref rid="B144-vaccines-12-01344" ref-type="bibr">144</xref>,<xref rid="B145-vaccines-12-01344" ref-type="bibr">145</xref>,<xref rid="B146-vaccines-12-01344" ref-type="bibr">146</xref>,<xref rid="B147-vaccines-12-01344" ref-type="bibr">147</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory syncytial virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ABRYSVO<sup>&#x000ae;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSVPreF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pfizer (New York, NY, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B148-vaccines-12-01344" ref-type="bibr">148</xref>,<xref rid="B149-vaccines-12-01344" ref-type="bibr">149</xref>,<xref rid="B150-vaccines-12-01344" ref-type="bibr">150</xref>,<xref rid="B151-vaccines-12-01344" ref-type="bibr">151</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01344-t005"><object-id pub-id-type="pii">vaccines-12-01344-t005_Table 5</object-id><label>Table 5</label><caption><p>In-development mammalian cell-expressed viral antigens.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Line</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Application</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Classical swine fever virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E2 Protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental mucosal vaccine demonstrating protection in pigs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B152-vaccines-12-01344" ref-type="bibr">152</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hendra virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sG<sub>HeV</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HeLa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine demonstrating protective efficacy in African green monkeys and cats.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B153-vaccines-12-01344" ref-type="bibr">153</xref>,<xref rid="B154-vaccines-12-01344" ref-type="bibr">154</xref>,<xref rid="B155-vaccines-12-01344" ref-type="bibr">155</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hendra virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sG<sub>HeV</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">293F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine demonstrating protective efficacy in ferrets and horses.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-vaccines-12-01344" ref-type="bibr">156</xref>,<xref rid="B157-vaccines-12-01344" ref-type="bibr">157</xref>,<xref rid="B158-vaccines-12-01344" ref-type="bibr">158</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD-nanoparticle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HEK-293</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine eliciting strong neutralizing antibody responses and rapid viral clearance in nasal washes.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B159-vaccines-12-01344" ref-type="bibr">159</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pan-HLA-DR mAb fused to RBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HEK-293</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine demonstrating robust protection, strong neutralizing antibody responses and viral clearance in ferret nasal washes.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B160-vaccines-12-01344" ref-type="bibr">160</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01344-t006"><object-id pub-id-type="pii">vaccines-12-01344-t006_Table 6</object-id><label>Table 6</label><caption><p>In-development yeast-expressed viral antigens.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Yeast Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">H. polymorpha</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Papillomavirus</td><td align="center" valign="middle" rowspan="1" colspan="1">L1 protein</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B188-vaccines-12-01344" ref-type="bibr">188</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hepatitis B virus</td><td align="center" valign="middle" rowspan="1" colspan="1">VrHB-IB</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B189-vaccines-12-01344" ref-type="bibr">189</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porcine circovirus type 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCV2b capsid protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B190-vaccines-12-01344" ref-type="bibr">190</xref>]</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">P. pastoris</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Dengue virus</td><td align="center" valign="middle" rowspan="1" colspan="1">Envelope glycoproteins </td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B191-vaccines-12-01344" ref-type="bibr">191</xref>,<xref rid="B192-vaccines-12-01344" ref-type="bibr">192</xref>,<xref rid="B193-vaccines-12-01344" ref-type="bibr">193</xref>,<xref rid="B194-vaccines-12-01344" ref-type="bibr">194</xref>,<xref rid="B195-vaccines-12-01344" ref-type="bibr">195</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hand, foot and mouth disease (HFMD)</td><td align="center" valign="middle" rowspan="1" colspan="1">P1 and 3CD proteins </td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B196-vaccines-12-01344" ref-type="bibr">196</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hepatitis B virus</td><td align="center" valign="middle" rowspan="1" colspan="1">HBsAg</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B197-vaccines-12-01344" ref-type="bibr">197</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hepatitis C virus</td><td align="center" valign="middle" rowspan="1" colspan="1">HCV Core protein</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B198-vaccines-12-01344" ref-type="bibr">198</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Papillomavirus</td><td align="center" valign="middle" rowspan="1" colspan="1">HPV 16L1, 18L1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B199-vaccines-12-01344" ref-type="bibr">199</xref>,<xref rid="B200-vaccines-12-01344" ref-type="bibr">200</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Influenza virus</td><td align="center" valign="middle" rowspan="1" colspan="1">Hemagglutinin protein</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B201-vaccines-12-01344" ref-type="bibr">201</xref>,<xref rid="B202-vaccines-12-01344" ref-type="bibr">202</xref>,<xref rid="B203-vaccines-12-01344" ref-type="bibr">203</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Classical swine fever virus</td><td align="center" valign="middle" rowspan="1" colspan="1">E2 glycoprotein</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B204-vaccines-12-01344" ref-type="bibr">204</xref>,<xref rid="B205-vaccines-12-01344" ref-type="bibr">205</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chikungunya virus</td><td align="center" valign="middle" rowspan="1" colspan="1">Structural protein VLPs</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B206-vaccines-12-01344" ref-type="bibr">206</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD monomers and dimers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B207-vaccines-12-01344" ref-type="bibr">207</xref>]</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">S. cerevisiae</italic>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Papillomavirus</td><td align="center" valign="middle" rowspan="1" colspan="1">VLPs of hrHPV16 and 18, and lrHPV6 and 11&#x02014;Gardasil<sup>&#x000ae;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B187-vaccines-12-01344" ref-type="bibr">187</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPV16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B208-vaccines-12-01344" ref-type="bibr">208</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Hepatitis B virus</td><td align="center" valign="middle" rowspan="1" colspan="1">Hepatitis B surface antigen (HBsAg)&#x02014;Recombivax<sup>&#x000ae;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B209-vaccines-12-01344" ref-type="bibr">209</xref>,<xref rid="B210-vaccines-12-01344" ref-type="bibr">210</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HBV X, S and C antigens</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B211-vaccines-12-01344" ref-type="bibr">211</xref>,<xref rid="B212-vaccines-12-01344" ref-type="bibr">212</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Surface protein GS-4774</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B213-vaccines-12-01344" ref-type="bibr">213</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Enterovirus 71 (hand, foot and mouth disease)</td><td align="center" valign="middle" rowspan="1" colspan="1">EV71 Structural antigens</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B214-vaccines-12-01344" ref-type="bibr">214</xref>,<xref rid="B215-vaccines-12-01344" ref-type="bibr">215</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Parvovirus B19</td><td align="center" valign="middle" rowspan="1" colspan="1">VP</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B216-vaccines-12-01344" ref-type="bibr">216</xref>,<xref rid="B217-vaccines-12-01344" ref-type="bibr">217</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dengue virus</td><td align="center" valign="middle" rowspan="1" colspan="1">Dengue envelope domain III</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B218-vaccines-12-01344" ref-type="bibr">218</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human immunodeficiency virus-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Envelope glycoprotein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B219-vaccines-12-01344" ref-type="bibr">219</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01344-t007"><object-id pub-id-type="pii">vaccines-12-01344-t007_Table 7</object-id><label>Table 7</label><caption><p>In-development plant-expressed viral antigens.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Plant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Application</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">Nicotiana benthamiana</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" rowspan="1" colspan="1">H1 and H5 VLPs</td><td align="center" valign="middle" rowspan="1" colspan="1">Experimental vaccine eliciting strong humoral and long-term cell-mediated responses in adults.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B270-vaccines-12-01344" ref-type="bibr">270</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" rowspan="1" colspan="1">H7N9 VLP</td><td align="center" valign="middle" rowspan="1" colspan="1">Experimental vaccine demonstrating strong antibody response in mice and ferrets.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B271-vaccines-12-01344" ref-type="bibr">271</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" rowspan="1" colspan="1">HA subunit</td><td align="center" valign="middle" rowspan="1" colspan="1">Experimental vaccine demonstrating immunogenicity in mice, rabbits and ferrets. </td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B272-vaccines-12-01344" ref-type="bibr">272</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" rowspan="1" colspan="1">H6 VLP</td><td align="center" valign="middle" rowspan="1" colspan="1">Experimental vaccine demonstrating reduced viral shedding in chickens.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B273-vaccines-12-01344" ref-type="bibr">273</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Infectious bronchitis virus</td><td align="center" valign="middle" rowspan="1" colspan="1">S protein VLP</td><td align="center" valign="middle" rowspan="1" colspan="1">Experimental vaccine demonstrating immunogenicity in chickens.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B274-vaccines-12-01344" ref-type="bibr">274</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental vaccine shown to induce neutralizing antibodies in mice and NHPs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B275-vaccines-12-01344" ref-type="bibr">275</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01344-t009"><object-id pub-id-type="pii">vaccines-12-01344-t009_Table 9</object-id><label>Table 9</label><caption><p>Comparison of cellular vs. cell-free antigen expression systems.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cellular Expression</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell-Free Expression</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Time</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;2 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24&#x02013;72 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B308-vaccines-12-01344" ref-type="bibr">308</xref>,<xref rid="B344-vaccines-12-01344" ref-type="bibr">344</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Protein Toxicity</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Often a major issue</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High tolerance for toxic proteins</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B289-vaccines-12-01344" ref-type="bibr">289</xref>,<xref rid="B359-vaccines-12-01344" ref-type="bibr">359</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Membrane Proteins</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Overexpression can cause cytotoxicity and cell death</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variety of different sizes can be produced depending on lysate source</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B331-vaccines-12-01344" ref-type="bibr">331</xref>,<xref rid="B332-vaccines-12-01344" ref-type="bibr">332</xref>,<xref rid="B360-vaccines-12-01344" ref-type="bibr">360</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Protein Yield</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High yields (mg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yield varies depending on the protein from &#x000b5;g/mL to mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B288-vaccines-12-01344" ref-type="bibr">288</xref>,<xref rid="B304-vaccines-12-01344" ref-type="bibr">304</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Post-translational Modifications</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All possible depending on the system.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mainly in eukaryotic CF systems with translationally active microsomes. Limited in prokaryotic and eukaryotic lysates without endogenous microsomes. O-linked glycosylation does not occur.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B302-vaccines-12-01344" ref-type="bibr">302</xref>,<xref rid="B361-vaccines-12-01344" ref-type="bibr">361</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Scalability</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minimum volume of 5 mL to several litres.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Range from 5 &#x000b5;L (chip-based, Eppendorf tube) to 100 L (fermenter, commercial bioreactor)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B362-vaccines-12-01344" ref-type="bibr">362</xref>,<xref rid="B363-vaccines-12-01344" ref-type="bibr">363</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Flexibility and Manipulation</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Closed system, difficult to manipulate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Open system, easy to manipulate reaction conditions, no cell membrane constraints.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B364-vaccines-12-01344" ref-type="bibr">364</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Point-of-care protein production</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Difficult due to time-consuming process, infrastructural facilities and cold storage.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lyophilization allows for removal of cold-chain and on-site production without major facilities.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B298-vaccines-12-01344" ref-type="bibr">298</xref>,<xref rid="B365-vaccines-12-01344" ref-type="bibr">365</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Applications</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cells need to be lysed for membrane protein applications.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Simple as protein can be purified and reconstituted immediately post-synthesis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B288-vaccines-12-01344" ref-type="bibr">288</xref>,<xref rid="B364-vaccines-12-01344" ref-type="bibr">364</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Acceptance</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reliable, current standard for protein production approved by regulatory authorities.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Currently limited to research at laboratory level with few, limited commercial applications</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B289-vaccines-12-01344" ref-type="bibr">289</xref>,<xref rid="B304-vaccines-12-01344" ref-type="bibr">304</xref>,<xref rid="B344-vaccines-12-01344" ref-type="bibr">344</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>